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ABSTRACT	  
	   The	  Mitogen-­‐activated	  protein	  kinase(MAPK)	  signaling	  pathway	  has	  been	  studied	  intensively	  in	  the	  context	  of	  neoplastic	  transformation.	  Other	  studies	  have	  focused	  on	  the	  roles	  of	  this	  pathway	  during	  development	  and	  have	  modeled	  syndromes,	  such	  as	  Noonan	  Syndrome	  (NS),	  that	  are	  caused	  by	  aberrant	  germline	  Ras/MAPK	  signaling.	  One	  hallmark	  of	  these	  developmental	  syndromes	  is	  a	  defect	  in	  the	  skeletal	  development	  of	  the	  patients.	  However,	  the	  in	  vivo	  role	  of	  MAPK	  signaling	  during	  bone	  development	  is	  still	  controversial,	  with	  some	  studies	  supporting	  a	  positive	  role	  of	  the	  MAPK	  pathway	  during	  this	  process,	  and	  others	  arguing	  for	  a	  suppressive	  role.	  To	  analyze	  in	  depth	  the	  bone	  defects	  caused	  by	  aberrant	  K-­‐ras/MAPK	  signaling	  during	  development	  and	  to	  understand	  how	  bone	  mass	  is	  regulated	  via	  K-­‐ras/MAPK	  control	  of	  osteoblast	  differentiation	  we	  have	  generated	  two	  novel	  mouse	  models.	  Specifically,	  to	  investigate	  how	  hyperactive	  K-­‐ras	  affects	  skeletal	  development	  when	  expressed	  in	  a	  spatial	  and	  temporal	  specific	  manner	  we	  activated	  K-­‐rasG12D	  at	  various	  stages	  during	  limb	  development,	  either	  in	  all	  mesenchymal	  lineages	  (Prx1-­Cre;K-­rasG12D	  mutants),	  or	  specifically	  in	  the	  osteoblasts	  (Osx1-­Cre;K-­rasG12D).	  The	  Prx1-­Cre;K-­rasG12D	  mutant	  mice	  display	  greatly	  shortened	  and	  thickened	  bones	  that	  mirror	  the	  defects	  found	  in	  patients	  with	  NS.	  We	  determined	  that	  this	  bone	  defect	  appears	  during	  embryogenesis	  around	  E14.5	  and	  is	  distinguished	  by	  impairment	  in	  formation	  of	  the	  bone	  collar.	  Furthermore,	  we	  describe	  a	  treatment	  strategy	  that	  rescues	  the	  skeletal	  phenotype,	  and	  identify	  a	  narrow	  developmental	  time	  window,	  where	  in	  utero	  treatment	  with	  MEK	  inhibitor	  is	  sufficient	  to	  completely	  rescue	  the	  bone	  phenotype.	  The	  Osx1-­Cre;K-­rasG12D	  mutant	  mice	  allowed	  us	  to	  activate	  expression	  of	  hyperactive	  K-­‐ras	  in	  the	  osteoblast	  population	  at	  different	  times	  during	  the	  development	  of	  the	  organism.	  Using	  this	  model,	  we	  defined	  two	  time	  windows	  when	  expression	  of	  active	  K-­‐ras	  results	  in	  opposing	  bone	  phenotypes	  in	  the	  mutant	  mice.	  In	  the	  first	  time	  window	  (approximately	  between	  E11.5	  and	  E14.5)	  induction	  of	  active	  K-­‐rasG12D	  in	  osteoblasts	  precursors	  impairs	  terminal	  differentiation	  and	  leads	  to	  profound	  bone	  loss.	  In	  the	  second	  time	  window,	  activation	  of	  K-­‐rasG12D	  at	  birth	  acts	  to	  promote	  osteoblast	  differentiation	  and	  consequently	  long	  bone	  mineralization.	  	  Taken	  together,	  our	  data	  has	  revealed	  a	  critical	  involvement	  of	  K-­‐ras/MAPK	  signaling	  in	  osteoblast	  differentiation	  during	  skeletal	  development,	  in	  embryogenesis	  and	  after	  birth.	  	  They	  also	  show	  how	  the	  MAPK	  pathway	  can	  be	  modulated	  chemically	  to	  rescue	  the	  skeletal	  defects	  seen	  in	  a	  mouse	  model	  for	  NS.	  These	  findings	  yield	  insight	  into	  diseases	  of	  the	  bone,	  including	  both	  developmental	  syndromes	  caused	  by	  aberrant	  MAPK	  activation,	  such	  as	  NS,	  and	  diseases	  characterized	  by	  an	  imbalance	  in	  the	  bone	  mass,	  such	  as	  osteoporosis.	  	  Thesis	  Supervisor:	  Jacqueline	  A.	  Lees	  Title:	  Professor	  of	  Biology	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This	  thesis	  presents	  two	  novel	  mouse	  models	  in	  which	  a	  constitutive	  mutation	  of	  K-­‐ras	  is	  expressed	  at	  various	  stages	  during	  limb	  development.	  These	  models	  are	  used	  to	  investigate	  how	  K-­‐rasG12D	  affects	  skeletal	  development	  when	  expressed	  in	  a	  spatial	  and	  temporal	  specific	  manner.	  In	  this	  introduction	  I	  will	  review	  general	  aspects	  of	  bone	  development,	  a	  complex	  process	  in	  which	  various	  cell	  types	  and	  several	  signaling	  pathways	  are	  carefully	  coordinated	  to	  regulate	  the	  normal	  growth	  of	  the	  skeleton.	  I	  will	  also	  describe	  the	  major	  players	  and	  signaling	  pathways	  that	  coordinate	  bone	  growth	  with	  particular	  focus	  on	  the	  role	  of	  the	  Ras/	  MAPK	  signaling	  pathway.	  	  Finally,	  I	  will	  discuss	  developmental	  syndromes,	  and	  mouse	  models	  for	  these	  diseases,	  which	  are	  caused	  by	  abnormal	  activation	  of	  the	  MAPK	  pathway	  during	  development.	  	  In	  particular	  I	  will	  describe	  Noonan	  Syndrome	  because	  this	  thesis	  describes	  the	  generation	  and	  analysis	  of	  a	  mouse	  strain	  that	  models	  the	  bone	  defects	  arising	  in	  this	  disease.	  	  
PART	  I.	  BONE	  DEVELOPMENT	  
I.1.	  Anatomy	  and	  function	  of	  the	  skeleton	  	  The	  skeleton	  is	  a	  complex	  organ,	  consisting	  of	  more	  than	  200	  skeletal	  elements,	  two	  kinds	  of	  tissues	  (cartilage	  and	  bone)	  and	  3	  types	  of	  cells	  (chondrocytes,	  osteoblasts	  and	  osteoclasts).	  The	  skeleton	  provides	  support,	  offers	  body	  shape	  and,	  by	  acting	  as	  a	  protective	  case,	  prevents	  damage	  of	  vital	  organs	  such	  as	  the	  brain	  and	  the	  spinal	  cord.	  Bones	  are	  part	  of	  specialized	  joint	  structures,	  which	  work	  in	  conjunction	  with	  many	  associated	  muscles	  to	  control	  specific	  movements.	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They	  also	  function	  as	  a	  reservoir	  for	  inorganic	  ions,	  such	  as	  calcium	  and	  phosphate,	  and	  are	  important	  for	  maintaining	  blood	  calcium	  levels	  (Harada	  and	  Rodan,	  2003).	  There	  are	  two	  major	  kinds	  of	  bones:	  cortical	  bone,	  making	  up	  about	  80%	  of	  the	  skeleton,	  and	  trabecular	  or	  spongy	  bone,	  which	  accounts	  for	  the	  remaining	  20%.	  The	  cortical	  bone	  is	  thick,	  solid,	  and	  is	  located	  on	  the	  surface	  of	  long	  bones,	  such	  as	  the	  femur	  or	  tibia.	  It	  is	  also	  present	  in	  flat	  bones,	  such	  as	  the	  bones	  of	  the	  skull	  and	  the	  ribs.	  Its	  main	  function	  is	  to	  support	  body	  weight	  and	  protect	  internal	  organs.	  In	  contrast,	  the	  trabecular	  bone	  is	  localized	  at	  the	  end	  of	  the	  bones	  that	  bear	  weight.	  It	  is	  soft	  and	  it	  is	  found	  in	  vertebrae	  and	  the	  ends	  (epiphyses)	  of	  the	  long	  bones.	  It	  contains	  the	  bone	  marrow,	  where	  hematopoiesis	  occurs.	  Chemically,	  bones	  are	  made	  up	  of	  both	  inorganic	  and	  organic	  materials.	  The	  organic	  matrix	  is	  mainly	  composed	  of	  collagen,	  the	  most	  abundant	  protein	  in	  the	  body,	  which	  forms	  approximately	  10%	  of	  the	  adult	  bone.	  Collagen	  provides	  flexibility	  to	  the	  skeleton.	  The	  mineral	  component	  of	  bones	  is	  hydroxyapatite	  (~65%),	  an	  insoluble	  salt	  of	  calcium	  and	  phosphorus	  that	  represents	  the	  inorganic	  component	  of	  the	  mineralized	  bone	  matrix.	  Bones	  also	  contain	  water	  (25%)	  and	  small	  amounts	  of	  magnesium,	  sodium	  and	  bicarbonate.	  	  
I.2.	  Mechanisms	  of	  bone	  formation	  	  The	  first	  step	  in	  skeletal	  formation	  is	  skeletal	  morphogenesis,	  the	  process	  through	  which	  Prx	  expressing	  mesenchymal	  progenitors	  migrate	  from	  the	  cranial	  neural	  crest,	  somites	  and	  lateral	  plate	  mesoderm	  to	  the	  location	  of	  future	  bones	  (Zelzer	  and	  Olsen,	  2003).	  	  At	  these	  locations	  mesenchymal	  progenitors	  exclude	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blood	  vessels	  and	  form	  cell	  condensations	  in	  the	  respective	  matrices,	  collectively	  termed	  the	  'membranous	  skeleton'	  (Figure	  1A).	  	  In	  mammalian	  organisms,	  bone	  formation	  occurs	  through	  two	  distinct	  mechanisms:	  intramembranous	  and	  endochondral	  ossification.	  The	  latter	  mechanism	  is	  used	  for	  most	  bones	  in	  the	  body	  including	  all	  axial	  and	  apendicular	  skeletal	  elements,	  such	  as	  the	  long	  bones,	  ribs	  and	  vertebrae.	  During	  this	  process,	  condensed	  mesenchymal	  precursors	  give	  rise	  to	  both	  chondrocytes	  and	  osteoblasts.	  More	  specifically,	  the	  cells	  located	  at	  the	  center	  of	  these	  mesenchymal	  condensations	  will	  differentiate	  into	  chondrocytes	  and	  start	  proliferating	  	  (Figure	  1B)	  (Karsenty	  et	  al.,	  2009).	  These	  immature	  proliferative	  cells	  secrete	  a	  matrix	  rich	  in	  type	  II	  collagen	  (Col2),	  and	  form	  a	  cartilaginous	  template	  that	  is	  gradually	  replaced	  by	  bone.	  Chondrocytes	  at	  the	  center	  of	  the	  template	  stop	  proliferating,	  enlarge	  and	  subsequently	  mature	  into	  postmitotic	  hypertrophic	  chondrocytes	  that	  will	  undergo	  apoptosis	  (Figure	  1C).	  These	  postmitotic,	  hypertrophic	  chondrocytes	  secrete	  a	  matrix	  rich	  in	  type	  X	  collagen	  (ColX)	  and	  mineralize	  the	  matrix	  that	  surrounds	  them.	  The	  death	  of	  hypertrophic	  chondrocytes	  is	  followed	  by	  vascular	  invasion	  and	  recruitment	  of	  Osterix	  (Osx)	  expressing	  osteoblasts	  (Figure	  1D).	  This	  results	  in	  the	  formation	  of	  a	  new	  area	  of	  mineralization,	  the	  primary	  spongiosa	  (PS),	  in	  the	  shaft	  of	  long	  bones	  where	  invading	  osteoblasts	  secrete	  an	  osteoid	  matrix	  to	  form	  trabecular	  bone	  and	  hematopoietic	  cells	  to	  create	  bone	  marrow	  (Figure	  1E).	  At	  this	  location	  Osx	  expressing	  osteoblasts	  differentiate	  into	  committed	  osteoblasts,	  which	  express	  Col1.	  These	  Col1	  expressing	  osteoblasts	  further	  differentiate	  into	  Osetocalcin	  (OC)	  expressing	  osteoblasts,	  which	  will	  will	  further	  differentiate	  to	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Figure	  1.	  Schematic	  representation	  of	  endochondral	  bone	  formation.	  Adapted	  from	  Karsenty	  et	  al.,(2009).	  (A)	  Mesenchymal	  cells	  condense	  and	  (B)	  then	  become	  Col2	  positive	  chondrocytes,	  (C)	  Chondrocytes	  at	  the	  centre	  of	  the	  condensation	  stop	  proliferating,	  become	  hypertrophic	  and	  express	  ColX	  (shown	  in	  pink).	  (D)	  Perichondrial	  cells	  adjacent	  to	  hypertrophic	  chondrocytes	  become	  Col1	  positive	  osteoblasts,	  which	  form	  the	  bone	  collar.	  (E)	  Hypertrophic	  chondrocytes	  direct	  the	  formation	  of	  mineralized	  matrix,	  attract	  blood	  vessels,	  and	  undergo	  apoptosis.	  (F)	  Osteoblasts	  of	  primary	  spongiosa	  accompany	  vascular	  invasion,	  forming	  the	  primary	  spongiosa	  (ps).	  Chondrocytes	  continue	  to	  proliferate,	  lengthening	  the	  bone.	  At	  the	  end	  of	  the	  bone,	  the	  secondary	  ossification	  centre	  (soc)	  forms	  through	  cycles	  of	  chondrocyte	  hypertrophy,	  vascular	  invasion	  and	  osteoblast	  activity.	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mature	  osteoblasts.	  Some	  markers	  that	  characterize	  the	  final	  stages	  of	  osteblast	  differentiation	  are	  ALP	  (Alkaline	  Phosphatase)	  and	  BSP	  (Bone	  Sialo-­‐Protein).	  	  	  Concurrently,	  the	  cells	  at	  the	  periphery	  of	  the	  chondrocyte	  template	  will	  become	  the	  perichondrium	  (Kronenberg,	  2007).	  The	  perichondrial	  cells	  have	  specific	  functions	  during	  endochondral	  ossification.	  First,	  they	  are	  able	  to	  differentiate	  into	  either	  chondrocytes	  or	  osteoblasts,	  which	  will	  migrate	  to	  the	  trabecular	  and	  cortical	  bone.	  Second,	  they	  signal	  back	  and	  forth	  with	  the	  underlying	  cartilage.	  This	  specific	  signaling	  between	  the	  chondrocytes	  and	  perichondrial	  cells	  causes	  Col2	  expressing	  chondrocytes	  to	  differentiate	  and	  mature	  at	  the	  perichondrium	  into	  Col1	  expressing	  osteoblasts,	  which	  will	  specifically	  form	  the	  bone	  collar	  (Maes	  et	  al.,	  2010)	  (Figure	  1D).	  As	  bones	  grow	  in	  size,	  the	  secondary	  ossification	  centers	  (SOC)	  form,	  usually	  in	  the	  epiphysis	  of	  long	  bones.	  These	  regions	  form	  through	  cycles	  of	  chondrocyte	  hypertrophy,	  vascular	  invasion	  and	  osteoblast	  activity	  (Figure	  1F).	  In	  the	  long	  bones,	  chondrocytes	  continue	  to	  proliferate	  and	  cartilage	  matrix	  is	  deposited,	  causing	  the	  bone	  to	  grow	  in	  length.	  This	  process,	  which	  starts	  in	  embryogenesis,	  is	  completed	  usually	  at	  puberty.	  The	  alternate	  bone	  differentiation	  mechanism,	  intramembranous	  ossification	  is	  used	  for	  the	  cranial	  flat	  bones	  of	  the	  skull	  (frontal,	  parietal,	  occipital,	  and	  temporal	  bones)	  and	  the	  clavicles.	  In	  this	  process,	  condensed	  mesenchymal	  precursors	  differentiate	  directly	  into	  osteoblasts,	  without	  a	  cartilage	  intermediate.	  Like	  endochondral	  ossification,	  this	  process	  initiates	  in	  utero,	  but	  is	  completed	  after	  birth.	  Once	  bones	  have	  formed	  during	  embryonic	  development,	  either	  through	  endochondral	  or	  intramembranous	  ossification,	  they	  continue	  to	  be	  actively	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remodeled	  after	  birth	  during	  periods	  of	  growth	  or	  bone	  repair.	  This	  involves	  a	  tightly	  regulated	  interplay	  between	  the	  activities	  of	  chondrocytes,	  osteoblasts	  and	  osteoclasts,	  the	  three	  cell	  lineages	  involved	  in	  bone	  development.	  	  	  
I.3.	  Cell	  lineages	  involved	  in	  bone	  development	  Three	  key	  players	  are	  involved	  in	  bone	  formation:	  osteoblasts	  and	  chondrocytes,	  which	  originate	  from	  common	  mesenchymal	  progenitors	  and	  osteoclasts,	  which	  are	  of	  hematopoietic	  origin	  (Kronenberg,	  2003;	  Zelzer	  and	  Olsen,	  2003).	  Chondrocytes	  Early	  during	  endochondral	  ossification,	  mesenchymal	  progenitors	  differentiate	  into	  chondrocytes.	  This	  process	  is	  critically	  dependent	  upon	  the	  transcription	  factor	  Sox9	  (Figure	  2),	  which	  binds,	  and	  activates	  the	  transcription	  of	  chondrocyte-­‐specific	  genes	  (Bell	  et	  al.,	  1997;	  Zelzer	  and	  Olsen,	  2003).	  Sox9	  belongs	  to	  a	  large	  family	  of	  transcription	  factors,	  which	  also	  includes	  Sox5	  and	  Sox6.	  These	  two	  Sox	  family	  members	  also	  play	  important	  roles	  in	  chondrocyte	  differentiation.	  In	  particular,	  they	  actively	  cooperate	  to	  regulate	  the	  expression	  of	  cartilage-­‐specific	  components	  encountered	  in	  the	  extracellular	  matrix	  –	  such	  as	  type	  II	  collagen	  (Col2a1).	  Consistent	  with	  this,	  Sox	  5,	  6	  and	  9	  form	  complexes	  with	  other	  nuclear	  proteins	  in	  chondrocytes	  and	  are	  also	  co-­‐expressed	  at	  sites	  of	  chondrogenesis	  (Zhou	  et	  al.,	  1998).	  Furthermore,	  in	  Sox5-­‐	  and	  Sox6-­‐null	  mice	  the	  chondrocytes	  of	  the	  growth	  plate	  are	  unable	  to	  differentiate	  into	  hypertrophic	  chondrocytes	  (Lefebvre	  et	  al.,	  1998).	  Also,	  inactivation	  of	  Sox9	  in	  limb	  buds	  prior	  to
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Figure	  2.	  Differentiation	  factors	  involved	  in	  chondrocytic	  and	  osteoblastic	  
differentiation.	  Adapted	  from	  (Zelzer	  and	  Olsen,	  2003).	  Mesenchymal	  precursors,	  which	  express	  Prx,	  form	  mesenchymal	  condensations	  at	  the	  location	  of	  the	  future	  bones.	  The	  cells	  of	  these	  condesations	  will	  differentiate	  either	  into	  Col2	  expressing	  chondrocytes	  under	  the	  control	  of	  Sox9,	  Sox6	  and	  Sox5,	  or	  into	  Osx	  expressing	  osteoblasts.	  The	  Col2	  chondrocytes	  will	  differentiate	  into	  ColX	  expressing	  hypertrohic	  chondrocytes	  in	  the	  presence	  of	  Runx2	  and	  Sox9	  inhibits	  this	  process.	  The	  Osx	  osteoblasts	  will	  differentiate	  into	  Osteocalcin	  (OC)	  expressing	  mature	  osteocytes,	  capable	  of	  secreting	  mineralized	  matrix.	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the	  formation	  of	  mesenchymal	  condensations	  causes	  complete	  absence	  of	  both	  cartilage	  and	  bone	  (Akiyama	  et	  al.,	  2002).	  Additionally,	  RUNX2,	  a	  transcription	  factor	  that	  was	  first	  identified	  through	  its	  role	  in	  osteoblast	  has	  also	  been	  linked	  to	  later	  stages	  of	  chondrocyte	  differentiation.	  Runx2	  is	  required	  for	  chondrocytes	  to	  exit	  the	  cell	  cycle	  and	  become	  hypertrophic,	  since	  Runx2-­‐deficient	  mice	  lack	  	  hypertrophic	  chondrocytes	  in	  their	  limbs	  (Kim	  et	  al.,	  1999).	  Runx2	  positively	  regulates	  maturation	  to	  hypertrophic	  chondrocyte,	  while	  Sox9	  negatively	  regulates	  this	  process	  (Figure	  2).	  	  Other	  important	  factors	  involved	  in	  proper	  chondrocyte	  differentiation	  are	  the	  signaling	  molecules	  Indian	  Hedgehog	  (Ihh)	  and	  Parathyroid	  hormone-­‐related	  protein	  (PTHrP).	  These	  will	  be	  discussed	  in	  more	  detail	  in	  Section	  I.4	  of	  this	  introduction.	  Osteoblasts	  Osteoblasts	  originate	  from	  mesenchymal	  progenitor	  cells	  and	  go	  through	  several	  stages	  of	  differentiation	  to	  become	  mineralizing	  mature	  osteoblasts.	  Different	  proteins	  are	  expressed	  at	  different	  stages	  of	  osteoblast	  differentiation	  and	  are	  therefore	  used	  as	  markers	  to	  study	  the	  dynamics	  of	  osteoblast	  differentiation	  from	  osteoblast	  progenitors	  to	  mature	  osteoblasts	  (Figure	  2).	  Early	  in	  development,	  osteoblast	  progenitors	  express	  RUNX2.	  This	  promotes	  differentiation,	  resulting	  in	  the	  formation	  of	  Osx-­‐expressing	  osteoblast	  precursors	  that	  commit	  to	  an	  osteoblastic	  fate	  through	  expression	  of	  alkaline	  phosphatase	  (ALP)	  and	  type	  I	  collagen	  (Col1).	  Mid-­‐stage	  markers	  of	  osteoblast	  differentiation	  are	  osteopontin	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(OPN)	  and	  osteonectin,	  while	  the	  late	  stage	  marker	  osteocalcin	  (OC)	  is	  expressed	  specifically	  by	  mature	  osteoblasts.	  Osteocytes,	  the	  most	  abundant	  bone	  cells	  (95%)	  in	  adult	  bone,	  are	  the	  terminal	  stage	  of	  osteoblast	  differentiation	  and	  they	  are	  embedded	  deep	  within	  the	  bone	  matrix	  during	  bone	  formation	  (Franz-­‐Odendaal	  et	  al.,	  2006;	  Fulzele	  et	  al.,	  2012).	  These	  cells	  are	  important	  for	  regulating	  bone	  remodeling,	  due	  to	  their	  ability	  to	  secrete	  RANKL,	  which	  promotes	  osteoclast	  differentiation	  (Xiong	  et	  al.,	  2011)	  and	  also	  expression	  of	  sclerostin,	  a	  suppressor	  of	  osteoblast	  proliferation	  (Winkler	  et	  al.,	  2003).	  	  Runx2	  is	  the	  earliest	  transcription	  factor	  absolutely	  required	  for	  the	  differentiation	  of	  mesenchymal	  progenitors	  into	  osteoblasts	  (Figure	  2).	  Runx2	  regulates	  the	  expression	  of	  several	  osteoblast	  specific	  proteins,	  such	  as	  osteocalcin,	  alkaline	  phosphatase	  and	  type	  I	  collagen	  (Ducy	  et	  al.,	  1997;	  Lee	  et	  al.,	  2007).	  Interestingly,	  overexpression	  of	  Runx2	  in	  other	  cell	  types	  in	  vitro,	  such	  as	  fibroblasts	  or	  myoblasts,	  is	  sufficient	  to	  induces	  the	  expression	  of	  osteoblasts	  specific	  markers	  (Ducy,	  2000).	  	  Conversely,	  deletion	  of	  Runx2	  in	  mice	  prevents	  expression	  of	  early	  or	  late	  osteoblast	  markers	  and	  formation	  of	  mature	  bone	  tissue	  (Ducy	  et	  al.,	  1997).	  As	  noted	  above,	  these	  Runx2	  null	  mice	  also	  lack	  hypertrophic	  chondrocytes,	  despite	  other	  types	  of	  chondrocytes	  being	  present	  (Komori	  et	  al.,	  1997;	  Otto	  et	  al.,	  1997).	  Taken	  together,	  these	  observations	  prove	  that	  Runx2	  is	  a	  critical	  factor	  required	  for	  proper	  osteoblast	  differentiation.	  	  Osterix1	  (OSX1)	  is	  the	  other	  transcription	  factor	  known	  to	  be	  essential	  for	  osteoblast	  differentiation	  (Figure	  2).	  Osx1-­‐null	  mice	  do	  not	  express	  any	  bone-­‐specific	  markers	  (Nakashima	  et	  al.,	  2002).	  However,	  it	  was	  shown	  by	  in	  situ	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hybridization	  analysis	  that	  Osx-­‐null	  mice	  express	  Runx2.	  At	  the	  same	  time	  Runx2-­‐null	  mice	  do	  not	  express	  Osx,	  indicating	  that	  Osx	  acts	  downstream	  Runx2	  in	  the	  osteoblast	  differentiation	  lineage	  (Nakashima	  et	  al.,	  2002).	  As	  Runx2	  has	  a	  role	  in	  both	  chondrocytic	  and	  osteoblastic	  differentiation,	  Osterix	  is	  likely	  the	  factor	  that	  provides	  specificity	  in	  osteoblastic	  differentiation.	  Osx	  expression	  is	  highly	  specific	  to	  the	  osteoblast	  lineage,	  but	  low-­‐level	  expression	  has	  been	  detected	  in	  chondrocytes	  in	  vivo	  (Nakashima	  et	  al.,	  2002;	  Rodda	  and	  McMahon,	  2006;	  Yagi	  et	  al.,	  2003).	  In	  an	  in	  vitro	  setting,	  Osx	  is	  sufficient	  to	  induce	  expression	  of	  osteoblast	  markers	  (Tai	  et	  al.,	  2004).	  Importantly,	  normal	  cartilage	  development	  is	  required	  for	  proper	  osteoblast	  differentiation.	  This	  is	  supported	  by	  in	  vivo	  mouse	  studies	  showing	  that	  mutation	  of	  chondrocyte	  specific	  factors,	  such	  as	  Ihh,	  cause	  defects	  in	  osteoblasts	  differentiation.	  
In	  vivo	  bone	  development	  is	  also	  negatively	  impacted	  when	  mutations	  are	  introduced	  into	  Ihh.	  Specifically,	  Ihh-­‐null	  mice	  exhibit	  severe	  dwarfism	  in	  axial	  and	  appendicular	  skeletal	  elements	  and	  do	  not	  form	  endochondral	  bones	  (St-­‐Jacques	  et	  al.,	  1999);	  (Long	  et	  al.,	  2004;	  Rodda	  and	  McMahon,	  2006).	  	  Osteoclasts	  Osteoclasts	  originate	  from	  the	  hematopoietic	  lineage,	  specifically	  from	  mature	  monocytes	  and	  macrophages,	  and	  their	  role	  is	  to	  release	  specific	  enzymes	  that	  can	  lyse	  adjacent	  bone.	  The	  balance	  between	  osteoblast	  activity	  (which	  build	  bone)	  and	  osteoclast	  activity	  (which	  destroy	  it)	  is	  crucial	  for	  maintaining	  bone	  density	  and	  regulating	  proper	  bone	  remodeling.	  Notably,	  osteoblasts	  can	  influence	  osteoclast	  differentiation	  in	  either	  a	  positive	  or	  negative	  manner,	  through	  secretion	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of	  regulatory	  factors,	  such	  as	  CSF-­‐1,	  RANKL	  and	  Osteoprotegerin	  (OPG).	  CSF-­‐1	  and	  RANKL	  play	  a	  promoting	  role	  via	  activation	  of	  osteoclast	  specific	  genes.	  OPG	  is	  a	  receptor	  for	  RANKL	  that	  acts	  to	  sequester	  it,	  and	  thereby	  inhibits	  osteoclast	  formation	  (Simonet	  et	  al.,	  1997).	  Animal	  studies	  have	  shown	  that	  mice	  without	  CSF-­‐1	  or	  the	  receptor	  for	  RANKL	  are	  unable	  to	  make	  osteoclasts	  (Kong	  et	  al.,	  1999;	  Yoshida	  et	  al.,	  1990)	  and	  they	  develop	  osteopetrosis.	  In	  cartilage,	  RUNX2	  promotes	  expression	  of	  RANKL,	  the	  key	  ligand	  driving	  osteoclast	  differentiation.	  Hyperactive	  osteoclasts	  are	  responsible	  for	  many	  adult	  skeletal	  diseases,	  including	  osteoporosis,	  rheumatoid	  arthritis	  and	  periodontal	  disease	  (Rodan	  and	  Martin,	  2000).	  Reduced	  osteoclast	  activity	  leads	  to	  diseases	  where	  excessive	  bone	  fills	  out	  the	  bone	  marrow	  cavity,	  such	  as	  osteopetrosis.	  	  	  
I.4.	  Major	  signaling	  pathways	  involved	  in	  bone	  development	  Several	  major	  signaling	  pathways	  are	  important	  for	  bone	  development,	  including	  the	  Indian	  Hedgehog	  (Ihh)/Parathyroid	  hormone-­‐related	  protein	  (PTHrP),	  the	  fibroblast	  growth	  factor	  (FGF)	  and	  the	  bone	  morphogenetic	  protein	  (BMP)	  pathways	  (Kronenberg,	  2003).	  In	  general,	  these	  pathways	  function	  to	  coordinate	  proper	  chondrocyte	  and	  osteoblast	  differentiation.	  The	  Ihh/PTHrP	  and	  the	  FGF	  pathways	  will	  be	  discussed	  in	  more	  detail	  in	  the	  next	  section.	  Indian	  hedgehog/	  Parathyroid	  hormone-­‐related	  protein	  signaling	  	  Ihh	  and	  PTHrP	  signaling	  is	  complex,	  involving	  crosstalk	  and	  both	  negative	  and	  positive	  feedback	  loops	  (Figure	  3).	  Perichondrial	  cells	  and	  chondrocytes	  at	  the	  end	  of	  long	  bones	  secrete	  PTHrP.	  (Figure	  3.1).	  PTHrP	  acts	  on	  receptors	  found	  on	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proliferating	  chondrocytes	  and	  keeps	  the	  cells	  in	  a	  proliferative	  state	  and	  delays	  their	  secretion	  of	  Ihh	  (Kronenberg,	  2003;	  St-­‐Jacques	  et	  al.,	  1999).	  Ihh	  is	  produced	  by	  cells	  that	  fail	  to	  receive	  enough	  PTHrP	  to	  suppress	  its	  expression.	  Ihh	  acts	  on	  its	  own	  receptor	  found	  on	  proliferating	  chondrocytes,	  and	  it	  stimulates	  their	  continuous	  proliferation	  and	  prevents	  differentiation	  to	  hypertrophic	  chondrocytes	  (Figure	  3.2).	  Ihh	  also	  acts	  on	  chondrocytes	  at	  the	  end	  of	  the	  long	  bones	  and	  stimulates	  their	  production	  of	  PTHrP	  (Figure	  3.3).	  Importantly,	  Ihh	  signals	  to	  perichondrial	  cells	  immediately	  adjacent	  to	  the	  prehypertrophic	  and	  hypertrophic	  cells,	  and	  it	  directs	  them	  to	  move	  away	  from	  the	  chondrocyte	  pathway	  and	  differentiate	  to	  osteoblasts.	  These	  osteoblasts	  end	  up	  forming	  the	  bone	  collar	  (Figure	  3.4).	  In	  vivo	  studies	  have	  shown	  that	  Ihh-­‐null	  mice	  exhibit	  severe	  dwarfism	  in	  axial	  and	  appendicular	  skeletal	  elements	  and	  do	  not	  form	  endochondral	  bones	  (St-­‐Jacques	  et	  al.,	  1999).	  	  Null	  mutations	  of	  PTHrP	  or	  its	  receptor	  decreases	  the	  number	  of	  proliferating	  growth	  plate	  chondrocytes	  and	  increases	  the	  size	  of	  the	  hypertrophic	  zone	  (Lanske	  et	  al.,	  1996).	  	  Fibroblast	  growth	  factor	  (FGF)	  signaling	  FGF	  signaling	  has	  an	  important	  role	  in	  chondrocyte	  proliferation	  and	  differentiation.	  The	  mechanism	  by	  which	  this	  signaling	  pathway	  works	  is	  complex	  and	  still	  not	  fully	  understood.	  This	  is	  mainly	  due	  to	  the	  fact	  that	  various	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Figure	  3.	  Indian	  hedgehog	  (Ihh)/parathyroid	  hormone-­related	  protein	  
(PTHrP)	  negative-­feedback	  loop.	  Adapted	  from	  Kronenberg	  (2003).	  (1)	  Chondrocytes	  at	  the	  end	  of	  long	  bones	  secrete	  PTHrP.	  PTHrP	  acts	  on	  receptors	  found	  on	  proliferating	  chondrocytes	  to	  keep	  them	  in	  a	  proliferative	  state.	  (2)	  Ihh	  is	  produced	  by	  cells	  that	  fail	  to	  receive	  enough	  PTHrP	  to	  suppress	  its	  expression.	  Ihh	  acts	  on	  its	  own	  receptor	  found	  on	  proliferating	  chondrocytes,	  stimulates	  their	  continuous	  proliferation	  and	  prevents	  their	  differentiation	  to	  hypertrophic	  chondrocytes.	  (3)	  Ihh	  also	  acts	  on	  chondrocytes	  at	  the	  end	  of	  the	  long	  bones	  and	  stimulates	  their	  production	  of	  PTHrP.	  (4)	  Ihh	  signals	  to	  perichondrial	  cells	  immediately	  adjacent	  to	  the	  prehypertrophic	  and	  hypertrophic	  cells,	  and	  it	  directs	  them	  to	  differentiate	  to	  osteoblasts.
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  members	  of	  the	  FGF	  family,	  and	  also	  many	  FGF	  receptors,	  are	  expressed	  early	  in	  bone	  development	  and	  these	  have	  overlapping	  functions.	  Early	  during	  endochondral	  bone	  development,	  FGFR-­‐2	  is	  expressed	  in	  the	  condensing	  mesenchyme.	  In	  vitro	  studies	  in	  mesenchymal	  cell	  lines	  showed	  that	  FGFs	  stimulate	  expression	  of	  Sox9,	  the	  transcription	  factor	  essential	  for	  early	  stage	  chondrocyte	  differentiation	  (Figure	  2).	  Thus,	  expression	  of	  FGFR-­‐2	  early	  in	  the	  limb	  mesenchyme	  is	  thought	  to	  induce	  the	  expression	  of	  Sox-­‐9.	  At	  late	  times	  in	  development,	  proliferating	  chondrocytes	  express	  FGFR-­‐3,	  while	  pre-­‐hypertrophic	  and	  hypertrophic	  chondrocytes	  express	  FGFR-­‐2.	  FGF	  signaling	  through	  FGFR-­‐3	  was	  studied	  in	  more	  depth	  and	  shown	  to	  have	  a	  negative	  effect	  on	  chondrocyte	  proliferation.	  This	  conclusion	  is	  based	  on	  the	  finding	  that	  activating	  mutations	  in	  FGFR-­‐3	  decrease	  the	  proliferation	  rate	  of	  chondrocytes,	  partially	  through	  the	  JAK-­‐STAT1	  pathway	  (Sahni	  et	  al.,	  1999).	  Notably,	  Fgfr3	  null	  mice	  show	  an	  increase	  in	  the	  rate	  of	  chondrocyte	  proliferation	  and	  expansion	  of	  chondrocyte	  columns	  (Colvin	  et	  al.,	  1996;	  Deng	  et	  al.,	  1996).	  Concomitantly,	  FGF	  signaling	  partially	  works	  through	  regulating	  the	  Ihh/	  PTHrP	  negative	  loop,	  by	  suppressing	  Ihh	  expression	  and	  inducing	  a	  decrease	  in	  chondrocyte	  proliferation	  (Naski	  et	  al.,	  1998;	  Ornitz	  and	  Marie,	  2002).	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PART	  II.	  THE	  RAS	  ONCOGENES	  Proper	  cellular	  proliferation	  is	  essential	  for	  normal	  development	  and	  growth	  of	  organisms.	  Tight	  regulation	  of	  the	  cell	  cycle	  machinery,	  through	  various	  intracellular	  and	  extracellular	  signals,	  is	  very	  important	  for	  cells	  to	  know	  when	  to	  divide,	  or	  stop	  dividing,	  under	  the	  right	  conditions	  (Hanahan	  and	  Weinberg,	  2000).	  In	  cancer,	  this	  regulation	  is	  disrupted	  and	  tumor	  cancer	  cells	  proliferate	  excessively.	  Mutations	  in	  the	  mitogenic	  signaling	  pathways,	  such	  as	  in	  members	  of	  the	  RAS	  family,	  are	  some	  of	  the	  most	  common	  mutations	  in	  cancer	  and	  result	  in	  an	  uncoupling	  of	  cell	  cycle	  regulation	  from	  extracellular	  cues.	  Given	  the	  importance	  of	  these	  proteins	  in	  proliferation	  and	  tumorigenesis,	  it	  is	  not	  surprising	  that	  their	  deregulation	  also	  has	  profound	  effects	  on	  normal	  development.	  RASopathies	  are	  a	  group	  of	  developmental	  disorders	  caused	  by	  germline	  mutations	  in	  components	  of	  the	  Ras/MAPK	  pathway	  that	  result	  in	  increased	  signaling.	  These	  will	  be	  discussed	  in	  further	  detail	  in	  Part	  III	  of	  this	  introduction.	  This	  thesis	  presents	  two	  novel	  mouse	  models	  in	  which	  a	  constitutive	  mutation	  of	  K-­‐ras	  is	  expressed	  at	  various	  stages	  during	  limb	  development.	  These	  models	  are	  used	  to	  investigate	  how	  K-­‐rasG12D	  affects	  skeletal	  development	  when	  expressed	  in	  a	  spatial	  and	  temporal	  specific	  manner.	  	  	  
II.	  1.	  Discovery	  Initially,	  the	  Ras	  genes	  were	  discovered	  as	  the	  transforming	  sequences	  from	  the	  genomes	  of	  Harvey	  and	  Kirsten	  rat	  sarcoma	  viruses	  (Chien	  et	  al.,	  1979;	  Ellis	  et	  al.,	  1981).	  Independently,	  the	  same	  sequences,	  cloned	  from	  various	  cancer	  cells	  lines	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(Pulciani	  et	  al.,	  1982;	  Shih	  and	  Weinberg,	  1982)	  or	  isolated	  from	  chemically	  treated	  cells	  (Shih	  et	  al.,	  1981)	  were	  identified	  as	  inducers	  of	  transformation	  of	  NIH	  3T3	  cells.	  Soon	  after,	  it	  was	  realized	  that	  the	  sequences	  in	  the	  two	  different	  contexts,	  viruses	  (viral	  Ras	  genes)	  and	  cancer	  cells,	  are	  homologous	  (Parada	  et	  al.,	  1982).	  This	  led	  to	  the	  discovery	  of	  the	  3	  members	  of	  the	  Ras	  family:	  H-­Ras,	  K-­Ras	  and	  lastly	  N-­ras	  (Capon	  et	  al.,	  1983;	  Johnson	  et	  al.,	  2001).	  	  Further	  work	  has	  shown	  that	  a	  single	  point	  mutation	  in	  these	  genes	  can	  transform	  the	  normal	  cellular	  gene	  into	  an	  oncogene	  (Tabin	  et	  al.,	  1982;	  Taparowsky	  et	  al.,	  1982).	  RAS	  genes	  represent	  frequent	  mutational	  targets	  in	  cancer	  and	  have	  been	  shown	  to	  be	  mutated	  in	  ~30%	  of	  human	  tumors	  (Johnson	  et	  al.,	  2001).	  Interestingly,	  mutations	  in	  the	  RAS	  genes	  are	  not	  randomly	  distributed	  among	  the	  different	  isoforms,	  and	  the	  majority	  of	  mutations	  occur	  in	  K-­RAS,	  especially	  in	  lung,	  pancreas	  and	  colon	  tumors	  (Bos,	  1989;	  Johnson	  et	  al.,	  2001).	  It	  is	  clear	  that	  mutations	  in	  different	  members	  of	  the	  Ras	  family	  lead	  to	  different	  tumor	  types	  (Karnoub	  and	  Weinberg,	  2008).	  	  
H-­ras	  and	  N-­ras	  are	  dispensable	  for	  development,	  both	  individually	  and	  in	  combination	  (Janssen	  et	  al.,	  2005).	  K-­ras	  encodes	  two	  splice	  variants	  with	  KRASA	  expressed	  in	  a	  tissue	  specific	  and	  developmentally	  restricted	  fashion	  and	  KRASB	  being	  ubiquitously	  expressed. Mice	  with	  a	  homozygous	  null	  mutation	  in	  K-­ras	  are	  not	  viable	  and	  die	  during	  embryogenesis	  due	  to	  a	  wide	  spectrum	  of	  defects	  (cardiac,	  liver,	  neurological	  and	  hematopoietic	  defects),	  indicating	  that	  K-­ras	  is	  essential	  for	  embryonic	  development	  (Tuveson	  et	  al.,	  2004).	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II.2.	  Ras	  proteins	  and	  the	  GTPase	  cycle	  Early	  studies	  identified	  Ras	  proteins	  as	  small	  21kD	  proteins	  localized	  to	  the	  cell	  membrane.	  	  These	  could	  both	  bind	  GTP,	  and	  hydrolyze	  it,	  proof	  of	  an	  internal	  GTP-­‐ase	  activity	  (Shih	  et	  al.,	  1980).	  Soon	  after,	  these	  proteins	  were	  classified	  as	  small	  G-­‐proteins	  (Hurley	  et	  al.,	  1984)	  that	  function	  as	  molecular	  switches	  in	  controlling	  the	  signaling	  from	  membrane	  receptors	  to	  intracellular	  effector	  cascades.	  They	  are	  regulated	  by	  binding	  to	  either	  GTP	  (in	  their	  ON	  state)	  or	  to	  GDP	  (in	  their	  OFF	  state;	  Figure	  4).	  Following	  the	  discovery	  that	  the	  mitogenic	  signaling	  molecule,	  induces	  GTP	  binding	  (Kamata	  and	  Feramisco,	  1984),	  it	  was	  concluded	  that	  the	  intracellular	  effector	  cascades	  controlled	  by	  Ras	  proteins	  were	  involved	  in	  cell	  proliferation,	  differentiation,	  and	  apoptosis.	  	  Subsequent	  studies	  and	  the	  discovery	  of	  many	  other	  players	  helped	  to	  establish	  the	  precise	  mechanism	  by	  which	  mitogenic	  signals	  are	  transmitted	  from	  the	  cell	  membrane	  to	  the	  cell	  machinery	  and	  a	  complex	  GTP-­‐GDP	  cycle	  was	  described	  (Figure	  4;	  McCormick,	  1993).	  Upon	  binding	  of	  mitogenic	  ligans	  to	  growth	  factor	  receptors,	  the	  intracellular	  domains	  of	  these	  receptors	  bind	  adaptor	  proteins	  (GRB2),	  which	  recruit	  guanine	  nucleotide	  exchange	  factors	  (GEFs,	  such	  as	  SOS)	  to	  the	  plasma	  membrane.	  This	  brings	  these	  in	  close	  proximity	  to	  the	  Ras	  proteins,	  which	  are	  tethered	  in	  the	  membrane,	  allowing	  interaction	  and	  to	  release	  GDP	  and	  bind	  GTP,	  which	  results	  in	  their	  activation	  and	  the	  activation	  of	  downstream	  pathways.	  This	  stimulates	  the	  Ras	  proteins	  as	  described	  in	  more	  detail	  below.	  The	  inactivation	  of	  the	  GTP-­‐bound	  Ras	  proteins	  occurs	  through	  the	  hydrolysis	  of	  GTP	  to	  GDP,	  catalyzed	  by	  GTPase-­‐activating	  proteins	  (GAPs)	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Figure	  4.	  Ras	  complex	  downstream	  signaling	  networks.	  Adapted	  form	  Karnoub	  and	  Weinberg	  (2008).	  The	  MAPK	  signaling	  pathway	  controls	  downstream	  effectors	  critically	  involved	  in	  cell	  proliferation,	  differentiation,	  motility,	  apoptosis	  and	  senescence.	  The	  binding	  of	  GTP	  to	  Ras	  protein	  locks	  it	  in	  an	  active	  state,	  which	  enables	  interactions	  with	  multiple	  downstream	  effectors.	  A	  slow	  intrinsic	  GTPase	  activity	  leads	  to	  Ras	  inactivation	  and	  signal	  termination.	  This	  ON–OFF	  cycle	  is	  tightly	  controlled	  by	  GTPase-­‐activating	  proteins	  (GAPs	  –	  p120GAP	  or	  NF1)	  and	  guanine-­‐nucleotide	  exchange	  factors	  (GEFs	  –	  SOS).	  	  	  GF=Growth	  Factor,	  RTK=Receptor	  Tyrosine	  Kinase.	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  including	  p210GAP	  and	  NF1	  (Cawthon	  et	  al.,	  1990;	  Karnoub	  and	  Weinberg,	  2008;	  Martin	  et	  al.,	  1990).	  	  Not	  surprisingly,	  mutations	  that	  disrupt	  the	  GTP-­‐GDP	  cycle	  of	  Ras	  proteins	  have	  been	  shown	  to	  be	  oncogenic.	  More	  specifically,	  these	  mutations	  cause	  an	  	  inhibition	  or	  reduction	  of	  the	  intrinsic	  GTPase	  activity	  or	  suppress	  their	  interaction	  with	  GAPs.	  This	  results	  in	  deregulated	  activation	  of	  the	  Ras	  proteins	  -­‐	  often	  in	  the	  absence	  of	  appropriate	  upstream	  signaling	  -­‐	  by	  increasing	  the	  ratio	  of	  the	  active	  GTP-­‐bound	  state	  relative	  to	  the	  GDP-­‐bound	  inactive	  state.	  The	  most	  common	  oncogenic	  point	  mutations	  in	  the	  Ras	  genes	  are	  found	  in	  codons	  12,	  13	  and	  61	  (Clark	  et	  al.,	  1985;	  Der	  et	  al.,	  1986;	  Trahey	  and	  McCormick,	  1987).	  These	  mutation	  lock	  Ras	  protein	  in	  a	  constitutively	  active	  form,	  by	  preventing	  it	  from	  releasing	  the	  bound	  GTP.	   	  
II.3.	  Ras	  downstream	  signaling	  pathways	  –	  MAPK	  pathway	  Ras	  downstream	  effectors	  can	  have	  a	  multitude	  of	  biological	  functions.	  Since	  growth	  factors	  such	  as	  EGF	  can	  stimulate	  Ras	  activity,	  it	  was	  concluded	  that	  one	  of	  the	  most	  important	  roles	  for	  Ras	  proteins	  is	  their	  role	  in	  mitogenic	  signaling	  (Mulcahy	  et	  al.,	  1985).	  Subsequently,	  it	  became	  clear	  that	  ras	  activates	  a	  multitude	  of	  downstream	  signaling	  pathways,	  and	  has	  numerous	  roles	  including	  controlling	  cell	  cycle	  and	  differentiation	  (MAPK	  pathway),	  cell	  survival	  (PI3K	  pathway),	  cell	  signaling	  (PLCε),	  endocytosis	  (Ral-­‐GEF)	  and	  many	  others	  (Karnoub	  and	  Weinberg,	  2008;	  Figure	  4).	  It	  is	  important	  to	  understand	  how	  Ras	  can	  execute	  all	  these	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downstream	  functions,	  as	  this	  can	  shed	  more	  light	  on	  the	  role	  of	  these	  proteins	  in	  development	  and	  cancer.	  I	  will	  further	  focus	  my	  discussion	  on	  the	  MAPK	  pathway,	  because	  this	  is	  most	  relevant	  to	  this	  thesis	  project.	  The	  Mitogen	  Activated	  Protein	  Kinase	  (MAPK)	  pathway	  is	  one	  of	  the	  best-­‐characterized	  downstream	  signaling	  pathways	  of	  the	  Ras	  proteins.	  The	  Ras/MAPK	  pathway	  transduces	  extracellular	  signals	  in	  the	  form	  of	  growth	  factors	  and	  small	  molecules	  to	  the	  intracellular	  environment. 	  Active	  Ras	  leads	  to	  the	  activation	  of	  the	  Raf	  family	  of	  kinases:	  A-­‐Raf,	  B-­‐Raf	  and/or	  C-­‐Raf.	  Raf,	  first	  identified	  as	  an	  oncogene	  (Vojtek	  et	  al.,	  1993),	  becomes	  localized	  to	  the	  plasma	  membrane	  and	  initiates	  activation	  of	  the	  MAPK	  signaling	  cascade	  (Figure	  4).	  In	  this	  cascade,	  Raf	  kinase	  phosphorylates	  MEK1/2	  (MAPK	  kinases),	  which	  then	  phosphorylate	  and	  activate	  ERK1/2	  kinases	  (Hagemann	  and	  Blank,	  2001).	  ERK1/2	  are	  the	  ultimate	  effectors	  and	  exert	  their	  function	  on	  a	  large	  number	  of	  downstream	  molecules	  including	  nuclear	  factors,	  transcription	  factors,	  membrane	  proteins,	  and	  protein	  kinases.	  All	  these	  molecules	  control	  vital	  cellular	  functions	  including	  cell	  cycle	  progression,	  differentiation,	  and	  cell	  growth	  (Yoon	  and	  Seger,	  2006).	  	  Some	  of	  the	  better-­‐characterized	  downstream	  ERK	  effectors	  are	  the	  Ets,	  ELK	  and	  AP-­‐1	  (c-­‐Fos-­‐c-­‐Jun)	  complex	  of	  transcription	  factors.	  Activation	  of	  these	  transcription	  factors	  leads	  to	  increased	  expression	  of	  cell	  cycle	  genes,	  such	  as	  cyclin	  D1	  (Hitomi	  and	  Stacey,	  1999),	  supporting	  the	  role	  of	  Ras	  as	  a	  mitogenic	  protein.	  The	  MAPK	  pathway	  can	  have	  other	  outputs	  as	  well,	  such	  as	  the	  p38	  pathway	  and	  the	  Jun	  N-­‐terminal	  kinase	  (JNK)	  pathway,	  with	  roles	  related	  to	  stress	  responses.	  Notably,	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Ras	  can	  direct	  distinct	  outputs	  and	  have	  different	  effects	  depending	  on	  which	  MAPK	  pathways	  it	  activates.	  ERK	  targets	  several	  core	  regulators	  of	  osteoblast	  differentiation.	  	  It	  phosphorylates	  the	  RUNX2	  transcription	  factor	  and	  positively	  regulates	  early	  osteoblast	  differentiation	  in	  vivo	  (Ge	  et	  al.,	  2007;	  Xiao	  et	  al.,	  2000;	  Figure	  5).	  Furthermore,	  active	  ERK,	  via	  its	  association	  with	  RUNX2,	  binds	  to	  the	  osteoblast	  specific	  promoters	  osteocalcin	  (Ocn)	  and	  bone	  sialoprotein	  (Bsp)	  (Li	  et	  al.,	  2009).	  Besides	  RUNX2,	  ERK	  also	  activates	  RSK2	  (Dalby	  et	  al.,	  1998),	  which	  phosphorylates	  ATF4,	  a	  pro-­‐collagen	  gene	  transcriptional	  regulator	  of	  late-­‐stage	  osteoblasts	  (Yang	  et	  al.,	  2004;	  Figure	  5).	  Given	  that	  Ras	  has	  a	  direct	  role	  in	  cellular	  transformation	  and	  during	  development,	  an	  important	  question	  becomes	  which	  of	  its	  downstream	  signaling	  pathways	  are	  critical	  for	  its	  tumorigenic	  functions,	  versus	  its	  various	  developmental	  roles.	  The	  complexity	  of	  Ras	  signaling	  underscores	  the	  importance	  of	  focusing	  on	  specific	  cell	  types	  when	  studying	  the	  Ras	  effector	  pathways.	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Figure	  5.	  MAPK	  (ERK)	  pathway	  in	  osteoblast	  differentiation.	  Adapted	  from	  (Greenblatt	  et	  al.,	  2013)	  During	  early	  osteoblast	  differentiation,	  ERK	  phosphorylates	  RUNX2	  to	  increase	  its	  transcriptional	  activity	  and	  induce	  osteoblast	  differentiation.	  Later	  in	  osteoblast	  differentiation,	  ERK	  activates	  the	  kinase	  RSK2,	  which	  in	  turn	  phosphorylates	  and	  activates	  ATF4.	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PART	  III.	  MAPK	  SIGNALING	  The	  role	  of	  MAPK	  signaling	  both	  during	  embryonic	  development,	  as	  well	  as	  during	  skeletal	  differentiation	  has	  been	  actively	  investigated.	  However,	  a	  clear	  understanding	  of	  its	  effects	  in	  these	  two	  settings	  is	  still	  not	  available.	  This	  thesis	  describes	  two	  mouse	  models	  that	  allow	  us	  to	  study	  and	  further	  investigate	  the	  effects	  of	  activating	  the	  MAPK	  pathway	  during	  embryonic	  development,	  specifically	  in	  the	  skeletal	  lineage.	  	  
III.1.	  MAPK	  signaling	  during	  development	  –	  human	  syndromes	  MAPK	  signaling	  has	  been	  shown	  to	  play	  an	  important	  role	  during	  embryonic	  development,	  as	  well	  as	  during	  postnatal	  development	  in	  various	  model	  organisms,	  including	  mice,	  zebrafish	  and	  drosophila	  (Furthauer	  et	  al.,	  2004;	  Gabay	  et	  al.,	  1997).	  Particularly	  in	  zebrafish,	  FGF	  signaling	  through	  the	  MAPK	  pathway	  is	  important	  for	  early	  embryo	  patterning	  (Curran	  and	  Grainger,	  2000).	  In	  mice,	  it	  was	  shown	  that	  ERK	  signaling	  is	  active	  during	  mouse	  embryogenesis,	  and	  ERK	  phosphorylation	  can	  be	  detected	  in	  the	  neural	  crest,	  peripheral	  nervous	  system	  and	  early	  structures,	  which	  will	  later	  become	  ear,	  eye,	  heart	  and	  blood	  vessels	  (Corson	  et	  al.,	  2003).	  Other	  transgenic	  mouse	  models	  with	  mutations	  in	  the	  genes	  of	  the	  Ras/MAPK	  pathway	  further	  elucidated	  the	  essential	  role	  that	  these	  genes	  play	  during	  development	  (Galabova-­‐Kovacs	  et	  al.,	  2006;	  Johnson	  et	  al.,	  1997).	  	  In	  humans,	  the	  RASopathies,	  a	  group	  of	  developmental	  disorders	  caused	  by	  germline	  mutations	  in	  genes	  encoding	  components	  of	  the	  Ras/MAPK	  pathway	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(Figure	  6)	  clearly	  illustrates	  the	  important	  role	  of	  this	  pathway	  during	  normal	  development.	  Some	  described	  RASopathies	  are	  Noonan,	  LEOPARD,	  gingival	  fibromatosis	  1,	  neurofibromatosis	  1,	  capillary	  malformation-­‐arteriovenous	  malformation,	  Costello,	  autoimmune	  lymphoproliferative	  (ALPS),	  cardio-­‐facio-­‐cutaneous	  and	  Legius	  syndromes	  (Tidyman	  and	  Rauen,	  2009).	  These	  are	  caused	  by	  constitutive	  active	  mutations	  in	  different	  members	  of	  the	  MAPK	  pathway	  that	  result	  in	  increased	  signaling.	  	  Some	  MAPK	  pathway	  members	  are	  seem	  in	  multiple	  syndromes,	  while	  others	  appear	  highly	  syndrome	  specific	  (Figure	  6).	  	  	  
	   35	  
	  	  
	  	  
Figure	  6.	  Ras/	  MAPK	  signaling	  pathway	  and	  associated	  developmental	  
syndromes.	  Adapted	  from	  Tidyman	  and	  Rauen,	  (2009).	  The	  blue	  dotted	  lines	  indicate	  specific	  components	  of	  the	  Ras/MAPK	  pathway	  whose	  germline	  	  mutations	  in	  its	  respective	  components	  is	  associated	  with	  Noonan,	  LEOPARD,	  neurofibromatosis	  1,	  Costello,	  cardio-­‐facio-­‐cutaneous	  and	  Legius	  syndromes.	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  Although	  the	  various	  syndromes	  each	  display	  some	  unique	  symptoms,	  they	  also	  have	  some	  overlapping	  defects.	  	  Frequently	  observed	  defects	  include	  characteristic	  craniofacial	  dysmorphology,	  cardiac	  malformations,	  cutaneous,	  musculoskeletal	  and	  ocular	  abnormalities,	  neurocognitive	  impairment	  and,	  in	  some	  syndromes,	  predisposition	  to	  certain	  malignancies	  (Tidyman	  and	  Rauen,	  2009).	  	  It	  should	  be	  noted	  that	  the	  common	  germline	  mutations	  that	  result	  in	  RASopathies	  differ	  from	  the	  somatic	  mutations	  commonly	  found	  in	  cancer.	  For	  example,	  the	  V600E	  oncogenic	  mutation	  in	  B-­‐RAF	  is	  not	  seen	  in	  Cardio-­‐Facial-­‐Cutaneous	  Syndrome,	  and	  the	  most	  common	  oncogenic	  mutations	  in	  K-­‐RAS	  are	  not	  encountered	  in	  patients	  with	  Noonan	  Syndrome	  (Mercer	  et	  al.,	  2005).	  Instead,	  the	  Rasopathy	  mutations	  are	  typically	  weaker	  acting	  mutations.	  The	  most	  likely	  explanation	  is	  that	  the	  cancer	  causing	  somatic	  mutations	  are	  too	  strong	  to	  be	  compatible	  with	  embryonic	  viability	  (Tuveson	  et	  al.,	  2004).	  Interestingly,	  patients	  with	  RASopathies	  do	  have	  a	  mild	  predisposition	  to	  cancer.	  For	  example,	  Noonan	  patients	  are	  prone	  to	  develop	  cancers	  of	  the	  blood,	  more	  specifically	  myeloproliferative	  diseases,	  which	  typically	  resolve	  but	  sometimes	  develop	  into	  leukemia	  (Johannes	  et	  al.,	  1995;	  Side	  and	  Shannon,	  1997).	  	  	   Noonan	  syndrome	  Noonan	  Syndrome	  (NS)	  is	  an	  autosomal	  dominant	  disorder	  that	  affects	  1/1000	  to	  1/2500	  newborns.	  Patients	  with	  NS	  have	  specific	  craniofacial	  features,	  short	  stature,	  skeletal	  abnormalities,	  congenital	  cardiac	  abnormalities,	  neurocognitive	  delay	  and	  a	  predisposition	  to	  cancer	  (Shaw	  et	  al.,	  2007).	  	  Activating	  germline	  mutations	  in	  PTPN11	  (Tartaglia	  et	  al.,	  2001),	  KRAS	  (Schubbert	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et	  al.,	  2006),	  SOS1	  (Roberts	  et	  al.,	  2007;	  Tartaglia	  et	  al.,	  2007)	  and	  RAF1	  (Pandit	  et	  al.,	  2007;	  Razzaque	  et	  al.,	  2007)	  have	  all	  been	  linked	  to	  NS.	  PTPN11	  missense	  mutations	  are	  responsible	  for	  50%	  of	  NS	  cases.	  PTPN11	  encodes	  for	  protein	  SHP2,	  a	  non-­‐receptor	  protein	  tyrosine	  phosphatase,	  which	  contains	  an	  N-­‐terminal	  SH2	  domain,	  a	  C-­‐terminal	  SH2	  domain	  and	  catalytic	  protein	  tyrosine	  phosphatase	  (PTP)	  domain.	  The	  majority	  of	  NS-­‐causing	  mutations	  in	  PTPN11	  are	  in	  residues	  involved	  in	  the	  interaction	  between	  the	  N-­‐SH2	  and	  PTP	  domains.	  This	  interaction	  inhibits	  the	  catalytic	  function	  of	  SHP2	  and	  causes	  increased	  signaling	  down	  the	  Ras/MAPK	  pathway	  (Keilhack	  et	  al.,	  2005).	  SOS1	  missense	  mutations	  are	  responsible	  for	  12%	  of	  Noonan	  cases.	  SOS1 encodes for the SOS1 protein, a Ras-GEF, responsible for the 
conversion of Ras from the GDP-bound form to the GTP-bound form. The majority of 
SOS1 mutations are in residues responsible for stabilizing the protein in an inhibited 
conformation. They result in a gain-of-function SOS1 and a subsequent increase in the 
active form of Ras and increased Ras/MAPK pathway signaling (Roberts et al., 2007). 3-­‐5%	  of	  NS	  cases	  are	  caused	  by	  mutations	  in	  RAF1,	  which	  encodes	  a	  serine/threonine	  kinase	  that	  is	  a	  downstream	  effector	  of	  Ras.	  The	  NS	  mutations	  result	  in	  a	  gain-­‐of-­‐function	  phenotype	  for	  Ras	  (Pandit	  et	  al.,	  2007).	  KRAS	  mutations	  account	  for	  about	  2%	  of	  the	  NS	  cases.	  These	  mutations	  cause	  an	  increase	  in	  the	  GTP-­‐bound	  form	  of	  KRAS	  and	  thus	  increased	  signaling	  down	  the	  Ras/MAPK	  pathway	  either	  by	  reducing	  the	  intrinsic	  GAP	  activity	  of	  the	  KRAS	  protein	  or	  by	  affecting	  the	  interaction	  of	  KRAS	  with	  guanine	  nucleotides	  (Schubbert	  et	  al.,	  2006).	  Studying	  and	  understanding	  the	  consequences	  of	  deregulating	  the	  Ras/MAPK	  pathway	  during	  development	  using	  various	  model	  organisms	  will	  shed	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light	  on	  the	  role	  that	  this	  pathway	  plays	  during	  embryonic	  and	  postnatal	  human	  development.	  In	  the	  next	  section	  I	  will	  describe	  the	  efforts	  that	  have	  been	  done	  to	  model	  Noonan	  Syndrome	  (NS)	  using	  various	  model	  organisms.	  	  Furthermore,	  my	  thesis	  describes	  a	  novel	  mouse	  model	  for	  NS,	  which	  allows	  us	  to	  study	  in	  more	  depth	  the	  skeletal	  defects	  associated	  with	  this	  syndrome.	  	  
III.	  2.	  Modeling	  Noonan	  syndrome	  using	  animal	  models	  Previous	  efforts	  to	  model	  RASopathies	  have	  been	  carried	  out	  in	  both	  fish	  and	  mice.	  Specific	  mutations	  encountered	  in	  Noonan	  Syndrome	  have	  been	  expressed	  in	  either	  the	  germline	  or	  a	  cell	  specific	  manner	  to	  generate	  animal	  models	  that	  recapitulate	  symptoms	  of	  patients	  with	  RASopathies.	  While	  these	  models	  have	  recapitulated	  the	  cardiac	  abnormalities	  and	  cranio-­‐facial	  deformities	  of	  NS	  patients,	  they	  have	  not	  offered	  a	  good	  model	  to	  study	  the	  limb	  abnormalities	  of	  these	  patients.	  	  With	  the	  mouse	  model	  I	  have	  generated	  in	  my	  thesis	  I	  am	  specifically	  modeling	  the	  skeletal	  defects	  found	  in	  patients	  with	  NS.	  	  Furthermore,	  other	  studies	  have	  shown	  that	  treatment	  with	  MEK	  inhibitors	  exclusively	  during	  embryonic	  development	  can	  rescue	  the	  cardiac	  defects	  associated	  with	  NS.	  In	  my	  thesis,	  I	  identify	  a	  defined	  period	  during	  embryonic	  development	  when	  giving	  MEK	  inhibitors	  can	  fully	  rescue	  the	  bone	  phenotype.	  	  In	  the	  next	  section	  I	  will	  summarize	  the	  existing	  literature	  on	  some	  of	  the	  animals	  that	  have	  been	  developed	  to	  model	  the	  Noonan	  syndrome.	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Germline	  mutations	  Araki	  et	  al,	  2004	  have	  generated	  a	  mouse	  model	  for	  Noonan	  Syndrome	  containing	  a	  germline	  heterozygous	  D61G	  mutation	  in	  Ptpn11,	  one	  of	  the	  genes	  known	  to	  cause	  NS	  when	  mutated.	  Their	  model	  recapitulates	  the	  short	  stature	  and	  craniofacial	  abnormalities	  of	  NS	  patients,	  as	  well	  some	  of	  the	  heart	  defects	  seen	  in	  patients	  that	  include	  atrial	  and	  atrioventricular	  septal	  defects,	  thinning	  of	  ventricular	  wall	  and	  hypertrophy	  of	  atrioventricular	  and	  outflow	  tract	  valves	  (Araki	  et	  al.,	  2004).	  The	  same	  group	  later	  analyzed	  the	  mechanisms	  underlying	  the	  cardiac	  defects	  and	  showed	  that	  they	  are	  caused	  by	  Shp2	  expression	  specifically	  in	  the	  endorcardium,	  but	  not	  in	  the	  myocardium	  or	  neural	  crest.	  The	  D61G	  mutation	  results	  in	  an	  increased	  MAPK	  activation	  and	  affects	  the	  endocardial	  to	  mesenchymal	  transformation	  of	  endocardial	  cells	  (Araki	  et	  al.,	  2009).	  In	  another	  germline	  model,	  researchers	  have	  generated	  mice	  with	  a	  specific	  Sos	  mutation.	  These	  mice	  exhibited	  NS-­‐associated	  phenotypes,	  such	  as	  growth	  delay,	  facial	  dysmorphia,	  hematological	  and	  cardiac	  abnormalities	  (Chen	  et	  al.,	  2010)	  The	  MAPK	  pathway,	  as	  well	  as	  Rac	  and	  Stat3,	  were	  found	  to	  be	  active	  in	  the	  mutant	  hearts.	  Importantly,	  symptoms	  were	  rescued	  by	  prenatal	  administration	  of	  a	  MEK	  inhibitor,	  demonstrating	  that	  this	  signaling	  pathway	  might	  represent	  a	  promising	  therapeutic	  target	  for	  NS.	  Wu	  et	  al,	  2011,	  use	  generated	  a	  NS	  mouse	  model	  with	  a	  germline	  mutation	  in	  Raf.	  These	  mice	  had	  short	  stature,	  craniofacial	  and	  hematological	  abnormalities	  and	  these	  defects	  were	  rescued	  by	  postnatal	  treatment	  with	  MEK	  inhibitors	  (Wu	  et	  al.,	  2011b)	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Spatial	  and	  temporal	  restricted	  mutations	  A	  more	  restricted	  approach	  has	  been	  used	  by	  Nakamura	  et	  al.,	  2007,	  who	  expressed	  the	  SHP2	  protein	  with	  a	  Q79R	  mutation	  selectively	  in	  cardiomyocytes	  in	  a	  time	  restricted	  manner,	  during	  gestation	  or	  after	  birth.	  They	  saw	  that	  the	  mutation	  caused	  a	  heart	  defect	  (ventricular	  septal	  defect),	  only	  when	  expressed	  during	  embryonic	  development.	  They	  further	  showed	  that	  activation	  of	  the	  ERK	  pathway	  is	  both	  necessary	  and	  sufficient	  for	  the	  mutant	  effects	  caused	  by	  the	  Q79R	  mutation,	  since	  the	  expression	  of	  mutant	  SHP2	  in	  an	  ERK	  1/2	  null	  background	  rescued	  the	  mutant	  phenotype.	  This	  study	  suggested	  that	  ERK	  pathway	  modulation	  could	  have	  important	  implications	  for	  the	  treatment	  of	  congenital	  cardiac	  defects	  (Nakamura	  et	  al.,	  2007).	  The	  same	  group	  showed	  in	  a	  subsequent	  study	  that	  repression	  of	  pERK	  activity	  using	  a	  MAPK/ERK	  kinase	  inhibitor	  administered	  during	  embryonic	  development	  rescues	  the	  NS	  specific	  phenotypes	  caused	  by	  expression	  of	  the	  mutant	  SHP2	  protein	  specifically	  in	  neural	  crest	  cells	  (Nakamura	  et	  al.,	  2009).	  	  
III.	  3.	  MAPK	  signaling	  pathway	  in	  skeletal	  development	  In	  the	  previous	  part	  I	  have	  discussed	  how	  deregulation	  of	  the	  MAPK	  pathway	  results	  in	  developmental	  defects	  in	  various	  model	  organisms.	  The	  open	  question	  still	  remains	  what	  is	  the	  molecular	  basis	  of	  these	  defects.	  My	  thesis	  investigates	  the	  molecular	  basis	  of	  the	  skeletal	  defects	  caused	  by	  a	  constitutive	  active	  K-­‐ras	  mutation	  expressed	  either	  in	  mesenchymal	  progenitors	  and	  subsequent	  lineages,	  or	  in	  osteoblast	  precursors.	  Here	  I	  will	  summarize	  the	  literature	  to	  date	  on	  various	  studies	  investigating	  the	  effects	  of	  increased	  MAPK	  signaling	  at	  various	  stages	  of	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skeletal	  development.	  	  Increased	  signaling	  through	  the	  MAPK	  pathway	  is	  commonly	  encountered	  in	  many	  cancers	  and	  is	  usually	  correlated	  with	  increased	  and	  unrestrained	  proliferation.	  However,	  in	  the	  context	  of	  bone	  development	  the	  effects	  of	  the	  MAPK	  pathway	  on	  cell	  proliferation	  and	  differentiation	  are	  less	  clear.	  Thus,	  a	  thorough	  analysis	  of	  the	  importance	  of	  MAPK	  signaling	  pathways	  in	  osteoblasts	  and	  chondrocytes	  is	  essential	  to	  understand	  how	  bone	  mass	  is	  regulated.	  Various	  in	  vitro	  and	  in	  vivo	  studies	  suggest	  a	  key	  role	  of	  the	  MAPK	  signaling	  pathway	  in	  osteogenesis.	  However,	  the	  physiological	  role	  of	  the	  MAPK	  pathway	  in	  osteoblasts	  remains	  controversial,	  with	  some	  studies	  supporting	  a	  stimulatory	  role	  in	  osteoblast	  differentiation	  and	  others	  proposing	  that	  this	  pathway	  is	  actually	  inhibitory.	  Several	  studies	  have	  shown	  that	  the	  MAPK-­‐ERK	  pathway	  regulates	  bone	  formation	  by	  osteoblasts	  (Ge	  et	  al.,	  2007;	  Greenblatt	  et	  al.,	  2010;	  Zou	  et	  al.,	  2011).	  	  Expression	  of	  a	  dominant-­‐negative	  form	  of	  MEK1	  in	  osteoblasts	  results	  in	  low	  bone	  mineralization,	  especially	  in	  the	  clavicle	  and	  the	  calvaria	  (Ge	  et	  al.,	  2007).	  Furthermore,	  mice	  with	  a	  germline	  deletion	  of	  Erk1	  and	  also	  a	  conditional	  deletion	  of	  Erk2	  in	  the	  limb	  mesenchyme	  display	  reduced	  bone	  mineralization,	  proving	  the	  necessity	  of	  ERK	  activity	  for	  proper	  osteoblast	  functioning	  (Matsushita	  et	  al.,	  2009).	  	  	  
In	  vivo	  deletion	  of	  NF1	  (a	  Ras	  inhibitor)	  in	  late	  stage	  osteoblasts,	  using	  the	  Ocn	  promoter	  to	  express	  Cre	  recombinase,	  shows	  increased	  RSK2	  phosphorylation	  and	  ATF4	  expression,	  and	  an	  increase	  in	  bone	  mass	  (Elefteriou	  et	  al.,	  2006).	  Treatment	  with	  ERK	  inhibitors	  rescued	  these	  defects,	  supporting	  the	  idea	  that	  ERK	  is	  critical	  for	  regulating	  RSK2	  and	  ATF4	  expression	  and	  its	  activation	  leads	  to	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increased	  collagen	  synthesis	  and	  bone	  matrix	  deposition.	  Surprisingly,	  deleting	  NF1	  in	  osteochondral	  progenitors,	  using	  the	  Col2	  promoter	  to	  express	  Cre,	  causes	  reduced	  bone	  mass	  and	  impaired	  osteoblast	  differentiation	  (Wang	  et	  al.,	  2011;	  Wu	  et	  al.,	  2011a).	  In	  vitro	  studies	  further	  showed	  that	  osteoprogenitors	  collected	  from	  NF1	  deficient	  mice	  exhibited	  lower	  induction	  of	  osteoblast	  differentiation	  (Kolanczyk	  et	  al.,	  2007;	  Yu	  et	  al.,	  2005).	  The	  contradictory	  results	  observed	  in	  these	  two	  NF1-­‐deficient	  models	  argue	  that	  NF1	  and	  subsequently,	  the	  MAPK	  pathway	  exert	  different	  effects	  at	  different	  stages	  of	  osteoblast	  differentiation.	  Additionally,	  the	  data	  suggests	  that	  ectopic	  ERK	  activation	  has	  different	  effects	  when	  targeting	  Runx2	  (in	  early	  differentiation)	  versus	  RSK2/	  ATF4	  (in	  late	  differentiation).	  In	  conclusion,	  Ras-­‐MAPK	  signaling	  is	  essential	  for	  the	  commitment	  of	  multipotent	  progenitors	  to	  an	  osteoblast	  cell	  fate,	  but	  it	  can	  antagonize	  further	  osteogenic	  differentiation	  (Ge	  et	  al.,	  2007;	  Nakamura	  et	  al.,	  2009;	  Schindeler	  and	  Little,	  2006).	  	  MAPK	  pathway	  also	  plays	  an	  important	  role	  in	  chondrocyte	  differentiation	  during	  skeletal	  development	  (Hill	  et	  al.,	  2005;	  Rodda	  and	  McMahon,	  2006).	  In	  other	  differentiating	  systems,	  such	  as	  muscle	  and	  fat,	  ERK-­‐MAPK	  signaling	  has	  been	  shown	  to	  control	  stem	  cells/progenitor	  lineage	  decisions.	  	  In	  fat,	  ERK1	  phosphorylates	  PPARγ	  and	  inhibits	  its	  activity,	  blocking	  adipogenesis	  as	  a	  result	  (Adams	  et	  al.,	  1997).	  In	  X.	  laevis	  muscle	  differentiation,	  MAPK	  increases	  the	  levels	  of	  XMyoD,	  a	  master	  regulator	  of	  muscle	  differentiation	  (Zetser	  et	  al.,	  2001).	  Consequently,	  in	  the	  context	  of	  chondrogenesis,	  MAPK	  pathway	  is	  also	  believed	  to	  play	  a	  role	  in	  controlling	  progenitor/stem	  cell	  lineage	  decisions.	  Interestingly,	  mice	  with	  the	  MAPK	  pathway	  activated	  selectively	  in	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osteochondral	  progenitors,	  either	  by	  a	  constitutive	  active	  mutation	  in	  MEK1	  or	  by	  constitutively	  active	  FGF3,	  display	  chondrodysplasia	  (short	  limbs).	  Activating	  the	  MAPK	  pathway	  in	  osteochondral	  progenitors	  leads	  to	  an	  increase	  in	  the	  levels	  of	  Sox9,	  a	  master	  regulator	  of	  chondrocyte	  differentiation,	  which	  keeps	  chondrocytes	  in	  a	  pre-­‐hypertrophic	  state.	  As	  a	  result,	  the	  limbs	  are	  short	  due	  to	  a	  reduction	  of	  the	  hypertrophic	  zone	  (Murakami	  et	  al.,	  2000).	  In	  these	  mice,	  the	  chondrocyte	  hypertrophy	  is	  inhibited,	  but	  interestingly	  there	  is	  no	  effect	  on	  chondrocyte	  proliferation	  (Murakami	  et	  al.,	  2004;	  Murakami	  et	  al.,	  2000).	  Furthermore,	  mice	  with	  a	  deletion	  of	  Erk1	  and	  Erk2	  in	  the	  limb	  mesenchyme	  cannot	  clear	  hypertrophic	  chondrocytes	  (Matsushita	  et	  al.,	  2009),	  suggesting	  that	  MAPK-­‐ERK	  is	  a	  fundamental	  pathway	  for	  the	  regulation	  of	  Runx2	  activity	  in	  chondrocytes.	  
In	  vitro,	  increased	  activity	  of	  the	  MEK-­‐ERK	  cascade	  has	  been	  reported	  to	  be	  a	  positive	  regulator	  of	  cartilage	  markers	  in	  cultured	  costal	  chondrocytes	  (Murakami	  et	  al.,	  2000),	  but	  a	  negative	  regulator	  of	  cartilage	  markers	  in	  the	  embryonic	  limb	  mesenchyme	  (Bobick	  and	  Kulyk,	  2004).	  Furthermore,	  other	  studies	  have	  shown	  that	  the	  MEK/ERK	  pathway	  functions	  as	  a	  negative	  regulator	  of	  chondrocyte	  differentiation	  in	  micromass	  cultures	  prepared	  from	  frontonasal	  mesenchyme	  of	  stage	  24/25	  chick	  embryos	  (Bobick	  and	  Kulyk,	  2006).	  In	  contrast,	  the	  MEK/ERK	  cascade	  acts	  as	  a	  positive	  regulator	  of	  chondrogenesis	  in	  the	  mesenchyme	  of	  the	  stage	  24/25	  mandibular	  arch,	  as	  well	  as	  in	  the	  frontonasal	  mesenchyme	  of	  the	  stage	  28/29	  embryos.	  	  In	  conclusion,	  studies	  from	  the	  literature	  suggest	  that	  MAPK	  pathway	  may	  either	  activate	  or	  repress	  chondrocyte	  and	  osteoblast	  development	  depending	  on	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the	  stage	  at	  which	  it	  is	  activated	  in	  the	  osteo-­‐chondrogenic	  differentiation	  program.	  Specifically,	  it	  seems	  likely	  that	  uncommitted	  multipotent	  progenitors,	  committed	  osteoprogenitors,	  mature	  osteoblasts,	  and	  cells	  derived	  from	  other	  lineages	  respond	  differently	  to	  identical	  stimuli,	  thereby	  explaining	  some	  of	  the	  apparent	  conflict	  in	  the	  literature.	  Based	  on	  the	  two	  mouse	  models	  I	  have	  generated,	  in	  which	  constitutive	  K-­‐ras	  is	  expressed	  in	  a	  spatial	  and	  temporal	  specific	  manner	  during	  skeletal	  development,	  this	  thesis	  addresses	  two	  issues.	  The	  first	  is	  the	  nature	  of	  the	  skeletal	  defects	  encountered	  in	  patients	  with	  NS.	  This	  is	  important	  since	  limited	  information	  exists	  in	  the	  literature	  regarding	  the	  defects	  in	  bone	  mineralization	  seen	  in	  NS	  (Choudhry	  et	  al.,	  2012).	  The	  second	  is	  the	  effect	  that	  Ras/MAPK	  activation	  has	  on	  osteoblast	  and	  chondrocyte	  differentiation,	  and	  how	  this	  varies	  depending	  on	  the	  developmental	  stage	  at	  which	  K-­‐ras	  mutation	  is	  activated.	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ABSTRACT	  	  	   Activating	  germline	  K-­‐ras	  mutations	  cause	  Noonan	  syndrome	  (NS),	  which	  is	  characterized	  by	  several	  developmental	  deficits	  including	  cardiac	  defects,	  cognitive	  delays	  and	  skeletal	  abnormalities.	  NS	  patients	  have	  increased	  signaling	  through	  the	  MAPK	  pathway.	  To	  model	  NS	  skeletal	  defects	  and	  understand	  the	  effect	  of	  hyperactive	  K-­‐ras	  signaling	  on	  normal	  limb	  development,	  we	  generated	  a	  mouse	  model	  in	  which	  activated	  K-­‐rasG12D	  was	  expressed	  specifically	  in	  mesenchymal	  progenitors	  of	  the	  limb	  bud.	  These	  mice	  display	  short,	  abnormally	  mineralized	  long	  bones	  that	  phenocopy	  those	  of	  NS	  patients.	  	  This	  defect	  was	  first	  apparent	  at	  E14.5,	  and	  was	  characterized	  by	  a	  delay	  in	  bone	  collar	  formation.	  	  Coincident	  mutation	  of	  p53	  had	  no	  effect	  on	  the	  K-­‐rasG12D	  induced	  bone	  defect,	  arguing	  that	  it	  is	  does	  not	  result	  from	  senescence	  or	  apoptosis.	  	  Instead,	  our	  data	  indicate	  a	  defect	  in	  the	  appearance	  and	  localization	  of	  committed	  osteoblasts.	  	  Most	  importantly,	  we	  found	  that	  in	  utero	  delivery	  of	  a	  MEK	  inhibitor	  between	  E10.5	  and	  E14.5	  is	  sufficient	  to	  completely	  suppress	  the	  ability	  of	  activated	  K-­‐ras	  to	  induce	  NS-­‐like	  long	  bone	  defects	  in	  embryogenesis.	  	  Taken	  together,	  our	  data	  define	  a	  critical	  point	  in	  mid-­‐gestation	  in	  which	  elevated	  MAPK	  signaling	  impairs	  bone	  collar	  formation	  and	  yield	  NS-­‐like	  limb	  defects.	  	  	  Moreover,	  they	  offer	  insight	  into	  possible	  therapeutic	  strategies	  for	  skeletal	  defects	  in	  patients	  with	  Noonan	  Syndrome.	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INTRODUCTION	  	  	   Noonan	  Syndrome	  (NS)	  is	  an	  autosomal	  dominant	  genetic	  disease	  that	  appears	  with	  a	  frequency	  of	  1/1000-­‐1/2500	  in	  newborns	  (Allanson,	  1987;	  Noonan,	  1994);	  (Nora	  et	  al.,	  1974).	  	  	  It	  is	  one	  of	  a	  group	  of	  developmental	  disorders,	  called	  RASopathies,	  which	  result	  from	  germline	  mutations	  in	  components	  of	  the	  RAS/MAPK	  pathway	  that	  increase	  signaling	  (Tidyman	  and	  Rauen,	  2009).	  	  	  Mutations	  in	  PTPN11,	  SOS1,	  RAF1	  and	  KRAS	  have	  all	  been	  identified	  in	  NS	  (Tidyman	  and	  Rauen,	  2009).	  	  2%	  of	  NS	  patients	  have	  activating	  KRAS	  mutations	  (Schubbert	  et	  al.,	  2006;	  Zenker	  et	  al.,	  2007).	  KRAS	  encodes	  a	  small	  GTPase	  protein	  that	  functions	  as	  molecular	  switch	  to	  regulate	  cell	  proliferation,	  differentiation	  and	  apoptosis	  by	  propagating	  signals	  from	  the	  tyrosine	  kinase	  membrane	  receptors	  to	  various	  intracellular	  effector	  cascades	  including	  the	  MAPK	  pathway.	  	  NS	  is	  characterized	  by	  defects	  in	  various	  mesenchymal	  tissues	  including	  cardiovascular	  abnormalities,	  short	  stature,	  craniofacial	  dysmorphia	  and	  skeletal	  defects	  (Nora	  et	  al.,	  1974).	  	  Mouse	  models	  bearing	  germline	  mutations	  in	  PTPN11,	  
SOS1	  and	  RAF1	  have	  been	  developed,	  and	  these	  display	  the	  spectrum	  of	  gross	  anatomical	  defects	  characteristic	  of	  NS	  (Araki	  et	  al.,	  2009;	  Nakamura	  et	  al.,	  2007;	  Wu	  et	  al.,	  2011).	  	  	  Analysis	  of	  these	  models,	  as	  well	  as	  an	  endocardium-­‐specific	  
PTPN11	  mutant	  mouse	  strain,	  has	  yielded	  key	  insight	  into	  the	  underlying	  basis	  of	  the	  cardiac	  abnormalities	  that	  are	  the	  primary	  cause	  of	  death	  of	  NS	  patients	  (Araki	  et	  al.,	  2004;	  Araki	  et	  al.,	  2009;	  Nakamura	  et	  al.,	  2007).	  	  Other	  studies	  have	  investigated	  the	  nature	  of	  the	  craniofacial	  defects	  (Nakamura	  et	  al.,	  2009;	  Wu	  et	  al.,	  2011).	  	  Most	  importantly,	  analysis	  of	  these	  NS	  mouse	  models	  showed	  that	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continuous	  prenatal	  or	  postnatal	  treatment	  with	  MEK	  inhibitors	  is	  sufficient	  to	  rescue	  both	  the	  cardiac	  and	  craniofacial	  defects	  (Nakamura	  et	  al.,	  2009;	  Wu	  et	  al.,	  2011).	  	  Given	  these	  findings,	  MEK	  inhibitors	  and	  other	  Ras	  pathway	  modulators	  are	  being	  evaluated	  for	  treatment	  of	  NS	  patients	  (Rauen	  et	  al.,	  2011).	  	  	  The	  skeletal	  deformities	  represent	  a	  major	  challenge	  in	  the	  life	  of	  NS	  patients,	  but	  their	  etiology	  is	  not	  well	  understood.	  	  Dual-­‐energy	  X-­‐ray	  absorptiometry	  has	  shown	  that	  bone	  mineralization	  is	  decreased	  in	  NS	  children	  (Choudhry	  et	  al.,	  2012)	  and	  urine	  analysis	  suggests	  that	  this	  reflects	  increased	  bone	  resorption	  (Stevenson	  et	  al.,	  2011).	  	  However,	  no	  biopsies	  or	  histological	  sections	  of	  NS	  patients’	  bones	  have	  been	  reported.	  	  Similarly,	  the	  skeletal	  defects	  of	  the	  PTPN11,	  SOS1	  and	  
RAF1mutant	  NS	  mouse	  models	  have	  not	  been	  probed.	  At	  a	  broader	  level,	  the	  effect	  of	  constitutive	  MAPK	  pathway	  activation	  on	  osteoblast	  and	  chondrocyte	  differentiation	  is	  an	  area	  of	  active	  investigation	  (Nakamura	  et	  al.,	  2009;	  Schindeler	  and	  Little,	  2006).	  	  Indeed,	  the	  function	  of	  Ras/MAPK	  signaling	  in	  osteogenesis	  is	  controversial,	  as	  some	  studies	  suggest	  it	  promotes	  osteoblast	  differentiation	  while	  others	  support	  a	  suppressive	  role	  (Schindeler	  and	  Little,	  2006).	  	  In	  this	  study,	  we	  have	  generated	  a	  mouse	  strain	  in	  which	  activated	  K-­‐rasG12D	  is	  expressed	  in	  the	  mesenchyme	  of	  the	  developing	  embryo	  to	  yield	  hyperactivation	  of	  the	  Ras/MAPK	  pathway.	  	  These	  animals	  display	  severe	  skeletal	  abnormalities	  that	  resemble	  those	  occurring	  in	  NS	  patients.	  	  In	  particular,	  these	  animals	  have	  profoundly	  shorter	  and	  thicker	  long	  bones.	  	  Analysis	  of	  the	  timed	  pregnancies	  shows	  that	  these	  defects	  are	  first	  apparent	  around	  embryonic	  day	  E14.5,	  as	  evidenced	  by	  defective	  formation	  of	  the	  bone	  collar.	  	  Finally,	  we	  show	  that	  MEK	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K-­rasG12D	  expression	  in	  mesenchymal	  lineage	  results	  in	  skeletal	  defects	  that	  
are	  reminiscent	  of	  those	  seen	  in	  Noonan	  Syndrome	  patients.	  Our	  goal	  was	  to	  generate	  a	  mouse	  model	  that	  had	  hyperactivation	  of	  Ras/MAPK	  signaling	  within	  the	  mesenchymal	  progenitors	  of	  the	  developing	  embryo.	  	  To	  achieve	  this,	  we	  used	  a	  knock-­‐in	  mouse	  strain	  (Supplemental	  Fig	  1)	  in	  which	  expression	  of	  an	  activating	  K-­ras	  allele,	  K-­rasG12D,	  is	  controlled	  by	  the	  CRE	  recombinase	  (Tuveson	  et	  al.,	  2004).	  	  Germline	  K-­rasG12D	  mutation	  is	  not	  seen	  in	  NS	  patients	  presumably,	  extrapolating	  from	  mouse	  studies	  (Tuveson	  et	  al.,	  2004),	  because	  it	  causes	  embryonic	  lethality.	  	  However,	  we	  chose	  it	  for	  this	  study	  because	  it	  yields	  potent	  Ras/MAPK	  signaling.	  	  We	  crossed	  the	  conditional	  inducible	  K-­rasG12D	  mouse	  with	  the	  Prx1-­Cre	  transgenic	  (Harada	  and	  Rodan,	  2003;	  Martin	  and	  Olson,	  2000),	  which	  expresses	  CRE	  in	  mesenchymal	  progenitors	  of	  the	  limb	  bud	  from	  embryonic	  day	  9.5.	  	  Using	  reporter	  mice,	  we	  have	  previously	  confirmed	  that	  Prx1-­
Cre	  yields	  efficient	  recombination	  in	  bone,	  cartilage,	  skeletal	  muscle	  and	  fat	  lineages	  (Calo	  et	  al.,	  2010).	  	  	  We	  found	  that	  Prx1-­Cre;K-­rasG12D	  mutants	  were	  present	  at	  the	  expected	  Mendelian	  ratio	  at	  E18.5	  (data	  not	  shown).	  	  However,	  these	  mutants	  failed	  to	  thrive.	  	  The	  majority	  died	  soon	  after	  birth,	  but	  rare	  mutants	  lived	  up	  to,	  but	  never	  beyond,	  three	  weeks	  of	  age.	  	  Notably,	  the	  Prx1-­Cre;K-­rasG12D	  mutants	  were	  all	  significantly	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smaller	  than	  their	  wild	  type	  littermates,	  as	  illustrated	  with	  representative	  P18	  littermates	  (Figure	  1A).	  	  Most	  importantly,	  these	  animals	  had	  profound	  skeletal	  abnormalities.	  	  In	  particular,	  the	  front	  and	  hind	  limbs	  were	  greatly	  shortened,	  and	  the	  fingers	  and	  toes	  were	  clubbed	  (Figure	  1B).	  	  These	  anatomical	  defects	  are	  reminiscent	  of	  those	  occurring	  in	  human	  NS	  patients.	  	  Additionally,	  we	  found	  that	  the	  hind	  limbs	  of	  Prx1-­Cre;K-­rasG12D	  mutants	  were	  paralyzed,	  impeding	  their	  ability	  to	  feed	  from	  their	  mothers	  and	  likely	  explaining	  their	  failure	  to	  thrive.	  	  	   We	  conducted	  H&E	  staining	  of	  limb	  sections	  taken	  from	  neonatal	  animals,	  and	  found	  that	  the	  limbs	  of	  Prx1-­Cre;K-­rasG12D	  mutants	  were	  consistently	  shorter	  and	  thicker	  than	  those	  of	  wildtype	  controls	  (see	  Figure	  1C,	  D).	  	  The	  mutant	  limbs	  had	  abnormal	  mineralization	  in	  both	  the	  primary	  and	  the	  secondary	  ossification	  centers,	  and	  there	  was	  a	  dramatic	  increase	  in	  the	  density	  of	  the	  trabecular	  bone.	  	  Indeed,	  the	  bone	  marrow	  space	  was	  almost	  completely	  absent	  in	  Prx1-­Cre;K-­rasG12D	  mutants.	  	  Additionally,	  cartilage	  defects	  were	  clearly	  apparent.	  	  The	  growth	  plates	  of	  the	  long	  bones	  were	  highly	  disorganized	  (Figure	  1C)	  and	  higher	  magnification	  showed	  that	  the	  layer	  of	  hypertrophic	  chondrocytes	  was	  much	  thinner	  in	  the	  mutants	  than	  in	  littermate	  controls	  (Figure	  1D).	  	  Notably,	  these	  cartilage	  defects	  resembled	  those	  arising	  in	  mice	  with	  activating	  MEK1	  mutations	  (Ge	  et	  al.,	  2007),	  suggesting	  that	  the	  bone	  defects	  reflect	  hyperactivation	  of	  the	  MAPK	  pathway;	  a	  conclusion	  we	  validate	  below.	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Figure	  1.	  Expression	  of	  K-­rasG12D	  in	  mesenchymal	  progenitors	  causes	  Noonan-­
like	  skeletal	  defects.	  (A)	  Representative	  18-­‐days	  old	  Prx1-­Cre;K-­rasG12D	  neonates	  are	  smaller	  than	  their	  wildtype	  littermates	  and	  (A,B)	  their	  front	  and	  hind	  limbs	  are	  greatly	  shortened	  and	  have	  clubbed	  feet.	  (C).	  H&E	  staining	  of	  femurs	  sections	  from	  P18	  neonates	  shows	  that	  the	  mutant	  femur	  is	  shorter	  and	  thicker	  and	  it	  has	  increased	  mineralization	  of	  the	  trabecular	  region.	  This,	  and	  (D)	  higher	  magnification	  shows	  that	  the	  mutant	  growth	  plate	  is	  disorganized	  and	  layer	  of	  hypertrophic	  chondrocytes	  is	  reduced.	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  We	  also	  conducted	  a	  careful	  analysis	  of	  other	  tissues	  within	  Prx1-­Cre;K-­rasG12D	  mutants.	  We	  observed	  no	  detectable	  craniofacial	  abnormalities	  (even	  though	  the	  heads	  appeared	  slightly	  smaller)	  and	  no	  cardiac	  defects	  (data	  not	  shown).	  	  This	  is	  entirely	  consistent	  with	  the	  fact	  that	  Prx-­cre	  is	  poorly	  expressed	  in	  the	  bones	  of	  the	  head	  and	  in	  cardiac	  tissue	  (Martin	  and	  Olson,	  2000).	  	  We	  confirmed	  that	  the	  conditional	  K-­rasG12D	  allele	  was	  efficiently	  recombined	  in	  all	  of	  the	  known	  Prx-­Cre	  expressing	  tissues	  including	  the	  long	  bones,	  skeletal	  muscle	  and	  adipose	  tissue	  but	  found	  that	  the	  resulting	  K-­‐rasG12D	  expression	  yielded	  developmental	  abnormalities	  only	  in	  the	  bone	  (Figure	  1	  and	  data	  not	  shown).	  	  This	  striking	  specificity	  for	  bone,	  but	  not	  muscle	  or	  fat,	  defects	  recapitulates	  that	  seen	  in	  human	  NS	  patients	  with	  germline	  RAS/MAPK	  pathway	  mutations.	  	  	  	  To	  confirm	  the	  skeletal	  defect	  results	  solely	  from	  the	  expression	  of	  K-­‐rasG12D	  expression	  in	  bone	  and	  cartilage,	  we	  also	  crossed	  the	  conditional	  K-­rasG12D	  allele	  with	  the	  Col2-­Cre	  transgenic	  mice.	  	  This	  induces	  Cre	  expression	  to	  the	  Col2-­‐positive	  osteochondral	  progenitors,	  which	  give	  rise	  to	  both	  chondrocytes	  and	  osteoblasts	  in	  the	  developing	  bone.	  	  As	  anticipated,	  these	  animals	  displayed	  skeletal	  defects	  similar	  to	  those	  of	  the	  Prx1-­Cre;K-­rasG12D	  mutants	  including	  shorter	  and	  thicker	  long	  bones	  with	  increased	  trabecular	  and	  cortical	  bone	  mineralization	  and	  aberrant	  growth	  plates	  (Supplemental	  Figure	  2).	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The	  skeletal	  defects	  in	  Prx1-­Cre,	  K-­rasG12D	  mice	  reflect	  a	  defect	  in	  bone	  collar	  
development	  at	  E14.5.	  	  To	  establish	  the	  etiology	  of	  the	  skeletal	  defects	  resulting	  from	  K-­‐rasG12D	  expression,	  we	  used	  timed	  pregnancies	  to	  compare	  skeletal	  development	  in	  Prx1-­
Cre;K-­rasG12D	  mutants	  with	  those	  of	  wildtype	  controls	  at	  various	  stages	  of	  embryonic	  development.	  	  Initially,	  we	  examined	  skeletons	  of	  E18.5	  embryos	  using	  whole	  mount	  staining	  with	  Alizarin	  Red,	  which	  detects	  calcium	  deposits	  within	  mineralized	  bone,	  and	  Alcian	  Blue,	  which	  detects	  the	  cartilage	  matrix	  (Figure	  2A).	  As	  with	  the	  neonatal	  mutant	  phenotypes,	  the	  Prx1-­Cre;K-­rasG12D	  E18.5	  embryos	  clearly	  displayed	  major	  skeletal	  abnormalities	  of	  which	  the	  most	  striking	  was	  the	  shortening	  and	  thickening	  of	  both	  front	  and	  hind	  limbs	  (Figure	  2A	  and	  B).	  	  We	  also	  conducted	  Alizarin	  Red	  staining	  of	  histological	  sections	  from	  E18.5	  limbs	  (Figure	  2C).	  	  Again,	  we	  found	  that	  the	  site	  of	  mineralization	  was	  abnormal	  and	  the	  level	  of	  trabecular	  and	  cortical	  bone	  was	  greatly	  increased	  (Figure	  2C).	  	  The	  defective	  nature	  of	  long	  bone	  differentiation	  was	  further	  illuminated	  by	  H&E	  staining	  of	  sections,	  which	  revealed	  both	  the	  abnormal	  pattern	  of	  mineralization	  and	  the	  presence	  of	  atypical	  growth	  plates	  within	  the	  greatly	  shortened	  and	  thickened	  bones	  (Figure	  2D).	  	  	  We	  examined	  successively	  earlier	  development	  stages	  to	  determine	  when	  these	  defects	  arose.	  	  At	  E16.5,	  we	  observed	  a	  similar	  aberrant	  bone	  morphology	  that	  included	  both	  shortened	  and	  thickened	  long	  bones	  (data	  not	  shown).	  	  Our	  analysis	  traced	  the	  earliest	  morphological	  indication	  of	  bone	  abnormalities	  to	  E14.5	  (Figure	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2D).	  	  At	  this	  stage,	  the	  cartilage	  template	  of	  the	  developing	  long	  bones	  was	  the	  appropriate	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Figure	  2.	  Defects	  in	  Prx1-­Cre;	  K-­rasG12D	  mutants	  appear	  early	  during	  
embryonic	  development.	  (A,	  B)	  Whole	  mount	  skeletal	  staining	  with	  Alizarin	  Red	  (staining	  bone)	  and	  Alcian	  Blue	  (staining	  cartilage)	  of	  E18.5	  embryos	  show	  that	  mutants	  have	  aberrant	  skeletal	  development	  and	  that	  the	  mutant	  limbs	  are	  much	  smaller	  than	  wildtype	  controls.	  (C)	  Alizarin	  Red	  staining	  of	  E18.5	  humerus	  sections	  shows	  an	  increased	  level	  of	  trabecular	  bone	  in	  the	  mutants.	  (D)	  H&E	  staining	  of	  sections	  from	  representative	  E18.5	  and	  E14.5	  embryo	  limbs	  shows	  defects	  at	  all	  stages.	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  size	  in	  Prx1-­Cre;K-­rasG12D	  mutants	  and	  the	  perichondrium	  also	  appeared	  grossly	  normal.	  	  However,	  while	  we	  consistently	  detected	  both	  bone	  collar	  formation	  and	  the	  invasion	  of	  osteoblasts	  into	  the	  center	  of	  the	  bone	  in	  wildtype	  E14.5	  embryos	  (n	  =	  5/5)	  both	  processes	  were	  completely	  absent	  in	  the	  Prx1-­Cre;K-­rasG12D	  E14.5	  (n	  =	  5/5)	  littermates	  (Figure	  2D).	  	  Since	  these	  are	  observed	  in	  E16.5	  Prx1-­Cre;K-­rasG12D	  embryos,	  we	  conclude	  that	  hyperactivation	  of	  K-­‐ras	  signaling	  acts	  to	  delay	  bone	  differentiation	  at	  this	  critical	  developmental	  stage.	  	  	  	   It	  is	  well	  established	  that	  the	  activated	  K-­‐ras	  can	  induce	  senescence	  and/or	  apoptosis	  in	  vitro	  or	  in	  vivo	  in	  a	  p53	  dependent	  manner.	  	  We	  hypothesized	  that	  these	  events	  could	  be	  responsible	  for	  the	  disrupted	  bone	  development	  in	  our	  Prx1-­Cre;K-­
rasG12D	  mutants.	  	  To	  test	  this	  possibility,	  we	  crossed	  a	  conditional	  p53	  mutant	  allele	  into	  our	  Prx1-­Cre;K-­rasG12D	  model.	  Remarkably,	  we	  found	  that	  p53	  loss	  did	  not	  alter	  the	  bone	  phenotype	  of	  Prx1-­Cre;K-­rasG12D	  embryos	  (data	  not	  shown),	  arguing	  that	  the	  defect	  is	  unlikely	  to	  result	  from	  either	  programmed	  cell	  death	  or	  senescence.	  	  These	  findings	  suggest	  that	  activated	  K-­‐ras	  has	  a	  more	  direct	  effect	  on	  the	  differentiation	  process.	  	  To	  address	  this	  possibility,	  we	  examined	  humerus	  sections	  from	  E16.5	  and	  E14.5	  embryos	  by	  in	  situ	  hybridization	  (ISH)	  for	  classic	  bone	  and	  cartilage	  markers.	  	  Specifically,	  we	  stained	  for	  Col2,	  a	  marker	  of	  osteochondral	  progenitors	  and	  also	  some	  adult	  chondrocytes,	  and	  Col1,	  a	  marker	  of	  committed	  osteoblasts.	  Col2	  staining	  was	  observed	  in	  the	  epiphyses	  of	  Prx1-­Cre;K-­rasG12D	  mutant	  bones	  at	  both	  E16.5	  and	  E14.5	  and,	  despite	  the	  aberrant	  bone	  morphology,	  the	  pattern	  closely	  resembled	  that	  of	  wildtype	  controls	  (Figure	  3A	  and	  B).	  	  In	  
	   69	  
contrast,	  Col1	  staining	  differed	  greatly	  between	  mutants	  and	  controls.	  	  At	  E16.5,	  Col1	  was	  detected	  at	  significant	  levels	  in	  both	  genotypes,	  confirming	  the	  presence	  of	  committed	  osteoblasts,	  but	  the	  locations	  were	  completely	  different	  (Figure	  3A).	  	  Specifically,	  Col1	  staining	  was	  detected	  along	  the	  length	  of	  the	  bone	  shaft	  and	  the	  internal	  region	  where	  trabecular	  bone	  is	  formed	  in	  wildtype	  limbs,	  but	  it	  was	  largely	  concentrated	  outside	  of	  the	  developing	  bone	  structure	  in	  the	  mutants.	  	  Furthermore,	  at	  E14.5,	  we	  found	  that	  Col1	  staining	  was	  restricted	  to	  the	  bone	  collar	  in	  wildtypes	  but	  was	  completely	  absent	  in	  Prx1-­Cre;K-­rasG12D	  mutant	  long	  bones.	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Figure	  3.	  	  In	  situ	  hybridization	  for	  bone	  and	  cartilage	  markers	  on	  E16.5	  and	  
E14.5	  limb	  sections.	  (A)	  ISH	  for	  Col1	  and	  Col2	  in	  E16.5	  embryos.	  (B).	  ISH	  for	  Col2	  and	  Col1	  in	  E14.5	  embryos	  (staining	  is	  described	  in	  more	  detail	  in	  the	  text).	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Taken	  together,	  these	  findings	  argue	  that	  hyperactivation	  of	  K-­‐rasG12D	  in	  the	  limb	  mesenchymal	  progenitors	  does	  not	  prevent	  the	  formation,	  or	  appropriate	  localization,	  of	  the	  Col2-­‐positive	  osteochondral	  progenitors	  or	  committed	  chondrocytes.	  	  Instead,	  K-­‐rasG12D	  significantly	  delays	  the	  timing	  of	  appearance	  of	  the	  Col1-­‐positive,	  osteoblastic	  lineages	  and	  thus	  formation	  of	  the	  bone	  collar.	  	  These	  Col1-­‐positive	  cells	  eventually	  arise	  but	  they	  accumulate	  in	  an	  aberrant	  location	  surrounding,	  rather	  than	  inside,	  the	  bone.	  	  This	  has	  the	  potential	  to	  explain	  the	  observed	  deposition	  of	  bone	  in	  the	  lateral	  rather	  than	  the	  longitudinal	  axis,	  which	  results	  in	  thicker	  but	  shorter	  bones.	  	  	  	  
Administration	  of	  MEK	  inhibitor	  during	  E10.5	  to	  E14.5	  is	  sufficient	  to	  rescue	  
the	  Noonan	  Syndrome-­like	  bone	  defect	  in	  Prx1-­Cre;	  K-­rasG12D	  mutants.	  	  There	  is	  considerable	  evidence	  to	  indicate	  that	  the	  defects	  in	  RASopathies,	  including	  NS,	  result	  from	  deregulation	  of	  MAPK	  signaling.	  	  Thus,	  we	  screened	  our	  K-­‐rasG12D	  mutant	  long	  bones	  for	  evidence	  of	  MAPK	  activation	  by	  conducting	  IHC	  for	  phospho-­‐MEK	  (pMEK),	  the	  active	  form	  of	  MEK.	  	  At	  E14.5,	  we	  detected	  elevated	  expression	  of	  pMEK	  in	  the	  nuclei	  of	  the	  chondrocytes	  in	  Prx1-­Cre;K-­rasG12D	  mutants	  versus	  wildtype	  littermates	  (Figure	  4A).	  	  Thus,	  the	  MAPK	  pathway	  is	  hyperactivated	  at	  the	  timepoint	  we	  identified	  as	  being	  critical	  in	  the	  development	  of	  the	  NS-­‐like	  mutant	  bone	  phenotype.	  	  Given	  this	  finding,	  we	  wanted	  to	  determine	  whether	  inhibition	  of	  MAPK	  signaling	  could	  suppress	  this	  bone	  development	  defect.	  	  For	  this,	  we	  used	  the	  ATP-­‐noncompetitive	  MEK	  inhibitor	  PD0325901	  (Barrett	  et	  al.,	  2008).	  	  This	  drug	  (at	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Figure	  4.	  MEK	  inhibitor	  treatment	  during	  embryonic	  development	  rescues	  the	  
bone	  phenotypes	  in	  Prx1-­Cre;K-­rasG12D	  mutants.	  (A)	  IHC	  for	  pMEK	  at	  E14.5	  shows	  that	  there	  is	  increased	  pMEK	  expression	  in	  the	  mutant.	  (B)	  MEK	  inhibitor	  treatment	  strategy	  described	  in	  more	  detail	  in	  text.	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  5mg/kg	  body	  weight),	  or	  vehicle	  control,	  was	  injected	  into	  the	  peritoneal	  cavity	  of	  pregnant	  mothers	  for	  various	  time	  periods.	  	  Initially,	  we	  began	  treatment	  at	  E10.5	  and	  continued	  daily	  until	  E17.5	  to	  essentially	  encompass	  the	  full	  time	  period	  of	  K-­‐rasG12D	  activation.	  	  The	  females	  (n=6	  for	  drug	  and	  4	  for	  vehicle	  control)	  were	  sacrificed	  at	  E18.5	  and	  the	  limbs	  of	  the	  resulting	  Prx1-­Cre;	  K-­rasG12D	  mutant	  embryos	  (n=4	  for	  drug	  and	  3	  for	  vehicle	  control)	  were	  compared	  to	  those	  of	  littermate	  controls	  (n=4	  for	  drug	  and	  3	  for	  vehicle	  control)	  by	  sectioning	  and	  H&E	  analysis.	  	  Importantly,	  we	  saw	  no	  detectable	  difference	  in	  the	  long	  bones	  of	  wildtype	  pups	  treated	  with	  drug	  versus	  vehicle	  control	  (Figure	  4B	  and	  data	  not	  shown),	  indicating	  that	  MEK	  inhibition	  does	  not	  modulate	  normal	  bone	  development.	  	  In	  stark	  contrast,	  we	  found	  that	  treatment	  with	  MEK	  inhibitor,	  but	  never	  the	  vehicle	  control,	  was	  sufficient	  to	  completely	  rescue	  the	  bone	  defect	  of	  the	  Prx1-­Cre,K-­rasG12D	  mutants	  (Figure	  4B).	  	  Specifically,	  the	  PD0325901-­‐treated,	  mutant	  limbs	  were	  of	  normal	  length	  and	  thickness,	  and	  their	  levels	  of	  mineralization	  and	  of	  trabecular	  bone	  were	  now	  comparable	  to	  wildtype	  controls.	  	  Thus,	  we	  conclude	  that	  MAPK	  signaling	  is	  the	  primary	  cause	  of	  the	  bone	  growth	  defect	  in	  the	  Prx1-­Cre,	  K-­rasG12D	  mice,	  and	  that	  MEK	  inhibition	  is	  an	  effective	  treatment.	  	  We	  wanted	  to	  determine	  whether	  shorter	  periods	  of	  drug	  treatment	  could	  also	  suppress	  the	  bone	  defects.	  	  Thus,	  we	  conducted	  additional	  experiments	  using	  treatment	  only	  between	  E15.5	  and	  E18.5	  or	  E10.5	  and	  E14.5.	  	  Again,	  embryos	  were	  collected	  at	  E18.5	  and	  their	  limbs	  analyzed.	  	  As	  with	  the	  longer	  treatment,	  bone	  development	  was	  unaltered	  in	  wildtype	  pups	  exposed	  to	  drug	  in	  either	  time	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window	  (Figure	  4B	  and	  data	  not	  shown).	  	  For	  the	  E15.5	  to	  E18.5	  treatment	  window,	  the	  Prx1-­Cre,	  K-­rasG12D	  limbs	  displayed	  the	  full	  spectrum	  of	  NS-­‐like	  defects	  in	  the	  case	  of	  both	  vehicle	  (n=5)	  and	  drug	  (n=3)	  treated	  animals.	  	  In	  contrast,	  the	  mutant	  bone	  defect	  was	  completely	  rescued	  in	  animals	  treated	  from	  E10.5	  to	  E14.5	  with	  MEK	  inhibitor	  (n=5)	  but	  not	  vehicle	  (n=3)	  (Figure	  4B).	  	  Taken	  together,	  these	  experiments	  define	  a	  critical	  time	  in	  bone	  development,	  between	  E10.5	  and	  approximately	  E14.5,	  in	  which	  upregulation	  of	  MAPK	  pathway	  signaling	  is	  sufficient	  to	  derail	  the	  process	  of	  bone	  development	  and	  yield	  long	  bone	  defects	  that	  phenocopy	  those	  of	  NS	  patients.	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DISCUSSION	  	  	   In	  this	  study,	  we	  have	  generated	  mouse	  models	  in	  which	  activation	  of	  K-­‐rasG12D	  in	  either	  the	  mesenchymal	  progenitors	  of	  the	  limb	  bud,	  or	  the	  Col2-­‐positive	  oestochondroprogenitors,	  recapitulates	  the	  stunted	  long	  bones	  encountered	  in	  patients	  with	  Noonan	  Syndrome.	  	  We	  show	  that	  the	  bones	  are	  greatly	  shortened	  and	  thickened,	  and	  they	  display	  abnormal	  mineralization	  in	  both	  primary	  and	  secondary	  ossification	  centers	  and	  a	  stark	  increase	  in	  the	  density	  of	  the	  trabecular	  bone.	  	  We	  also	  see	  disorganization	  of	  the	  growth	  plate,	  and	  a	  thinning	  of	  hypertrophic	  chondrocyte	  layer.	  	  The	  presence	  of	  both	  bone	  and	  cartilage	  abnormalities	  suggests	  defects	  in	  both	  osteoblast	  and	  chondrocyte	  differentiation	  and/or	  disruption	  of	  interplay	  between	  the	  two.	  	  	  Our	  phenotypic	  analysis	  tracked	  the	  origin	  of	  the	  K-­‐rasG12D	  mutant	  bone	  defects	  to	  around	  E14.5.	  	  At	  this	  time,	  the	  mutant	  bones	  show	  no	  sign	  of	  either	  bone	  collar	  formation	  or	  invasion	  of	  osteoblasts	  into	  the	  center	  of	  the	  bone.	  	  The	  osteoblasts	  that	  form	  the	  bone	  collar	  are	  known	  to	  originate	  from	  Col2-­‐positive	  osteochondroprogenitors,	  which	  migrate	  to	  the	  site	  of	  the	  future	  bone	  collar	  and	  differentiate	  into	  Col1-­‐positive	  cells	  (Maes	  et	  al.,	  2010).	  	  We	  showed	  that	  the	  K-­‐rasG12D	  mutant	  bones	  display	  a	  normal	  pattern	  of	  Col2	  staining	  at	  both	  E14.5	  and	  E16.5.	  	  In	  contrast,	  Col1	  staining	  is	  completely	  absent	  at	  E14.5	  and	  it	  accumulates	  in	  an	  aberrant	  location	  surrounding,	  rather	  than	  inside,	  the	  bone	  at	  E16.5.	  	  Based	  on	  these	  observations,	  we	  hypothesize	  that	  activated	  K-­‐rasG12D	  somehow	  impairs	  the	  migration	  of	  Col2-­‐positive	  osteochondroprogenitors,	  such	  that	  they	  eventually	  differentiate	  into	  Col1-­‐positive	  osteoblasts	  in	  the	  wrong	  location.	  	  Notably,	  this	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migration	  defect	  hypothesis	  is	  supported	  by	  prior	  analyses	  of	  zebrafish	  models	  for	  Noonan	  and	  Cardio-­‐Facio-­‐Cutaneous	  syndromes,	  which	  showed	  that	  expression	  of	  mutant	  RAS,	  BRAF	  or	  MEK	  disrupts	  cell	  movement	  defects	  during	  gastrulation	  (Anastasaki	  et	  al.,	  2009;	  Runtuwene	  et	  al.,	  2011).	  	  In	  the	  future,	  it	  would	  be	  interesting	  to	  stain	  for	  Indian	  Hedgehog	  (Ihh)	  because	  this	  signals	  to	  the	  Col2-­‐positive	  osteochondroprogenitors	  at	  the	  perichondrium	  and	  directs	  them	  to	  commit	  to	  the	  osteoblast	  lineages.	  	  Additionally,	  we	  could	  conduct	  lineage	  tracing	  of	  the	  Col2-­‐positive	  osteochondroprogenitors	  through	  the	  generation	  and	  analysis	  of	  Col2-­
CreERt;K-­rasG12D;GFP	  embryos.	  	  Ultimately,	  regardless	  of	  the	  underlying	  mechanism,	  we	  believe	  that	  the	  inappropriate	  positioning	  of	  the	  Col1-­‐positive	  osteoblasts	  is	  responsible	  for	  the	  aberrant	  deposition	  of	  bone	  in	  the	  lateral,	  rather	  than	  the	  longitudinal,	  axis.	  	  	  In	  addition	  to	  elucidating	  the	  etiology	  of	  NS	  bone	  defects,	  our	  study	  provided	  insight	  into	  their	  potential	  treatment.	  	  Specifically,	  we	  found	  that	  delivery	  of	  the	  MEK	  inhibitor	  PD0325901	  in	  utero	  was	  sufficient	  to	  completely	  prevent	  the	  NS-­‐like	  long	  bone	  defects	  up	  to	  E18.5.	  	  Indeed,	  this	  treatment	  was	  effective	  when	  limited	  to	  a	  relatively	  small	  time	  window	  between	  E10.5	  and	  around	  E14.5.	  	  This	  yields	  two	  key	  conclusions.	  	  First,	  it	  argues	  that	  MAPK	  pathway	  activation	  is	  important	  for	  the	  development	  of	  the	  NS-­‐like	  mutant	  bone	  phenotype.	  	  Second,	  it	  proves	  that	  the	  bone	  developmental	  defects	  result	  from	  errors	  that	  occur	  during	  the	  establishment	  of	  bone	  commitment,	  presumably	  the	  defect	  in	  bone	  collar	  formation	  discussed	  above.	  	  	  It	  is	  important	  to	  note	  that	  our	  data	  do	  not	  establish	  whether	  the	  bone	  defects	  are	  a	  direct	  consequence	  of	  elevated	  MAPK	  signaling,	  or	  whether	  it	  reflects	  a	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downstream	  event.	  	  Specifically,	  prior	  studies	  have	  established	  that	  MAPK	  signaling	  can	  induce	  negative	  feedbacks	  loops	  (REF)	  and	  that	  treatment	  with	  MEK	  inhibitors	  modulates	  the	  expression	  of	  such	  upstream	  MAPK	  regulators	  in	  K-­‐ras	  mutant	  tumors	  (Nissan	  et	  al.,	  2013).	  	  	  Additionally,	  since	  we	  examined	  the	  PD0325901	  treated	  embryos	  at	  E18.5,	  we	  cannot	  preclude	  the	  possibility	  that	  the	  presence	  of	  activated	  K-­‐rasG12D	  signaling	  post	  birth	  might	  lead	  to	  the	  formation	  of	  other	  bone	  defects	  in	  neonates/adult	  animals.	  We	  tried	  to	  address	  this	  issue	  by	  allowing	  treated	  mothers	  to	  give	  birth.	  	  Unfortunately,	  we	  found	  that	  almost	  all	  of	  the	  pups	  died	  irrespective	  of	  their	  genotype,	  and	  irrespective	  of	  whether	  the	  mother	  was	  injected	  with	  MEK	  inhibitor	  or	  vehicle	  control.	  	  Thus,	  we	  believe	  that	  injection	  scheme	  itself	  causes	  the	  mothers	  to	  reject	  their	  pups,	  and	  additional	  experiments	  will	  be	  required	  to	  address	  this	  question.	  	  	  	  Over	  the	  past	  decade,	  the	  development	  and	  performance	  of	  clinical	  trials	  in	  patients	  with	  Noonan	  Syndrome	  has	  rapidly	  increased	  (Rauen	  et	  al.,	  2011).	  Many	  of	  these	  trials	  aim	  to	  modify	  signaling	  through	  the	  aberrantly	  activated	  Ras/MAPK	  pathway.	  	  MEK	  inhibitors	  have	  been	  tested	  in	  preclinical	  mouse	  models,	  including	  PTPN11	  and	  RAF	  mutant	  models	  of	  Noonan	  Syndrome	  and	  an	  FGFR	  model	  of	  Apert	  Syndrome,	  and	  shown	  to	  suppress	  both	  the	  cardiac	  and	  craniofacial	  defects	  (Chen	  et	  al.,	  2010;	  Nakamura	  et	  al.,	  2009;	  Wu	  et	  al.,	  2011)	  Our	  study	  now	  shows	  that	  such	  treatments	  would	  also	  successfully	  rescue	  the	  skeletal	  defects	  of	  NS	  patients.	  	  	  





Supplemental	  Figure	  1.	  (Tuveson	  et	  al.,	  2004)	  Schematic	  representation	  of	  the	  K-­‐rasG12D	  gene	  showing	  the	  loxP	  sites	  and	  location	  of	  the	  STOP	  cassette.	  	  Expression	  of	  Cre	  removes	  the	  STOP	  cassette	  located	  in	  front	  of	  the	  second	  exon	  containing	  the	  G12D	  point	  mutation,	  and	  allows	  expression	  of	  a	  constitutive	  form	  of	  K-­‐ras.	  	  




Supplemental	  Figure	  2.	  Col2;K-­rasG12D	  mice	  (at	  day	  1	  after	  birth)	  have	  a	  similar	  phenotype	  as	  the	  Prx1-­Cre;K-­rasG12D	  mutant	  mice	  as	  shown	  by	  (A)	  H&E	  sections	  and	  (B)	  Alizarin	  Red	  staining	  of	  limb	  sections.	  The	  limbs	  are	  shorter	  and	  thicker,	  and	  display	  increased	  trabecular	  and	  cortical	  mineralization.	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MATERIALS	  AND	  METHODS	  
	  
Mouse	  husbandry	  and	  tissue	  collection	  Animal	  procedures	  followed	  protocols	  approved	  by	  MIT's	  Committee	  on	  Animal	  Care.	  The	  Osxl-­Cre,	  Prx1-­Cre	  and	  K-­rasG12D/+	  animals	  were	  maintained	  on	  a	  mixed	  genetic	  background.	  Tissues	  were	  fixed	  in	  PBS	  with	  3.7%	  formaldehyde.	  Prior	  to	  paraffin	  sectioning,	  soft	  tissues	  were	  dehydrated	  via	  an	  ethanol	  series,	  while	  bone-­‐containing	  tissue	  was	  decalcified	  in	  0.46M	  EDTA,	  2.5%	  Ammonium	  Hydroxide	  pH	  7.2.	  All	  paraffin	  embedded	  sections	  were	  cut	  at	  5pm,	  dewaxed	  and	  stained	  with	  H&E.	  	  
Skeletal	  stainings	  Embryos	  were	  sacrificed,	  skinned	  and	  eviscerated.	  The	  remaining	  tissue	  was	  fixed	  in	  95%	  ethanol	  for	  4	  days,	  transferred	  to	  acetone	  for	  3	  days,	  and	  subsequently	  transferred	  to	  staining	  solution	  of	  0.015%	  Alcian	  Blue	  8GX	  (Sigma),	  0.005%	  Alizarin	  Red	  S(Sigma),	  and	  5%	  glacial	  acetic	  acid	  in	  ethanol	  at	  370C	  for	  2	  days	  and	  at	  room	  temperature	  for	  a	  one	  more	  day.	  Tissue	  was	  cleared	  in	  1%	  potassium	  hydroxide	  for	  several	  days	  and	  then	  stored	  in	  glycerol.	  	  
Alizarin	  Red	  staining	  For	  Alizarin	  red	  staining,	  sections	  were	  rinsed	  in	  water,	  placed	  in	  2%	  Alizarin	  Red	  S	  (pH	  4.2)	  for	  5	  min,	  dipped	  20	  times	  in	  acetone	  followed	  by	  acetone:xylene	  (1:1),	  and	  then	  mounted.	  	  
	   81	  
In	  situ	  hybridization	  Tissues	  were	  fixed	  in	  4%	  paraformaldehyde/PBS	  overnight	  at	  4°C,	  processed,	  embedded	  in	  paraffin,	  and	  cut.	  Non-­‐radioactive	  ISH,	  with	  digoxigenin	  (DIG)-­‐labeled	  probes	  (Chung	  et	  al.,	  1998;	  Murtaugh	  et	  al.,	  2001)	  was	  performed	  as	  described	  previously	  (Chung	  et	  al.,	  1998).	  In	  brief,	  sections	  were	  postfixed	  with	  4%	  PFA-­‐PBS	  for	  15	  min.	  After	  washing	  with	  PBS,	  sections	  were	  digested	  with	  1	  pg/ml	  proteinase-­‐K	  (37	  C;	  15	  min)	  in	  PBS	  and	  again	  treated	  with	  4%	  PFA-­‐PBS	  (10	  min).	  Sections	  then	  were	  sequentially	  washed	  with	  PBS,	  acetylated	  with	  0.25%	  acetic	  anhydride	  in	  the	  presence	  of	  triethanolamine	  (1	  M;	  10	  min),	  dehydrated	  with	  increasing	  concentrations	  of	  ethanol,	  and	  air	  dried.	  Hybridizations	  with	  complementary	  RNAs	  were	  performed	  in	  a	  humidified	  chamber	  in	  a	  solution	  containing	  50%	  formamide,	  10%	  dextran	  sulfate,	  1	  X	  Denhardt’s	  solution,	  600	  mM	  NaCl,	  10	  rnM	  Tris-­‐HCl,	  1	  rnM	  EDTA,	  50	  rnM	  dithiothreitol,	  0.25%	  sodium	  dodecyl	  sulfate,	  and	  200	  pg/ml	  transfer	  RNA	  (18	  h;	  55	  Cl.	  After	  hybridization,	  sections	  were	  washed	  briefly	  with	  5	  X	  SSC	  at	  500C,	  50%	  formamide-­‐	  X	  SSC	  (50	  C;	  30	  min),	  and	  10	  rnM	  Tris-­‐HCl	  (pH	  7.6)-­‐500	  rnM	  NaCl-­‐1	  rnM	  EDTA	  (TNE;	  37	  C;	  10	  min).	  Sections	  were	  then	  treated	  with	  10	  pg/ml	  ribonuclease-­‐A	  in	  TNE	  (37	  C;	  30	  min).	  After	  being	  washed	  with	  TNE,	  sections	  were	  incubated	  once	  with	  2	  X	  SSC	  (50	  C;	  20	  min)	  and	  twice	  with	  0.2	  X	  SSC	  (50	  C;	  20	  min),	  dehydrated	  with	  increasing	  concentrations	  of	  ethanol,	  and	  air-­‐dried.	  	  
Immunohistochemistry	  pMEK	  immunohistochemistry	  was	  performed	  with	  a	  modified	  citric	  acid	  unmasking	  protocol.	  Briefly,	  paraffin	  was	  removed	  from	  slides,	  followed	  by	  incubation	  in	  0.5%	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H2O2/methanol	  for	  15	  min	  and	  antigen	  retrieval	  using	  citrate	  buffer	  (pH	  6.0)	  in	  a	  microwave	  for	  15	  min.	  Slides	  were	  blocked	  for	  1	  h	  at	  room	  temperature	  in	  10%	  goat	  serum	  in	  PBS.	  pMEK	  (1:100;	  Cell	  Signaling,	  9661)	  antibodies	  were	  used	  in	  0.15%	  Triton/PBS	  overnight	  at	  4°C.	  Secondary	  antibodies	  (Vector	  Laboratories)	  were	  used	  at	  1:200	  in	  PBS	  with	  2%	  goat	  serum,	  detected	  using	  a	  DAB	  substrate	  kit	  (Vector	  Laboratories),	  and	  counterstained	  with	  haematoxylin.	  
	  
Drug	  treatment	  N-­‐([R]-­‐2,3-­‐dihydroxy-­‐propoxy)-­‐3,4-­‐difluoro-­‐2-­‐(2-­‐fluoro-­‐4-­‐iodo-­‐phenylamino)-­‐benzamide	  (PD0325901)	  was	  synthesized	  according	  to	  the	  disclosure	  in	  document	  WO2007042885(A2).	  All	  chemicals	  necessary	  for	  the	  synthesis	  were	  purchased	  from	  Sigma-­‐Aldrich.	  PD0325901	  was	  dissolved	  in	  DMSO	  at	  a	  concentration	  of	  50	  mg/ml,	  then	  resuspended	  in	  vehicle	  (0.5%	  hydroxypropyl	  methylcellulose	  with	  0.2%	  Tween	  80)	  at	  a	  concentration	  of	  0.5	  mg/ml,	  and	  injected	  i.p.	  (5	  mg/kg	  BW)	  daily	  for	  the	  indicated	  times.	  Control	  mice	  were	  injected	  with	  vehicle.	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ABSTRACT	  The	  Ras/mitogen-­‐activated	  protein	  kinase	  (MAPK)	  pathway	  provides	  a	  major	  link	  between	  the	  cell	  surface	  and	  the	  nucleus	  to	  control	  cell	  proliferation	  and	  differentiation	  upon	  stimulation	  with	  various	  extracellular	  signals.	  However,	  its	  in	  
vivo	  role	  in	  skeletal	  development	  is	  still	  controversial,	  with	  some	  studies	  supporting	  a	  positive	  role	  for	  Ras/MAPK,	  and	  others	  arguing	  for	  a	  suppressive	  role.	  In	  this	  study,	  wehave	  elucidated	  the	  effects	  of	  ectopic	  K-­‐ras/MAPK	  signaling	  on	  skeletal	  development	  by	  using	  transgenic	  mice	  in	  which	  expression	  of	  K-­‐rasG12D	  was	  induced	  specifically	  in	  osteoblasts	  precursors	  at	  different	  times	  during	  the	  development.	  This	  analysis	  defined	  two	  distinct	  time	  windows	  when	  during	  which	  expression	  of	  active	  K-­‐ras	  resulted	  in	  opposing	  phenotypes.	  In	  the	  first	  time	  window,	  between	  approximately	  E11.5	  and	  E14.5,	  K-­‐rasG12D	  expression	  greatly	  impaired	  osteoblast	  terminal	  differentiation	  and	  thus	  caused	  dramatic	  bone	  loss.	  	  In	  stark	  contrast,	  activation	  of	  K-­‐rasG12D	  at	  birth	  greatly	  enhanced	  osteoblast	  differentiation	  and	  consequently	  mineralization	  of	  the	  long	  bones.	  	  Thus,	  our	  data	  show	  that	  	  appropriate	  Ras/MAPK	  pathway	  signaling	  plays	  a	  critical	  role	  in	  osteoblast	  differentiation	  and	  that	  K-­‐rasG12D	  has	  distinct,	  temporal	  dependent	  roles	  on	  osteoblastic	  fate.	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INTRODUCTION	  
	   Bone	  development	  is	  a	  carefully	  regulated	  process,	  in	  which	  expression	  of	  specific	  factors	  characterizes	  each	  stage	  of	  development.	  The	  first	  step	  in	  endochondral	  bone	  formation,	  is	  the	  migration	  of	  Prx	  expressing	  mesenchymal	  progenitors	  to	  the	  matrices	  of	  the	  future	  bones	  (Supp	  Fig	  1-­‐A).	  	  The	  cells	  located	  at	  the	  center	  of	  these	  mesenchymal	  condensations	  will	  differentiate	  into	  Col2	  expressing	  chondrocytes	  and	  start	  proliferating	  (Supp	  Fig	  1-­‐B).	  Chondrocytes	  at	  the	  center	  of	  the	  template	  stop	  proliferating	  and	  mature	  into	  ColX	  hypertrophic	  chondrocytes	  that	  will	  undergo	  apoptosis	  (Supp	  Fig	  1-­‐C).	  The	  death	  of	  hypertrophic	  chondrocytes	  is	  followed	  by	  recruitment	  of	  Osx	  expressing	  osteoblasts	  (Supp	  Fig	  1-­‐D).	  At	  the	  primary	  spongiosa	  (PS),	  Osx	  expressing	  osteoblasts	  differentiate	  into	  Col1-­‐expressing	  committed	  osteoblasts.	  The	  Col1	  osteoblasts	  further	  differentiate	  into	  Osetocalcin	  (OC)	  expressing	  osteoblasts.	  Some	  other	  markers	  that	  characterize	  final	  stages	  of	  osteoblast	  differentiation	  are	  ALP	  (Alkaline	  phosphatase),	  BSP	  (Bone	  sialo-­‐protein)	  and	  OPN	  (Osteopontin).	  	  Concurrently,	  the	  cells	  at	  the	  periphery	  of	  the	  chondrocyte	  template	  will	  become	  the	  perichondrium	  which	  signals	  back	  and	  forth	  with	  the	  underlying	  cartilage	  and	  causes	  Col2	  expressing	  chondrocytes	  to	  differentiate	  into	  Col1-­‐osteoblasts,	  that	  form	  the	  bone	  collar	  (Supp	  Fig	  1-­‐D).	  In	  the	  long	  bones,	  chondrocytes	  continue	  to	  proliferate	  and	  cartilage	  matrix	  is	  deposited,	  causing	  the	  bone	  to	  grow	  in	  length.	  This	  is	  a	  process	  that	  starts	  in	  embryogenesis	  and	  is	  completed	  around	  puberty.	  In	  bone	  biology,	  the	  MAPK	  signaling	  pathway	  has	  been	  implicated	  in	  the	  response	  of	  bone	  to	  a	  variety	  of	  signals,	  including	  growth	  factors	  (Chen	  et	  al.,	  2004;	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Hurley	  et	  al.,	  1996;	  Xiao	  et	  al.,	  2002),	  extracellular	  matrix–integrin	  binding	  (Takeuchi	  et	  al.,	  1997),	  and	  mechanical	  loading	  (You	  et	  al.,	  2001).	  Direct	  evidence	  for	  the	  importance	  of	  MAPK	  itself	  in	  bone	  development	  comes	  from	  analysis	  of	  Erk	  1	  mutant	  mice.	  	  Specifically,	  deletion	  of	  Erk1,	  in	  either	  the	  germline	  or	  only	  in	  the	  developing	  limb	  mesenchyme,	  yields	  reduced	  bone	  mineralization	  thereby	  establishing	  the	  necessity	  of	  ERK	  activity	  for	  proper	  osteoblast	  function	  (Matsushita	  et	  al.,	  2009).	  	  	  Many	  other	  mouse	  models	  have	  probed	  the	  role	  of	  upstream	  regulators	  of	  MAPK	  in	  bone	  development	  (Ge	  et	  al.,	  2007;	  Greenblatt	  et	  al.,	  2010;	  Zou	  et	  al.,	  2011).	  These	  have	  led	  to	  some	  confusion	  as	  some	  studies	  support	  a	  stimulatory	  role	  for	  this	  signaling	  pathway	  while	  others	  propose	  an	  inhibitory	  role.	  Indeed,	  even	  the	  same	  player	  has	  been	  reported	  to	  have	  opposing	  roles	  in	  different	  settings.	  	  For	  example,	  
in	  vivo	  deletion	  of	  NF1	  (a	  Ras	  inhibitor)	  in	  committed	  osteoblasts	  using	  the	  Col1	  promoter	  yielded	  increased	  bone	  mass	  (Elefteriou	  et	  al.,	  2006)	  whereas	  NF1	  deletion	  in	  osteochondral	  progenitors	  using	  the	  Col2	  promoter	  impaired	  osteoblast	  differentiation	  and	  reduced	  bone	  mass	  (Wang	  et	  al.,	  2011;	  Wu	  et	  al.,	  2011b).	  These	  contradictory	  results	  strongly	  suggest	  that	  loss	  of	  NF1,	  and	  consequent	  deregulation	  of	  MAPK,	  can	  either	  activate	  or	  repress	  osteoblast	  development	  when	  triggered	  in	  uncommitted	  multipotent	  progenitors	  versus	  mature	  osteoblasts.	  	  In	  Chapter	  2,	  we	  showed	  that	  constitutive	  expression	  of	  K-­‐ras	  in	  limb	  mesenchymal	  progenitors	  and	  subsequent	  lineages,	  including	  osteoblasts,	  yielded	  abnormal	  mineralization	  of	  the	  long	  bones.	  	  Here,	  we	  wanted	  to	  directly	  assess	  the	  consequences	  of	  inducing	  constitutive	  K-­‐ras	  expression	  only	  in	  osteoblast	  
	   90	  
precursors.	  	  To	  this	  end,	  we	  developed	  a	  transgenic	  mouse	  strategy	  involving	  selective	  expression	  of	  an	  active	  form	  of	  K-­‐ras	  specifically	  in	  osteoblast	  progenitors	  using	  the	  osterix	  (Osx1)	  promoter.	  	  Importantly,	  the	  Osx1-­Cre	  mice	  were	  designed	  such	  that	  the	  expression	  of	  Cre	  recombinase	  is	  under	  the	  transcriptional	  regulation	  of	  the	  Osx1	  promoter	  and	  also	  a	  Tet-­‐Off	  cassette.	  	  This	  Tet-­‐Off	  cassette	  provides	  an	  additional	  level	  of	  temporal	  control	  specifically	  within	  the	  osteoblast	  lineage	  (Rodda	  and	  McMahon,	  2006).	  Thus,	  we	  can	  not	  only	  restrict	  the	  expression	  of	  activated	  K-­‐ras	  to	  osteoblasts	  progenitors,	  but	  further	  limit	  its	  activation	  to	  specific	  time	  points	  during	  embryonic	  development	  or	  after	  birth.	  Using	  this	  system,	  we	  show	  that	  expression	  of	  K-­‐rasG12D	  during	  embryonic	  development	  leads	  to	  a	  decrease	  in	  bone	  mass,	  while	  expression	  of	  K-­‐rasG12D	  after	  birth	  leads	  to	  an	  increase	  in	  bone	  mass.	  This	  explains	  previously	  contradictory	  results	  in	  the	  field	  about	  the	  effects	  of	  aberrant	  MAPK	  during	  bone	  development	  by	  suggesting	  that	  activated	  K-­‐ras	  can	  both	  stimulate	  and	  inhibit	  osteoblast	  differentiation,	  depending	  on	  the	  time	  it	  is	  expressed	  in	  osteoblasts.	  Additionally,	  our	  data	  reinforce	  our	  prior	  conclusion	  (Chapter	  2)	  that	  E14.5	  is	  a	  critical	  period	  in	  bone	  development,	  and	  it	  directly	  proves	  that	  hyperactive	  K-­‐rasG12D	  acts	  to	  disrupt	  osteoblast	  fate	  commitment	  in	  vivo	  and	  in	  vitro.
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RESULTS	  	  
Embryonic	  expression	  of	  K-­rasG12D	  in	  osteoblast	  progenitors	  leads	  to	  strong	  
skeletal	  defects	  in	  both	  long	  bones	  and	  the	  calvaria.	  
To	  test	  the	  consequences	  of	  osteoblast-­‐restricted	  expression	  of	  K-­‐rasG12D,	  we	  utilized	  Osterix-­‐Cre	  transgenic	  mice	  (Osx1-­Cre)	  to	  restrict	  Cre	  expression	  to	  osteoblasts	  progenitors.	  Endogenous	  Osx	  is	  first	  expressed	  around	  E12.5	  (Nakashima	  et	  al.,	  2002).	  However,	  the	  Osx1-­‐Cre	  mice	  were	  designed	  such	  that	  the	  
Osx1	  promoter	  controls	  the	  expression	  of	  a	  Tet-­‐Off	  Cre	  recombinase	  protein	  (Rodda	  and	  McMahon,	  2006).	  In	  a	  Tet-­‐Off	  system	  a	  tetracycline-­‐controlled	  transactivator	  protein	  (tTA)	  regulates	  expression	  of	  a	  target	  gene	  that	  is	  under	  transcriptional	  control	  of	  a	  tetracycline-­‐responsive	  promoter	  element	  (TRE).	  In	  the	  absence	  of	  doxycycline	  (Dox),	  tTA	  binds	  to	  the	  TRE	  and	  activates	  transcription	  of	  the	  target	  gene.	  In	  contrast,	  the	  presence	  of	  Dox	  prevents	  tTA	  binding	  to	  the	  TRE	  and	  thus	  the	  target	  gene	  remains	  inactive	  (Gossen	  and	  Bujard,	  1992;	  Kistner	  et	  al.,	  1996).	  Thus,	  in	  Osx1-­Cre	  mice	  Cre	  should	  be	  expressed	  in	  the	  osteoblast	  lineage	  specifically	  in	  the	  absence,	  but	  not	  the	  presence,	  of	  doxycycline.	  	  
	  First,	  we	  wanted	  to	  validate	  the	  tissue-­‐specific	  localization	  of	  the	  Osx1-­‐Cre	  transgene	  expression.	  For	  this,	  we	  crossed	  Osx1-­Cre	  mice	  with	  the	  LSL-­‐LacZ	  reporter	  mice.	  We	  performed	  β-­‐galactosidase	  staining	  of	  whole	  Osx1-­Cre;LacZ	  embryos	  at	  day	  1	  of	  life	  and	  showed	  that	  the	  Osx	  transgene	  expression	  is	  restricted	  to	  the	  bones	  of	  the	  skeleton	  and	  the	  calvaria,	  and	  is	  not	  present	  in	  muscle	  or	  fat	  (Figure	  1A).	  	  Having	  established	  this	  specificity,	  we	  generated	  Osx1-­Cre;K-­rasG12D	  mice.	  	  Initially,	  we	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allowed	  these	  to	  develop	  in	  the	  absence	  of	  doxycycline	  administration,	  such	  that	  activated	  K-­‐rasG12D	  is	  induced	  at	  the	  normal	  time	  of	  Osx	  expression.	  	  Osx1-­Cre;K-­
rasG12D	  mice	  were	  expected	  to	  arise	  from	  our	  cross	  at	  a	  frequency	  of	  1	  in	  4	  but	  we	  found	  no	  surviving	  mutants	  from	  more	  than	  10	  litters.	  	  Our	  analysis	  showed	  that	  the	  
Osx1-­Cre;K-­rasG12D	  mutants	  all	  died	  at	  birth.	  	  The	  mutant	  mice	  were	  all	  smaller	  than	  the	  wild	  type	  littermates	  and	  they	  displayed	  strong	  bone	  abnormalities	  (Figure	  1B).	  	  Whole	  mount	  skeletal	  staining	  with	  Alizarin	  Red	  and	  Alcian	  Blue	  showed	  that	  the	  skeleton	  of	  P1	  mutants	  was	  severely	  abnormal;	  their	  spines	  were	  severely	  deformed	  and	  there	  were	  also	  clear	  defects	  in	  the	  development	  of	  the	  long	  bones	  and	  the	  calvaria	  (Figure	  1B).	  	  Specifically,	  the	  mutant	  long	  bones	  were	  shorter	  and	  much	  thinner	  than	  those	  of	  wild	  type	  littermate	  controls.	  Furthermore,	  mutant	  limbs	  were	  thin,	  brittle	  and	  fractured	  at	  the	  middle	  (Figure	  1C).	  Additionally,	  the	  calvaria	  of	  the	  
Osx1-­Cre;K-­rasG12D	  mutants	  was	  under-­‐mineralized,	  reminiscent	  of	  the	  long	  bones	  phenotype	  (Figure	  1D).	  Since	  the	  calvaria	  forms	  through	  direct	  differentiation	  of	  mesenchymal	  progenitors	  to	  osteoblasts,	  with	  no	  cartilage	  intermediate,	  we	  can	  conclude	  that	  hyperactive	  K-­‐ras	  expression	  causes	  a	  cell	  intrinsic	  defect	  in	  osteoblast	  differentiation.	  	   	  




Figure	  1.	  Embryonic	  expression	  of	  K-­rasG12D	  in	  osteoblast	  precursors	  under	  
the	  control	  of	  the	  Osx1	  promoter	  leads	  to	  strong	  skeletal	  defects.	  (A)	  β-­‐galactosidase	  staining	  of	  Osx1-­Cre;LacZ	  mice	  shows	  that	  the	  Osx	  transgene	  is	  exclusively	  expressed	  in	  the	  bones	  of	  the	  skeleton	  and	  in	  the	  skull.	  (B)	  Whole	  mount	  staining	  with	  Alizarin	  Red	  and	  Alcian	  Blue	  of	  P1	  pups	  shows	  that	  Osx1-­Cre;K-­rasG12D	  mice	  have	  strong	  skeletal	  defects.	  (C)	  Limbs	  of	  the	  mutant	  mice	  are	  shorter	  than	  those	  of	  wildtype	  controls	  and	  they	  are	  fractured	  at	  the	  middle.	  (D)	  The	  calvaria	  of	  mutant	  mice	  is	  undermineralized	  compared	  to	  controls,	  as	  visualized	  by	  staining	  with	  Alizarin	  Red	  and	  Alcian	  Blue.	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Bone	  fractures	  appear	  early	  during	  embryonic	  development	  in	  Osx1-­Cre;K-­
rasG12D	  mutants	  We	  analyzed	  limbs	  at	  consecutive	  days	  of	  embryonic	  development	  to	  identify	  when	  the	  defect	  appears	  in	  Osx1-­Cre;K-­rasG12D	  mutants.	  	  Additionally,	  we	  wanted	  to	  determine	  whether	  the	  fractures	  we	  see	  at	  birth	  result	  from	  the	  mechanical	  stress	  of	  birth	  or	  whether	  they	  exist	  in	  utero	  and	  thus	  reflect	  a	  developmental	  defect.	  	  At	  E18.5,	  H&E	  analysis	  showed	  that	  the	  mutant	  long	  bones	  were	  under-­‐mineralized	  compared	  to	  wildtype	  control	  and	  they	  appeared	  to	  be	  fractured	  (Figure	  2A).	  Morevoer,	  connective	  tissue	  seemed	  to	  have	  replaced	  bone	  in	  the	  shaft	  of	  the	  long	  bones.	  The	  same	  phenotype	  wass	  seen	  in	  the	  long	  bones	  at	  E16.5	  (Figure	  2B).	  	  At	  E14.5	  the	  defects	  were	  more	  subtle	  but	  still	  clearly	  apparent	  (Figure	  2C).	  	  At	  this	  stage,	  in	  the	  wild	  type	  limbs	  osteoblasts	  had	  invaded	  the	  middle	  of	  the	  bone	  and	  they	  were	  clearly	  secreting	  mineralized	  matrix	  to	  replace	  the	  cartilage.	  	  In	  the	  mutants,	  there	  was	  no	  sign	  of	  mineralization	  on	  the	  sides	  of	  the	  bone	  and	  no	  detectable	  osteoblast	  invasion.	  Instead,	  at	  this	  early	  stage,	  the	  limbs	  already	  appeared	  fractured.	  	  Alizarin	  Red	  staining	  of	  E18.5	  limb	  sections	  augmented	  what	  we	  saw	  in	  the	  H&E	  sections;	  there	  was	  little	  staining	  in	  the	  mutant	  bones	  indicating	  that	  there	  are	  very	  few	  calcium	  deposits	  and	  thus	  reduced	  bone	  mineralization	  (Figure	  2D).	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Figure	  2.	  Consecutive	  analysis	  of	  embryonic	  stages	  reveals	  that	  the	  fracture	  
defect	  appears	  early	  during	  embryonic	  development.	  (A-­‐B)	  H&E	  sections	  of	  (A)	  E18.5	  and	  (B)	  E16.5	  embryo	  limbs	  show	  the	  fracture	  and	  under	  mineralization	  defects	  resulting	  from	  K-­‐rasG12D	  expression	  in	  osteoblast	  precursors.	  (C)	  H&E	  sections	  of	  E14.5	  embryos	  show	  a	  subtle	  difference	  between	  mutant	  and	  control	  limbs.	  (D)	  Alizarin	  Red	  staining	  of	  E18.5	  limb	  sections	  shows	  that	  there	  is	  very	  little	  mineralization	  present	  in	  the	  Osx1-­Cre;K-­rasG12D	  long	  bones.	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   In	  parallel	  with	  our	  analysis	  of	  H&E	  sections,	  we	  also	  screened	  for	  molecular	  markers	  of	  osteoblast	  differentiation	  using	  in	  situ	  hybridization	  (ISH).	  	  Col2	  is	  a	  marker	  of	  osteochondral	  progenitors,	  which	  give	  rise	  to	  both	  chondrocytes	  and	  osteoblasts.	  	  (Maes	  et	  al.,	  2010)	  have	  established	  that	  these	  Col2-­‐postive	  osteochondral	  progenitors	  commit	  to	  the	  osteoblast	  lineage	  through	  two	  distinct	  differentiation	  schemes,	  depending	  on	  their	  location.	  	  Specifically,	  some	  give	  rise	  to	  Col1	  expressing	  cells	  that	  first	  appear	  in	  the	  region	  of	  the	  bone	  collar	  around	  E14.5,	  while	  others	  become	  Osx-­‐positive	  cells	  and	  migrate	  to	  the	  middle	  of	  the	  bone.	  Subsequently,	  these	  Osx-­‐positive	  cells	  further	  differentiate	  into	  Col1	  expressing,	  committed	  osteoblasts.	  Given	  these	  established	  differentiation	  mechanisms,	  we	  screened	  our	  mice	  for	  both	  Col2	  and	  Col1	  expression.	  	  ISH	  for	  Col2	  at	  E14.5	  showed	  that	  osteochondral	  progenitors	  were	  located	  appropriately	  and	  present	  at	  comparable	  levels	  in	  the	  Osx1-­Cre;K-­rasG12D	  mutants	  and	  wild	  type	  controls	  (Figure	  3A).	  ISH	  for	  Col1	  at	  E14.5	  showed	  that	  the	  bone	  collar	  was	  present	  at	  this	  stage	  in	  the	  mutants.	  However,	  at	  E18.5,	  Col1	  cells	  were	  present	  at	  high	  levels	  in	  wildtype	  controls	  but	  were	  largely	  absence	  in	  the	  mutants	  (Figure	  3B).	  	  We	  also	  conducted	  ISH	  for	  Osteopontin	  (OPN),	  a	  late	  stage	  differentiation	  marker	  that	  is	  expressed	  in	  both	  chondrocytes	  and	  osteoblasts.	  	  We	  found	  that	  OPN	  expression	  was	  present	  in	  the	  mutants	  at	  E18.5	  and	  it	  was	  essential	  normal	  in	  the	  chondrocytes	  compartment	  (Figure	  3B).	  	  In	  contrast,	  we	  found	  no	  detectable	  staining	  in	  the	  region	  of	  the	  bone	  where	  osteoblasts	  normally	  reside,	  which	  is	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Figure	  3.	  In	  situ	  hybridization	  analysis	  for	  osteoblast	  markers	  at	  different	  
stages	  of	  embryonic	  development.	  (A)	  ISH	  at	  E14.5	  shows	  similar	  expression	  of	  both	  Col2	  and	  Col1	  markers	  in	  mutant	  versus	  control	  limbs.	  (B)	  At	  E18.5,	  there	  a	  very	  few	  Col1	  cells	  present	  in	  the	  mutant	  limbs.	  OPN	  staining	  is	  present	  in	  both	  mutants	  and	  controls	  in	  the	  chondrocyte	  compartment	  but	  is	  absent	  in	  the	  region	  of	  the	  mutant	  bone	  where	  osteoblasts	  should	  reside.	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essentially	  the	  region	  of	  the	  fracture.	  	  Notably,	  in	  addition	  to	  be	  OPN	  negative,	  the	  tissue	  in	  this	  fracture	  site	  was	  also	  Col1	  negative	  suggesting	  that	  these	  cells	  do	  not	  originate	  from	  osteoblast	  precursors.	  	  We	  hypothesize	  that	  this	  is	  fibrotic	  tissue.	  Taken	  together,	  our	  analyses	  show	  that	  induction	  of	  hyperactive	  K-­‐ras	  expression	  within	  osteoblast	  precursors	  is	  sufficient	  to	  completely	  block	  terminal	  osteoblast	  differentiation.	  	  
Expression	  of	  K-­rasG12D	  has	  different	  effects	  on	  osteoblast	  terminal	  
differentiation	  when	  induced	  during	  embryonic	  development	  versus	  after	  
birth.	  	  	  
	   Experiments	  to	  date	  were	  conducted	  in	  the	  absence	  of	  Dox,	  and	  thus	  expression	  of	  K-­‐rasG12D	  wass	  triggered	  by	  the	  expression	  of	  Osx	  in	  osteoblast	  progenitors	  around	  E12.5.	  	  We	  wanted	  to	  extend	  this	  analysis	  to	  determine	  the	  consequences	  of	  activating	  K-­‐rasG12D	  in	  the	  same	  progenitor	  population	  (ie	  under	  the	  control	  of	  Osx)	  at	  other	  stages	  of	  skeletal	  development.	  	  For	  this,	  Osx1-­Cre	  males	  were	  crossed	  with	  K-­rasG12D	  females	  and,	  when	  plugs	  were	  detected,	  the	  pregnant	  females	  were	  transferred	  to	  doxycycline-­‐containing	  food.	  	  This	  acts	  to	  prevent	  the	  expression	  of	  the	  Cre	  recombinase,	  and	  thus	  K-­‐rasG12D	  expression	  in	  the	  developing	  embryos.	  	  At	  various	  stages	  of	  pregnancy,	  E9.5,	  E11.5,	  E14.5,	  E16.5	  and	  E18.5,	  the	  pregnant	  females	  were	  switched	  to	  normal	  food	  to	  relieve	  inhibition	  of	  Cre	  and	  allow	  K-­‐rasG12D	  expression	  specifically	  in	  Osx	  positive	  cells	  in	  the	  embryos.	  	  Skeletal	  development	  was	  then	  assessed	  at	  E18.5.	  	  When	  we	  released	  Cre	  at	  either	  E9.5	  or	  E11.5,	  the	  mice	  displayed	  short,	  under-­‐mineralized	  and	  fractured	  bones	  that	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phenocopied	  those	  of	  the	  non-­‐Dox	  treated	  mutants	  (Figure	  4A).	  	  In	  stark	  contrast,	  we	  found	  that	  delaying	  the	  expression	  of	  Cre	  until	  E14.5,	  E16.5	  and	  E18.5	  completely	  rescued	  both	  the	  bone	  defects	  and	  the	  embryonic	  lethality	  (Figure	  4A).	  This	  identifies	  a	  period	  of	  embryonic	  development	  somewhere	  around	  E14.5	  in	  which	  the	  Osx-­‐positive	  osteoblast	  precursors	  are	  especially	  vulnerable	  to	  the	  hyperactive	  K-­‐ras	  expression.	  We	  next	  wanted	  to	  investigate	  the	  effects	  of	  activating	  K-­‐rasG12D	  in	  the	  osteoblast	  lineage	  after	  birth.	  To	  do	  this,	  we	  followed	  the	  development	  of	  mice	  in	  which	  the	  Osx-­‐Cre	  expression	  was	  inhibited	  throughout	  gestation	  via	  Dox	  treatment	  and	  induced	  right	  after	  birth	  via	  Dox	  withdrawal.	  	  We	  analyzed	  the	  resulting	  Osx1-­
Cre;K-­rasG12D	  animals	  at	  2	  weeks	  and	  6	  weeks	  of	  age.	  	  The	  bone	  phenotype	  of	  these	  mice	  was	  remarkably	  different	  from	  that	  of	  animals	  in	  which	  K-­‐rasG12D	  was	  expressed	  in	  osteoablasts	  through	  embryogenesis.	  	  Specifically,	  instead	  of	  fractured	  and	  under-­‐mineralized	  bones,	  the	  long	  bones	  had	  increased	  mineralization	  in	  their	  trabecular	  area.	  	  Indeed,	  the	  bone	  matrix	  was	  abnormally	  thick	  and	  it	  had	  almost	  completely	  filled	  the	  bone	  marrow	  space	  (Figure	  4B).	  Thus,	  our	  data	  shows	  that	  hyperactivation	  of	  K-­‐rasG12D	  yields	  different	  outcomes	  at	  different	  stages	  of	  skeletal	  development;	  it	  blocks	  bone	  formation	  when	  induced	  in	  mid-­‐embryogenesis	  but	  greatly	  enhances	  this	  process	  when	  triggered	  in	  neonates.	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Figure	  4.	  Distinct	  temporal	  effects	  of	  K-­rasG12D	  expression	  in	  osteoblasts.	  (A)	  Inhibition	  of	  Cre	  in	  Osx1-­Cre;	  K-­rasG12D	  mice	  until	  E14.5,	  E16.5	  and	  E18.5	  completely	  rescues	  the	  bone	  phenotype	  in	  embryos	  analyzed	  at	  E18.5.	  When	  Cre	  is	  inhibited	  until	  E9.5	  and	  E11.5	  the	  phenotype	  is	  not	  rescued,	  and	  the	  bones	  are	  short	  and	  thin,	  fractured	  at	  the	  middle.	  (B)	  Osx1-­Cre;K-­rasG12D	  mice	  treated	  with	  Dox	  from	  conception	  until	  birth,	  were	  analyzed	  at	  6	  weeks	  old	  and	  show	  an	  increase	  in	  mineralization	  and	  a	  lack	  of	  bone	  marrow	  in	  the	  long	  bones.	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K-­rasG12D	  changes	  fate	  commitment	  of	  osteoblasts	  from	  bone	  to	  fat	  in	  an	  in	  
vitro	  setting	  
Having	  seen	  differential	  effects	  of	  K-­‐ras	  on	  osteoblast	  differentiation	  in	  different	  in	  vivo	  settings,	  we	  wanted	  to	  establish	  whether/how	  K-­‐ras	  affected	  osteoblast	  differentiation	  in	  vitro.	  	  By	  staining	  for	  β-­‐galactosidase	  in	  Osx1-­Cre;LacZ	  mice,	  	  we	  showed	  above	  that	  Osx1	  is	  highly	  expressed	  in	  the	  calvaria	  of	  mice	  at	  E18.5	  (Figure	  1A).	  	  Thus,	  we	  isolated	  osteoblast	  precursors	  from	  the	  calvaria	  of	  E18.5	  Osx1-­Cre;K-­rasG12D	  and	  wildtype	  littermates	  that	  had	  not	  been	  exposed	  to	  Dox,	  and	  thus	  expressed	  K-­‐rasG12D	  from	  mid-­‐gestation.	  	  These	  cells	  were	  placed	  in	  culture	  and	  tested	  for	  their	  ability	  to	  differentiate	  into	  either	  bone	  or	  fat	  in	  response	  to	  appropriate	  induction	  media	  (Figure	  5A).	  	  The	  extent	  of	  bone	  and	  fat	  differentiation	  was	  assessed	  by	  staining	  with	  Alizarin	  Red	  (for	  bone	  matrix)	  or	  Oil-­‐red-­‐O	  (for	  lipid	  droplets).	  	  As	  expected,	  the	  wildtype	  osteoblast	  precursors	  were	  able	  to	  differentiate	  into	  bone	  but	  not	  fat	  in	  vitro	  (Figure	  5B).	  	  In	  stark	  contrast,	  cells	  from	  
Osx1-­Cre;K-­rasG12D	  mutants	  displayed	  a	  reduced	  ability	  to	  make	  bone	  matrix	  and	  they	  had	  also	  acquired	  the	  capacity	  to	  differentiate	  into	  fat	  (n=5).	  	  	  These	  observations	  have	  important	  relevance	  for	  skeletal	  diseases	  that	  display	  a	  defect	  in	  the	  normal	  bone	  to	  fat	  ratio	  within	  limbs.	  Studies	  on	  animal	  models	  for	  osteoporosis	  indicate	  that	  this	  disease	  is	  caused	  by	  an	  unbalance	  between	  the	  amounts	  of	  mineralized	  bone	  and	  fat	  found	  in	  the	  long	  bones.	  When	  there	  is	  too	  much	  fat,	  osteoporosis	  occurs,	  making	  the	  bones	  fragile	  and	  brittle.	  Studies	  have	  suggested	  that	  osteoblasts	  can	  switch	  fate	  and	  differentiate	  to	  adipocytes,	  leading	  to	  the	  osteoporotic	  phenotypes	  (Wu	  et	  al.,	  2011a).	  	  




Figure	  5.	  Expression	  of	  K-­rasG12D	  inhibits	  in	  vitro	  the	  differentiation	  of	  
osteoblasts	  to	  bone	  and	  promotes	  fat	  differentiation.	  (A)	  Osteoblasts	  are	  isolated	  from	  the	  calvaria	  of	  Osx1-­Cre;	  K-­rasG12D	  mutants	  and	  cultured	  on	  6-­‐well	  plates	  in	  special	  bone	  or	  fat	  differentiation	  media.	  (B)	  After	  14	  days	  of	  in	  vitro	  differentiation	  K-­‐rasG12D	  osteoblasts	  do	  not	  form	  bone	  compared	  to	  wild	  type	  osteoblasts,	  however	  they	  acquire	  the	  new	  ability	  to	  differentiate	  into	  adipocytes.	  (C).	  Western	  Blot	  analysis	  shows	  that	  osteoblasts	  expressing	  K-­‐rasG12D	  express	  increased	  levels	  of	  Sprouty2	  when	  they	  are	  freshly	  collected	  from	  the	  calvaria.	  The	  expression	  of	  Spy2	  goes	  down	  after	  14	  days	  in	  bone	  differentiation	  medium.	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To	  better	  understand	  the	  molecular	  basis	  of	  the	  altered	  fate	  commitment	  of	  the	  Osx1-­Cre;K-­rasG12D	  mutant	  osteoblasts,	  we	  investigated	  the	  expression	  of	  other	  members	  of	  the	  MAPK	  pathway	  within	  these	  cells.	  	  Sprouty2	  is	  an	  inhibitor	  of	  Ras	  and	  the	  MAPK	  signaling	  pathway.	  By	  suppressing	  the	  Ras/MAPK	  pathway	  and	  generating	  a	  negative	  feedback	  loop	  during	  development,	  Sprouty	  is	  known	  to	  regulate	  several	  signaling	  pathways	  and	  affects	  common	  signal	  mediators.	  	  In	  particular,	  Sprouty	  has	  been	  shown	  to	  act	  as	  a	  switch	  of	  mesenchymal	  stem	  cell	  lineage	  allocation	  (Urs	  et	  al.,	  2010).	  Thus	  we	  examined	  the	  levels	  of	  Sprouty2	  in	  the	  calvarial	  osteoblast	  precursors	  from	  Osx1-­Cre;K-­rasG12D	  and	  wildtype	  mice	  by	  western	  blotting	  (Figure	  5C).	  	  This	  analysis	  showed	  that	  Sprouty2	  was	  expressed	  at	  higher	  levels	  in	  the	  K-­‐rasG12D-­‐expressing	  versus	  the	  wildtype	  osteoblasts.	  	  Notably,	  induction	  of	  bone	  differentiation	  caused	  the	  Sprouty2	  to	  be	  downregulated	  in	  both	  genotypes,	  but	  the	  levels	  were	  still	  higher	  in	  mutant	  versus	  wildtype	  cells.	  	  Thus,	  deregulation	  of	  members	  of	  the	  Sprouty	  family	  might	  contribute	  to	  the	  altered	  in	  
vitro	  differentiation	  capacity	  of	  the	  K-­‐ras	  mutant	  osteoblasts.	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DISCUSSION	  In	  this	  study,	  by	  specifically	  expressing	  hyperactive	  K-­‐ras	  in	  osteoblast	  precursors	  under	  the	  control	  of	  the	  Osx	  promoter,	  we	  have	  identified	  two	  important	  time	  windows	  in	  which	  K-­‐rasG12D	  expression	  yields	  divergent	  effects	  on	  osteoblast	  differentiation.	  First,	  our	  data	  show	  that	  K-­‐rasG12D	  expression	  negatively	  regulates	  osteoblast	  differentiation	  when	  it	  is	  expressed	  in	  osteoblasts	  precursors	  during	  embryonic	  development.	  In	  this	  context,	  hyperactive	  K-­‐ras	  yields	  fragile,	  fractured	  bones	  and	  an	  under	  mineralized	  calvaria	  in	  the	  mutant	  mice.	  In	  contrast,	  when	  K-­‐rasG12D	  is	  expressed	  in	  osteoblasts	  precursors	  after	  birth,	  we	  show	  that	  it	  positively	  regulates	  bone	  development	  and	  osteoblast	  differentiation,	  leading	  to	  increased	  mineralization	  in	  the	  long	  bones.	  	  One	  possible	  explanation	  for	  the	  opposing	  phenotypes	  described	  above,	  is	  that	  activation	  of	  K-­‐rasG12D	  causes	  a	  differentiation	  block	  in	  Osx-­‐expressing	  osteoblasts	  only	  in	  early,	  and	  not	  later,	  stages	  of	  development.	  This	  inability	  to	  produce	  mineralizing	  osteoblasts	  could	  be	  caused	  by	  the	  apoptosis	  of	  Osx-­‐expressing	  cells,	  a	  block	  in	  their	  differentiation	  potential	  and/or	  reflect	  an	  alteration	  in	  the	  fate	  commitment	  of	  the	  osteoblastic	  precursors.	  	  K-­‐rasG12D	  is	  known	  to	  induce	  apoptosis	  in	  a	  p53	  dependent	  manner.	  	  Thus,	  to	  assess	  whether	  K-­‐rasG12D	  expression	  induces	  osteoblast	  apoptosis,	  we	  generated	  Orx1-­Cre;p53c/c;K-­rasG12D	  mice	  and	  showed	  that	  E18.5	  animals	  display	  the	  same	  bone	  defects	  as	  Osx1-­Cre;K-­
rasG12D	  mutants,	  including	  thin,	  under-­‐mineralized	  and	  broken	  long	  bones.	  	  Based	  on	  these	  findings,	  we	  believe	  that	  the	  bone	  phenotype	  of	  Osx1-­Cre;K-­rasG12D	  is	  unlikely	  to	  be	  due	  to	  programmed	  cell	  death	  or	  senescence.	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  We	  note	  that	  expression	  of	  K-­‐rasG12D	  in	  Osx-­‐expressing	  cells	  after	  birth	  does	  not	  affect	  their	  survival,	  or	  their	  ability	  to	  differentiate	  normally	  and	  populate	  the	  center	  of	  the	  bone.	  We	  speculate	  that,	  at	  this	  stage,	  K-­‐rasG12D	  acts	  more	  as	  an	  oncogene,	  presumably	  by	  stimulating	  an	  abnormally	  high	  rate	  of	  proliferation	  in	  the	  Osx-­‐expressing	  cells	  and	  causing	  them	  to	  completely	  fill	  the	  bone	  marrow	  space	  within	  the	  long	  bones.	  	  Obviously,	  it	  will	  be	  interesting	  to	  understand	  why	  Osx-­‐expressing	  osteoblasts	  in	  mid-­‐gestation	  versus	  in	  neonates	  respond	  so	  differently	  to	  K-­‐rasG12D.	  	  It	  is	  possible	  that	  these	  cells	  have	  differences	  in	  their	  intrinsic	  gene	  expression	  pattern	  that	  accounts	  for	  their	  opposing	  responses	  to	  K-­‐rasG12D	  activation.	  	  Alternatively,	  the	  opposing	  response	  may	  result	  from	  distinct	  external/environmental	  cues	  that	  exist	  at	  each	  of	  these	  stages.	  	  Obviously,	  these	  two	  hypotheses	  are	  not	  mutually	  exclusive.	  	  	  We	  have	  identified	  a	  developmental	  time	  window,	  around	  embryonic	  day	  E14.5,	  when	  activated	  K-­‐ras	  is	  necessary	  to	  cause	  the	  mutant	  phenotype	  in	  Osx1-­
Cre;K-­rasG12D	  embryos.	  If	  we	  protect	  this	  period	  from	  constitutive	  K-­‐ras	  expression,	  by	  doxycycline	  treatment,	  we	  completely	  suppress	  the	  embryonic	  bone	  defect.	  	  We	  note	  that	  this	  critical	  developmental	  time	  window	  is	  not	  completely	  defined	  since	  the	  doxycycline	  regulatable	  Tet-­‐Off	  system	  has	  some	  caveats.	  First,	  since	  we	  did	  observe	  some	  positive	  LacZ	  staining	  in	  Osx1-­Cre;LacZ	  embryos	  that	  were	  treated	  with	  doxycycline	  from	  conception	  until	  the	  time	  of	  sacrifice	  at	  E18.5,	  we	  note	  that	  Dox	  does	  not	  completely	  prevent	  Cre	  expression.	  	  Second,	  the	  precise	  time	  of	  doxycycline	  clearance	  from	  the	  body	  once	  the	  diet	  has	  stopped	  is	  unclear,	  and	  may	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even	  vary	  at	  different	  locations	  in	  the	  body	  or	  at	  different	  stages	  of	  development.	  	  Despite	  these	  limitations,	  the	  embryonic	  time	  window	  identified	  in	  this	  current	  study	  converges	  on	  the	  same	  time	  window	  identified	  in	  chapter	  2	  in	  which	  MEK	  inhibitor	  treatment	  of	  the	  Prx1-­Cre;	  K-­rasG12D	  mutants	  until	  E14.5	  was	  sufficient	  to	  rescue	  their	  embryonic	  mutant	  limb	  phenotype.	  Future	  studies	  will	  be	  needed	  to	  determine	  which	  events	  in	  normal	  bone	  development	  at	  E14.5	  are	  derailed	  by	  K-­‐rasG12D	  expression	  in	  each	  of	  these	  models.	  We	  would	  also	  like	  to	  learn	  more	  about	  the	  bone	  overgrowth	  that	  arises	  in	  the	  Osx1-­Cre;K-­rasG12D	  mutants	  in	  which	  K-­‐rasG12D	  is	  activated	  starting	  at	  birth.	  	  Unfortunately,	  we	  found	  that	  these	  animals	  sometimes	  get	  lung	  tumors	  and	  skin	  papillomas	  around	  6	  weeks	  of	  age	  (data	  not	  shown).	  This	  is	  most	  probably	  due	  to	  leaky	  K-­‐rasG12D	  expression	  in	  other	  tissues,	  since	  K-­‐ras	  is	  a	  powerful	  oncogene	  known	  to	  cause	  lung	  and	  skin	  tumors	  in	  mice.	  We	  note	  that	  there	  are	  reports	  of	  human	  osteosarcomas	  caused	  by	  mutations	  in	  members	  of	  the	  K-­‐ras/MAPK	  pathway	  (Ikeda	  et	  al.,	  1989)	  and	  it	  is	  possible	  that	  the	  Osx1-­Cre;K-­rasG12D/+	  mouse	  model	  would	  eventually	  develop	  bone	  tumors.	  However,	  since	  the	  lung	  tumors	  appear	  faster,	  the	  mice	  die	  before	  we	  are	  able	  to	  assess	  whether	  osteosarcoma	  might	  develop.	  The	  MAPK	  pathway	  is	  known	  to	  control	  stem	  cell/	  progenitor	  lineage	  decision	  in	  differentiating	  systems,	  such	  as	  muscle	  and	  fat.	  For	  example,	  in	  fat	  ERK1	  phosphorylates	  PPARγ	  and	  inhibits	  its	  activity,	  blocking	  adipogenesis	  as	  a	  result	  (Adams	  et	  al.,	  1997).	  In	  X.	  laevis	  muscle	  differentiation,	  MAPK	  increases	  the	  levels	  of	  XMyoD,	  a	  master	  regulator	  of	  muscle	  differentiation	  (Zetser	  et	  al.,	  2001).	  Thus,	  it	  is	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possible	  that	  in	  the	  context	  of	  osteogenesis,	  MAPK	  pathway	  also	  plays	  a	  role	  in	  controlling	  the	  decision	  of	  osteoblasts	  to	  differentiate	  into	  bone-­‐forming	  cells	  versus	  adipocytes.	  The	  ability	  of	  K-­‐rasG12D	  expression	  to	  induce	  a	  fate	  change	  in	  osteoblasts	  from	  bone	  to	  fat	  may	  offer	  an	  explanation	  of	  the	  exhaustion	  of	  osteoblasts	  capable	  of	  forming	  mineralized	  bone	  we	  observe	  in	  the	  Osx1-­Cre;K-­rasG12D	  mutant	  limbs	  during	  embryonic	  development.	  Since	  we	  cannot	  test	  this	  hypothesis	  in	  vivo,	  due	  to	  embryonic	  bones	  being	  to	  young	  to	  accumulate	  fat,	  we	  have	  used	  an	  in	  vitro	  approach.	  Specifically,	  we	  isolated	  osteoblasts	  form	  the	  calvaria	  of	  Osx1-­Cre;K-­
rasG12D	  mutant	  mice	  and	  showed	  in	  vitro	  that	  they	  have	  acquired	  a	  novel	  ability	  to	  differentiate	  to	  adipocytes,	  while	  their	  osteogenic	  ability	  is	  impaired.	  These	  experiments	  suggest	  a	  role	  for	  the	  MAPK	  pathway	  in	  controlling	  the	  decision	  of	  osteoblasts	  to	  differentiate	  into	  mature	  osteoblasts	  capable	  of	  secreting	  mineralized	  matrix	  or	  into	  fat	  forming	  cells.	  We	  further	  show	  that	  Sprouty2	  is	  over-­‐expressed	  in	  osteoblasts	  that	  express	  K-­‐rasG12D,	  and	  its	  expression	  goes	  down	  as	  they	  differentiate	  into	  bone.	  Future	  studies	  could	  analyze	  in	  depth	  the	  molecular	  mechanisms	  through	  which	  aberrant	  MAPK	  signaling	  regulates	  osteoblast	  differentiation.	  For	  example,	  one	  can	  investigate	  if	  K-­‐rasG12D	  acts	  directly	  through	  Sprouty,	  and	  whether	  Sprouty	  is	  essential	  in	  determining	  the	  expanded	  fate	  specification	  conferred	  by	  K-­‐ras	  activation	  in	  osteoblasts.	  	  
Interestingly,	  it	  may	  be	  possible	  to	  use	  our	  model	  to	  investigate	  if	  K-­‐rasG12D	  has	  a	  similar	  effect	  on	  osteoblast	  fate	  specification	  in	  an	  in	  vivo	  setting.	  Specifically,	  we	  can	  analyze	  Osx1-­Cre;K-­rasG12D	  adults,	  in	  which	  K-­‐rasG12D	  was	  activated	  after	  birth.	  An	  increase	  in	  the	  amount	  of	  fat	  in	  the	  long	  bones	  of	  these	  mice	  would	  show	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that	  in	  vivo	  activated	  K-­‐ras	  is	  sufficient	  to	  induce	  osteoblasts	  to	  change	  fate	  and	  become	  adipocytes.	  This	  type	  of	  study	  would	  be	  very	  relevant	  to	  the	  field	  of	  osteoporosis	  research.	  Osteoporosis	  is	  a	  disease	  in	  which	  the	  bones	  become	  fragile	  and	  brittle	  because	  the	  bone	  mass	  is	  drastically	  reduced	  and	  replaced	  by	  fat.	  Thus,	  we	  have	  developed	  a	  mouse	  model	  that	  may	  be	  useful	  for	  addressing	  this	  important,	  disease	  relevant	  question.	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METHODS	  
Mouse	  husbandry	  and	  tissue	  collection	  Animal	  procedures	  followed	  protocols	  approved	  by	  MIT's	  Committee	  on	  Animal	  Care.	  The	  Osxl-­Cre,	  Prx1-­Cre	  and	  K-­rasG12D/+	  animals	  were	  maintained	  on	  a	  mixed	  genetic	  background.	  Tissues	  were	  fixed	  in	  PBS	  with	  3.7%	  formaldehyde.	  Prior	  to	  paraffin	  sectioning,	  soft	  tissues	  were	  dehydrated	  via	  an	  ethanol	  series,	  while	  bone-­‐containing	  tissue	  was	  decalcified	  in	  0.46M	  EDTA,	  2.5%	  Ammonium	  Hydroxide	  pH	  7.2.	  All	  paraffin	  embedded	  sections	  were	  cut	  at	  5pm,	  dewaxed	  and	  stained	  with	  H&E.	  
Skeletal	  stainings	  
Embryos	  were	  sacrificed,	  skinned	  and	  eviscerated.	  The	  remaining	  tissue	  was	  fixed	  in	  95%	  ethanol	  for	  4	  days,	  transferred	  to	  acetone	  for	  3	  days,	  and	  subsequently	  transferred	  to	  staining	  solution	  of	  0.015%	  Alcian	  Blue	  8GX	  (Sigma),	  0.005%	  Alizarin	  Red	  S	  (Sigma),	  and	  5%	  glacial	  acetic	  acid	  in	  ethanol	  at	  370C	  for	  2	  days	  and	  at	  room	  temperature	  for	  a	  one	  more	  day.	  Tissue	  was	  cleared	  in	  1%	  potassium	  hydroxide	  for	  several	  days	  and	  then	  stored	  in	  glycerol.	  	  
Alizarin	  Red	  staining	  For	  Alizarin	  Red	  staining,	  sections	  were	  rinsed	  in	  water,	  placed	  in	  2%	  Alizarin	  Red	  S	  (pH	  4.2)	  for	  5	  min,	  dipped	  20	  times	  in	  acetone	  followed	  by	  acetone:xylene	  (1:1)	  washing,	  and	  then	  mounted.	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Calvarial	  Osteoblasts	  Preparation	  and	  Culture	  Calvaria	  from	  embryonic	  day	  18.5	  embryos	  were	  removed	  and	  carefully	  cleaned	  in	  sterile	  PBS.	  Then	  calvaria	  was	  treated	  with	  several	  rounds	  of	  collagenase/trypsin	  digestion	  at	  370C,	  and	  plated	  onto	  six-­‐well	  plates	  for	  2	  days	  in	  αMEM	  with	  10%	  fetal	  bovine	  serum	  and	  penicillin/streptomycin.	  For	  differentiation,	  3.5x105	  cells	  were	  plated	  onto	  a	  well	  of	  a	  6-­‐well	  tissue	  culture	  plates.	  Upon	  reaching	  confluence,	  calvarial	  osteoblasts	  were	  treated	  with	  medium	  supplemented	  with	  50	  pg/mL	  of	  ascorbic	  acid	  and	  10	  mmol/L	  of	  p-­‐	  glycerol-­‐phosphate.	  Adenovirus	  (University	  of	  Iowa	  Gene	  Transfer	  Vector	  Core)	  was	  added	  to	  the	  medium	  at	  100	  plaque-­‐forming	  units	  per	  cell	  and	  washed	  away	  24	  h	  later.	  To	  assay	  for	  calcium	  deposits,	  plates	  were	  stained	  with	  1%	  Alizarin	  Red	  S	  solution	  (pH	  5.0)	  	  
X-­Gal	  Staining	  Adult	  and	  embryonic	  tissues	  were	  stained	  for	  β-­‐galactosidase	  activity	  as	  described	  in	  (Parisi	  et	  al.,	  2007).	  Briefly,	  dissected	  tissues	  were	  fixed,	  rinsed,	  and	  then	  stained	  overnight	  at	  370C	  in	  X-­‐Gal	  staining	  solution.	  Samples	  were	  then	  rinsed	  and	  fixed	  again	  before	  being	  processed	  for	  paraffin	  embedding.	  Sections	  were	  cut	  at	  5µm	  and	  counterstained	  with	  Nuclear	  Fast	  Red.	  	  
In	  situ	  hybridization	  Tissues	  were	  fixed	  in	  4%	  paraformaldehyde/PBS	  overnight	  at	  4°C,	  processed,	  embedded	  in	  paraffin,	  and	  cut.	  Non-­‐radioactive	  ISH,	  with	  digoxigenin	  (DIG)-­‐labeled	  probes	  (Chung	  et	  al.,	  1998;	  Murtaugh	  et	  al.,	  2001)	  was	  performed	  as	  described	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previously	  (Chung	  et	  al.,	  1998).	  In	  brief,	  sections	  were	  postfixed	  with	  4%	  PFA-­‐PBS	  for	  15	  min.	  After	  washing	  with	  PBS,	  sections	  were	  digested	  with	  1	  pg/ml	  proteinase-­‐K	  (37	  C;	  15	  min)	  in	  PBS	  and	  again	  treated	  with	  4%	  PFA-­‐PBS	  (10	  min).	  Sections	  then	  were	  sequentially	  washed	  with	  PBS,	  acetylated	  with	  0.25%	  acetic	  anhydride	  in	  the	  presence	  of	  triethanolamine	  (1	  M;	  10	  min),	  dehydrated	  with	  increasing	  concentrations	  of	  ethanol,	  and	  air	  dried.	  Hybridizations	  with	  complementary	  RNAs	  were	  performed	  in	  a	  humidified	  chamber	  in	  a	  solution	  containing	  50%	  formamide,	  10%	  dextran	  sulfate,	  1	  X	  Denhardt’s	  solution,	  600	  mM	  NaCl,	  10	  mM	  Tris-­‐HCl,	  1	  mM	  EDTA,	  50	  mM	  dithiothreitol,	  0.25%	  sodium	  dodecyl	  sulfate,	  and	  200	  pg/ml	  transfer	  RNA.	  After	  hybridization,	  sections	  were	  washed	  briefly	  with	  5	  X	  SSC	  at	  500C,	  50%	  formamide-­‐	  10X	  SSC	  (50	  C;	  30	  min),	  and	  10	  mM	  Tris-­‐HCl	  (pH	  7.6)-­‐500	  mM	  NaCl-­‐1	  mM	  EDTA	  (TNE;	  370C;	  10	  min).	  Sections	  were	  then	  treated	  with	  10	  pg/ml	  ribonuclease-­‐A	  in	  TNE	  (37	  C;	  30	  min).	  After	  being	  washed	  with	  TNE,	  sections	  were	  incubated	  once	  with	  2	  X	  SSC	  (50	  C;	  20	  min)	  and	  twice	  with	  0.2	  X	  SSC	  (50	  C;	  20	  min),	  dehydrated	  with	  increasing	  concentrations	  of	  ethanol,	  and	  air-­‐dried.
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Mitogen-­‐activated	  protein	  kinases	  (MAPKs)	  are	  well-­‐characterized	  signal	  transducers	  that	  have	  been	  intensively	  studied	  for	  their	  ability	  to	  mediate	  neoplastic	  transformation	  (Greenblatt	  et	  al.,	  2013).	  In	  addition	  to	  the	  role	  of	  MAPK	  signaling	  in	  cancer,	  other	  studies	  have	  expanded	  our	  understanding	  of	  how	  members	  of	  this	  pathway	  function	  during	  development	  (Corson	  et	  al.,	  2003;	  Galabova-­‐Kovacs	  et	  al.,	  2006).	  Many	  of	  these	  studies	  have	  focused	  on	  modeling	  developmental	  syndromes	  caused	  by	  aberrant	  Ras/MAPK	  signaling	  (Tidyman	  and	  Rauen,	  2009).	  Importantly,	  there	  is	  considerable	  interest	  in	  understanding	  of	  how	  MAPK	  pathway	  functions	  during	  skeletal	  development.	  	  In	  this	  thesis,	  we	  have	  generated	  two	  novel	  mouse	  models	  to	  investigate	  the	  effects	  of	  aberrant	  MAPK	  signaling	  during	  bone	  development	  and	  understand	  how	  bone	  mass	  is	  regulated	  via	  MAPK	  control	  of	  osteoblast	  differentiation.	  Specifically,	  we	  expressed	  a	  hyperactive	  form	  of	  K-­‐ras	  either	  in	  all	  mesenchymal	  lineages,	  including	  osteoblasts	  and	  chondrocytes,	  or	  specifically	  in	  osteoblasts.	  When	  we	  express	  K-­‐rasG12D	  in	  all	  mesenchymal	  lineages,	  using	  the	  Prx	  promoter,	  the	  Prx1-­Cre;K-­rasG12D	  mutant	  mice	  die	  at	  birth	  most	  of	  the	  time,	  and	  they	  all	  display	  abnormal	  skeletons.	  Their	  long	  bones	  are	  short	  and	  thick,	  and	  they	  have	  increased,	  abnormal	  cortical	  and	  trabecular	  mineralization.	  The	  bone	  defect	  becomes	  evident	  around	  embryonic	  day	  E14.5	  when	  we	  observe	  a	  delay	  in	  the	  formation	  of	  the	  bone	  collar	  in	  the	  mutant	  mice.	  Importantly,	  if	  we	  treat	  these	  K-­‐rasG12D	  expressing	  mutants	  with	  a	  MEK	  inhibitor	  from	  E10.5	  to	  E14.5	  then	  the	  bone	  phenotype	  is	  completely	  suppressed	  up	  to	  birth.	  Thus,	  by	  treatment	  with	  MEK	  inhibitors	  we	  identified	  a	  critical	  stage	  during	  development	  when	  aberrant	  K-­‐ras	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expression	  causes	  the	  mutant	  phenotype.	  	  In	  parallel	  with	  analyzing	  the	  Prx1-­Cre;K-­rasG12D	  mutant	  mice,	  we	  expressed	  K-­‐rasG12D	  specifically	  in	  osteoblast	  precusors,	  under	  the	  control	  of	  the	  Osx	  promoter.	  The	  Osx1-­Cre;K-­rasG12D	  mouse	  model	  also	  contains	  a	  Tet-­‐Off	  regulatable	  system	  and	  therefore	  has	  the	  added	  advantage	  of	  allowing	  temporal	  control	  of	  Cre	  expression,	  and	  thus	  K-­‐rasG12D	  induction,	  through	  doxycycline	  administration.	  In	  chapter	  3	  we	  show	  that	  by	  using	  doxycycline	  to	  inhibit	  Cre	  expression	  at	  various	  times	  during	  development,	  we	  identify	  the	  same	  critical	  time	  window	  during	  embryonic	  development	  (around	  day	  E14.5)	  when	  aberrant	  K-­‐ras	  signaling	  is	  sufficient	  to	  cause	  the	  mutant	  phenotype.	  Despite	  the	  fact	  that	  the	  two	  mouse	  models	  converge	  on	  the	  same	  developmental	  time	  window	  when	  the	  phenotype	  first	  becomes	  visible	  and	  when	  aberrant	  K-­‐ras	  signaling	  is	  absolutely	  required	  to	  cause	  the	  mutant	  phenotype,	  the	  defects	  we	  see	  in	  the	  two	  settings	  are	  drastically	  different.	  While	  
Prx1-­Cre;K-­rasG12D	  mutant	  mice	  have	  short,	  thick	  bones,	  with	  increased	  mineralization,	  the	  Osx1-­Cre;K-­rasG12D	  mutant	  mice	  have	  short,	  fractured	  and	  under-­‐mineralized	  limbs.	  In	  chapter	  3	  we	  also	  show	  that	  when	  we	  express	  K-­‐rasG12D	  under	  the	  control	  of	  the	  Osx	  promoter	  after	  birth,	  i.e.	  in	  the	  same	  population	  of	  cells	  but	  at	  a	  different	  time	  during	  the	  development	  of	  the	  organism,	  we	  obtain	  an	  increase	  in	  bone	  mass	  and	  in	  the	  mineralization	  of	  the	  limbs.	  Thus,	  we	  define	  a	  second	  time	  window,	  starting	  at	  birth,	  when	  aberrant	  K-­‐ras	  signaling	  in	  osteoblasts	  leads	  to	  a	  distinct	  phenotype	  (increased	  bone	  mass)	  from	  the	  one	  observed	  when	  this	  pathway	  is	  activated	  during	  the	  first	  embryonic	  developmental	  time	  window	  (decreased	  bone	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mass).	  	  Taken	  together,	  our	  findings	  have	  raised	  the	  following	  interesting	  questions	  that	  will	  be	  discussed	  in	  greater	  detail	  in	  this	  chapter:	  1. What	  are	  the	  events	  in	  bone	  development	  affected	  by	  aberrant	  K-­‐ras/	  MAPK	  signaling	  specifically	  at	  E14.5?	  2. Why	  do	  we	  see	  distinct	  phenotypes	  when	  we	  express	  hyperactive	  K-­‐ras	  in	  mesenchymal	  lineages	  versus	  osteoblast	  precursors?	  3. Why	  do	  we	  see	  distinct	  phenotypes	  when	  constitutive	  K-­‐ras	  expression	  is	  activated	  in	  Osx	  expressing	  osteoblasts	  precursors	  in	  mid-­‐gestation	  versus	  after	  birth?	  4. What	  are	  the	  implications	  of	  our	  studies	  for	  human	  diseases	  in	  which	  there	  is	  a	  skeletal	  phenotype	  caused	  by	  hyperactive	  MAPK	  signaling?	  	  
4.1.	  Identification	  of	  a	  critical	  developmental	  time	  period	  during	  bone	  
development	  specifically	  affected	  by	  aberrant	  MAPK	  signaling	  In	  chapters	  2	  and	  3	  we	  describe	  a	  key	  critical	  period	  during	  embryonic	  development	  when	  aberrant	  MAPK	  signaling	  affects	  bone	  development.	  In	  both	  
Prx1-­Cre;K-­rasG12D	  and	  Osx1-­Cre;K-­rasG12D	  	  mouse	  models	  we	  see	  that	  the	  defects	  become	  visible	  around	  embryonic	  day	  E14.5.	  In	  both	  mutants,	  if	  this	  restricted	  period	  is	  protected	  from	  K-­‐rasG12D	  expression,	  either	  by	  treatment	  with	  MEK	  inhibitor	  (for	  the	  Prx	  model)	  or	  by	  inhibition	  with	  doxycycline	  (for	  the	  Osx	  model),	  the	  bone	  phenotype	  is	  rescued.	  Future	  studies	  should	  focus	  on	  how	  activated	  K-­‐rasG12D	  signaling	  affects	  proper	  bone	  development	  specifically	  during	  this	  key	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embryonic	  period	  around	  E14.5.	  What	  are	  events	  that	  occur	  during	  normal	  bone	  development	  at	  this	  stage	  and	  are	  affected	  by	  aberrant	  MAPK	  signaling?	  	  In	  the	  Prx1-­Cre;K-­rasG12D	  mutants	  we	  identify	  a	  delay	  in	  the	  formation	  of	  the	  bone	  collar	  at	  E14.5.	  During	  bone	  development,	  the	  Col1	  osteoblasts	  that	  form	  the	  bone	  collar	  originate	  from	  Col2	  osteochondral	  progenitors	  (Maes	  et	  al.,	  2010).	  We	  hypothesize	  that	  there	  is	  a	  defect	  with	  the	  migration	  of	  the	  Col2	  progenitors	  to	  the	  location	  of	  the	  future	  bone	  collar	  caused	  by	  K-­‐rasG12D	  expression.	  This	  hypothesis	  is	  supported	  by	  other	  studies	  in	  literature,	  since	  aberrant	  MAPK	  signaling	  has	  been	  shown	  to	  affect	  cell	  migration	  in	  systems	  such	  as	  zebrafish	  development	  (Anastasaki	  et	  al.,	  2012)	  Lineage	  tracing	  experiments	  in	  Col2-­CreERT2;K-­rasG12D;GFP	  embryos	  could	  offer	  an	  answer	  to	  this	  question.	  For	  example,	  if	  we	  inject	  with	  tamoxifen	  into	  females	  carrying	  embryos	  with	  the	  above	  genotype	  at	  day	  E12.5	  or	  E13.5	  and	  analyze	  E14.5	  limb	  sections,	  we	  could	  assess	  the	  migration	  of	  the	  GFP-­‐labeled,	  Col2	  cells	  to	  the	  location	  of	  the	  future	  bone	  collar	  to	  determine	  whether	  there	  is	  a	  defect.	  	  In	  Osx1-­Cre;K-­rasG12D	  mutants	  the	  defect	  is	  more	  subtle,	  but	  still	  visible	  at	  this	  E14.5	  stage.	  In	  this	  model,	  we	  do	  see	  evidence	  of	  normal	  bone	  collar	  formation	  based	  on	  Col1	  in	  situ	  hybridization.	  However,	  as	  seen	  in	  the	  H&E	  limb	  sections,	  osteoblasts	  from	  the	  perichondrium	  do	  not	  migrate	  into	  the	  center	  of	  the	  bone.	  At	  subsequent	  days	  in	  embryonic	  development,	  we	  notice	  a	  drastic	  reduction	  in	  the	  number	  of	  mineralizing	  osteoblasts	  in	  the	  long	  bones	  of	  the	  mutants.	  Since	  we	  observe	  the	  absence	  of	  osteoblasts	  later	  in	  the	  embryonic	  development	  of	  the	  limbs	  we	  hypothesize	  that	  expression	  of	  K-­‐rasG12D	  in	  osterix	  expressing	  osteoblast	  progenitors	  does	  not	  impair	  migration	  of	  Col2	  osteoprogenitors	  into	  the	  center	  of	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the	  bone,	  but	  it	  affects	  their	  survival	  either	  by	  causing	  them	  to	  undergo	  apoptosis	  or	  by	  inducing	  a	  change	  in	  their	  cell	  fate.	  Unfortunately,	  immunohistochemistry	  (IHC)	  for	  cleaved	  caspase	  3	  in	  E14.5	  limbs	  did	  not	  offer	  conclusive	  results.	  This	  could	  be	  due	  to	  the	  fact	  that	  the	  apoptosis	  and	  clearance	  of	  the	  K-­‐rasG12D	  expressing	  osteoblasts	  occurs	  quickly	  and	  thus	  we	  cannot	  catch	  it	  by	  IHC	  staining.	  In	  many	  other	  settings,	  the	  ability	  of	  K-­rasG12D	  to	  induce	  apoptosis,	  or	  cellular	  senescence,	  is	  p53	  dependent.	  	  Thus,	  we	  generated	  Osx1-­Cre;p53c/c;K-­rasG12D	  mice	  to	  assess	  if	  indeed	  osteoblasts	  die	  due	  to	  programmed	  cell	  death.	  Embryos	  at	  E18.5	  show	  a	  bone	  phenotype	  similar	  to	  the	  one	  seen	  in	  the	  Osx1-­Cre;K-­rasG12D	  embryos,	  more	  specifically	  the	  limbs	  are	  short	  and	  thin.	  This	  shows	  that	  p53	  inactivation	  is	  not	  required	  for	  the	  bone	  phenotype	  in	  Osx1-­Cre;K-­rasG12D	  embryos,	  arguing	  that	  this	  defect	  is	  unlikely	  to	  be	  due	  to	  programmed	  cell	  death	  or	  senescence.	  In	  the	  section	  4.4	  of	  this	  chapter	  I	  will	  discuss	  in	  more	  detail	  our	  efforts	  trying	  to	  investigate	  a	  defect	  in	  cell	  fate	  specification	  of	  the	  mutant	  osteoblasts.	  
It	  is	  important	  to	  note	  that	  the	  embryonic	  developmental	  time	  window	  we	  have	  identified	  is	  approximate	  in	  both	  mouse	  models.	  In	  the	  Osx1-­Cre;K-­rasG12D	  mice	  treated	  with	  doxycycline	  we	  cannot	  be	  sure	  when	  doxycycline	  is	  completely	  eliminated	  from	  the	  system,	  and	  thus	  when	  Cre	  and	  K-­‐rasG12D	  start	  to	  be	  expressed.	  Similarly,	  in	  the	  Prx1-­Cre;K-­rasG12D	  mice	  the	  injections	  with	  MEK	  inhibitor	  are	  also	  a	  source	  of	  variability	  in	  terms	  of	  both	  how	  quickly	  MAPK	  inhibition	  is	  achieved	  and	  released.	  However,	  experiments	  in	  both	  of	  these	  models	  converge	  on	  a	  similar	  developmental	  time	  window	  around	  E14.5,	  affected	  by	  aberrant	  MAPK	  signaling,	  which	  is	  consistent	  with	  when	  the	  phenotype	  becomes	  visible	  in	  these	  mice.	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4.2.	  K-­rasG12D	  activation	  leads	  to	  divergent	  bone	  phenotypes	  when	  expressed	  
in	  all	  mesenchymal	  lineages	  versus	  exclusively	  in	  the	  osteoblast	  lineage	  In	  the	  Prx1-­Cre;K-­rasG12D	  mutant	  mice,	  K-­‐rasG12D	  is	  expressed	  in	  early	  progenitors	  of	  the	  limb	  bud	  and	  thus	  affects	  all	  mesenchymal	  lineages,	  including	  osteoblast	  and	  cartilage	  lineages.	  As	  described	  in	  chapter	  2,	  most	  of	  these	  mice	  die	  at	  birth	  and	  have	  short	  and	  thick	  long	  bones.	  In	  Osx1-­Cre;K-­rasG12D	  mutant	  mice,	  K-­‐rasG12D	  is	  expressed	  in	  all	  osteoblast	  progenitors	  and	  affects	  the	  osteoblast	  lineage	  exclusively.	  As	  described	  in	  chapter	  3,	  these	  mice	  have	  fragile	  and	  brittle	  bones,	  with	  reduced	  mineralization	  in	  both	  the	  long	  bones	  and	  in	  the	  calvaria.	  	  	  The	  defect	  we	  see	  in	  the	  calvaria	  of	  the	  Osx1-­Cre;K-­rasG12D	  mice,	  a	  bone	  that	  develops	  through	  direct	  differentiation	  of	  mesenchymal	  progenitors	  to	  osteoblasts,	  suggests	  that	  expression	  of	  K-­‐rasG12D	  in	  this	  setting	  directly	  impairs	  osteoblast	  differentiation.	  Interestingly,	  the	  expression	  of	  the	  same	  mutation	  in	  both	  the	  osteoblast	  and	  cartilage	  lineages	  in	  the	  Prx1-­Cre;K-­rasG12D	  mice	  does	  not	  impair	  the	  ability	  of	  osteoblasts	  to	  differentiate	  into	  functioning	  adult	  mineralizing	  osteocytes,	  since	  these	  mice	  display	  dense	  trabecular	  and	  cortical	  mineralization.	  	  It	  is	  possible	  that	  the	  different	  phenotypes	  of	  our	  two	  mouse	  models	  could	  be	  due	  to	  different	  strengths	  of	  the	  K-­‐ras	  signaling	  in	  the	  two	  settings.	  Since	  in	  the	  
Prx1-­Cre;K-­rasG12D	  and	  Osx1-­Cre;K-­rasG12D	  mice	  mutant	  K-­‐rasG12D	  is	  driven	  off	  different	  promoters,	  Prx	  versus	  Osx,	  it	  is	  possible	  that	  a	  difference	  in	  the	  promoter	  strength	  leads	  to	  the	  different	  phenotypes.	  	  Alternatively,	  and	  more	  interesting,	  it	  seems	  feasible	  that	  K-­‐rasG12D	  affects	  different	  mesenchymal	  lineages	  and/or	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different	  stages	  in	  the	  differentiation	  of	  mesenchymal	  progenitors	  to	  committed	  bone	  progenitors.	  Therefore,	  two	  possibilities,	  not	  mutually	  exclusive,	  emerge:	  a)	  defects	  in	  the	  chondrocyte	  –	  osteoblast	  crosstalk	  modulates	  the	  mutant	  osteoblast	  phenotype	  in	  Prx1-­Cre;K-­rasG12D	  mice	  and/or	  b)	  the	  expression	  of	  K-­‐rasG12D	  in	  early	  versus	  late	  bone	  progenitors	  causes	  the	  distinct	  phenotypes	  in	  the	  Prx1-­Cre;K-­
rasG12D	  versus	  Osx1-­Cre;K-­rasG12D	  models.	  According	  to	  the	  first	  hypothesis	  it	  is	  possible	  that	  abnormal	  signaling	  between	  the	  mutant	  cartilage	  and	  osteoblasts	  in	  the	  Prx1-­Cre;K-­rasG12D	  mice	  is	  key	  in	  determining	  the	  differential	  phenotypes.	  To	  investigate	  this	  hypothesis,	  we	  wanted	  to	  exclusively	  express	  K-­‐rasG12D	  in	  the	  cartilage	  and	  check	  the	  phenotype	  of	  the	  resulting	  mice.	  Unfortunately,	  there	  is	  no	  gene	  or	  Cre	  mouse	  strain	  that	  is	  specific	  exclusively	  for	  chondrocyte	  precursors.	  Col2-­Cre	  is	  often	  used	  to	  target	  cartilage,	  but	  Col2	  it	  is	  expressed	  in	  osteo-­‐chondral	  progenitors	  that	  differentiate	  into	  both	  bone	  and	  cartilage	  cells.	  Indeed,	  when	  we	  generated	  Col2-­Cre;K-­rasG12D	  mice	  we	  found	  the	  same	  phenotype	  as	  in	  Prx1-­Cre;K-­rasG12D	  mice.	  Thus,	  we	  cannot	  separate	  the	  functions	  of	  osteoblasts	  and	  chondrocytes	  completely	  using	  a	  mouse	  strategy.	  Instead,	  we	  need	  to	  test	  the	  possible	  involvement	  of	  chondrocytes	  in	  the	  Prx1-­Cre;K-­
rasG12D	  mouse	  phenotype	  at	  a	  molecular	  level.	  Staining	  for	  factors	  important	  in	  cartilage	  –	  osteoblast	  signaling,	  such	  as	  Ihh	  or	  Ptch,	  would	  indicate	  whether	  defects	  in	  the	  crosstalk	  between	  osteoblasts	  and	  chondrocytes	  plays	  a	  role	  in	  the	  skeletal	  phenotype	  of	  the	  Prx1-­Cre;K-­rasG12D	  mice.	  According	  to	  the	  second	  hypothesis,	  uncommitted	  multipotent	  progenitors	  (Prx	  expressing	  cells)	  and	  committed	  osteoprogenitors	  (Osx	  expressing	  osteoblasts)	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respond	  differently	  to	  the	  same	  stimulus,	  hyperactive	  K-­‐rasG12D,	  thereby	  explaining	  the	  differential	  phenotypes	  we	  observe	  in	  these	  mice.	  Notably,	  other	  scientists	  working	  in	  the	  bone	  field	  have	  observed	  such	  opposing	  phenotypes.	  For	  example,	  NF1	  deletion	  in	  late	  stage	  osteoblasts	  (using	  the	  Col1-­‐Cre	  mouse)	  results	  in	  an	  increase	  in	  bone	  mass,	  while	  deleting	  NF1	  in	  osteochondral	  progenitors	  (using	  the	  Col2	  promoter)	  causes	  reduced	  bone	  mass	  and	  impaired	  osteoblast	  differentiation	  (Elefteriou	  et	  al.,	  2006;	  Wang	  et	  al.,	  2011;	  Wu	  et	  al.,	  2011).	  Moreover,	  similar	  to	  the	  opposing	  phenotypes	  we	  see	  in	  the	  Prx1-­Cre;K-­rasG12D	  and	  Osx1-­Cre;K-­rasG12D	  mice,	  deletion	  of	  NF1	  in	  Col2	  uncommitted	  osteo-­‐chondral	  progenitors	  versus	  committed	  Ocn	  osteoblasts	  also	  leads	  to	  distinct	  manifestations	  of	  phenotypes.	  	  	  
4.3.	  K-­rasG12D	  activation	  leads	  to	  divergent	  bone	  phenotypes	  when	  expressed	  
in	  the	  osteoblast	  lineage	  during	  development	  versus	  after	  birth	  In	  chapter	  3	  we	  showed	  that	  when	  K-­‐rasG12D	  is	  expressed	  exclusively	  in	  the	  osteoblast	  linage,	  but	  starting	  at	  different	  times	  during	  the	  development	  of	  the	  organism,	  mice	  develop	  opposing	  bone	  phenotypes.	  We	  have	  observed	  this	  difference	  in	  phenotypes	  in	  two	  different	  mouse	  models.	  In	  the	  first	  model,	  generated	  in	  collaboration	  with	  Tatsuya	  Kobayashi	  from	  MGH,	  we	  injected	  tamoxifen	  in	  females	  carrying	  Osx1-­CreERT2;K-­rasG12D	  embryos	  at	  days	  E14.5	  and	  E16.5	  and	  analyzed	  the	  pups	  at	  2	  weeks	  of	  age	  (data	  not	  shown).	  In	  this	  setting,	  we	  noticed	  an	  increase	  in	  the	  mineralization	  of	  the	  long	  bones	  in	  the	  mutant	  Osx1-­
CreERT2;K-­rasG12D	  mice	  (data	  not	  shown).	  In	  the	  second	  model	  (described	  in	  Chapter	  3),	  using	  the	  Tet-­‐Off	  doxycycline	  system	  specific	  to	  the	  Osx-­Cre	  mouse,	  we	  activated	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K-­‐rasG12D	  starting	  at	  birth	  in	  Osx1-­Cre;K-­rasG12D	  mice	  and	  analyzed	  the	  mice	  at	  6	  weeks	  of	  age.	  	  We	  obtained	  a	  similar	  phenotype	  as	  above,	  an	  increase	  in	  the	  bone	  mass	  in	  the	  limbs.	  	  Future	  studies	  should	  aim	  to	  understand	  at	  a	  molecular	  level	  why	  we	  see	  the	  divergent	  Osx-­‐driven	  K-­‐ras	  mutant	  phenotypes,	  in	  utero	  versus	  post	  birth.	  One	  hypothesis	  is	  that	  it	  could	  be	  an	  osteoblast	  cell	  autonomous	  effect	  due	  to	  a	  difference	  in	  the	  gene	  expression	  pattern	  that	  characterizes	  different	  developmental	  windows.	  Alternatively,	  the	  opposing	  phenotypes	  could	  be	  due	  to	  differential	  external	  cues	  that	  are	  different	  at	  various	  stages	  of	  mouse	  development.	  One	  could	  investigate	  these	  hypotheses	  by	  isolating	  osteoblasts	  from	  Osx1-­
Cre;K-­rasG12D	  mice,	  either	  the	  embryonic	  mutants	  that	  have	  the	  under-­‐mineralized	  bone	  or	  the	  mutants	  who	  have	  the	  increase	  in	  bone	  mass	  caused	  by	  K-­‐rasG12D	  activation	  after	  birth,	  and	  examining	  them	  in	  vitro	  where	  there	  can	  be	  no	  influence	  of	  external	  cues.	  However,	  the	  difficulty	  with	  performing	  this	  type	  of	  experiments	  will	  be	  to	  isolate	  osteoblasts	  from	  Osx1-­Cre;K-­rasG12D	  embryos.	  These	  mice	  have	  very	  few	  osteoblasts,	  both	  because	  they	  are	  very	  young	  and	  because	  they	  have	  under-­‐mineralized,	  fractured	  bones	  with	  very	  few	  osteoblasts.	  	  	  
4.4.	  K-­rasG12D	  affects	  the	  fate	  of	  osteoblast	  differentiation	  in	  an	  in	  vitro	  setting	  In	  chapter	  3	  of	  this	  thesis	  we	  have	  shown	  that	  K-­‐rasG12D	  has	  an	  effect	  on	  osteoblast	  differentiation	  in	  an	  in	  vitro	  setting.	  We	  have	  isolated	  osteoblasts	  from	  
Osx1-­Cre;K-­rasG12D	  mutant	  calvaria	  and	  then	  cultured	  them	  in	  media	  that	  promotes	  either	  bone	  or	  fat	  differentiation.	  We	  found	  that	  osteoblasts	  from	  the	  Osx1-­Cre;K-­
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rasG12D	  mutants,	  but	  not	  control	  animals,	  had	  acquired	  adipogenic	  capacity,	  while	  their	  osteogenic	  ability	  was	  impaired.	  	  Two	  hypotheses	  to	  explain	  this	  observation	  are	  that	  osteoblasts	  expressing	  activated	  K-­‐ras	  form	  more	  adipocytes	  either	  by	  changing	  their	  fate	  (trans-­‐differentiation)	  or	  by	  de-­‐differentiating	  to	  a	  more	  primitive	  cell,	  which	  is	  then	  is	  capable	  of	  forming	  either	  bone	  or	  fat.	  Either	  possibility	  would	  bring	  interesting	  insights	  into	  a	  novel	  function	  of	  K-­‐rasG12D	  in	  modulating	  mesenchymal	  lineage	  specification.	  Future	  studies	  should	  investigate	  if	  this	  phenotype	  is	  also	  seen	  in	  an	  in	  
vivo	  setting.	  We	  looked	  in	  our	  Osx1-­Cre;K-­rasG12D	  embryos	  for	  signs	  of	  fat	  in	  their	  limbs;	  however,	  at	  embryonic	  stages	  the	  deposits	  of	  fat	  surrounding	  the	  limbs	  are	  very	  reduced,	  and	  we	  could	  not	  see	  any	  signs	  of	  fat	  increase	  in	  the	  long	  bones.	  Thus,	  one	  would	  have	  to	  look	  for	  this	  phenotype	  in	  adult	  mice.	  	  Thus,	  future	  studies	  should	  investigate	  Osx1-­Cre;K-­rasG12D	  adults,	  in	  which	  K-­‐rasG12D	  was	  activated	  later	  in	  development	  to	  avoid	  embryonic	  lethality.	  Interestingly,	  our	  collaborators	  from	  MGH,	  Tatsuya	  Kobayashi	  and	  Fay	  Papaioannou	  have	  performed	  a	  similar	  study	  where	  they	  injected	  tamoxifen	  in	  females	  carrying	  Osx1-­CreERT2;K-­rasG12D	  embryos	  at	  E18.5	  and	  followed	  the	  pups	  into	  adulthood.	  In	  Osx1-­CreERT2;K-­rasG12D	  mice	  around	  8	  weeks	  of	  age	  they	  notice	  an	  increase	  in	  the	  amount	  of	  fat	  in	  the	  long	  bones.	  	  	   Our	  analysis	  of	  the	  cultured	  osteoblasts	  also	  show	  that	  Sprouty2	  (a	  member	  of	  the	  Sprouty	  family,	  and	  a	  negative	  regulator	  of	  the	  MAPK	  pathway)	  is	  over-­‐expressed	  in	  the	  K-­‐rasG12D	  mutant	  cells,	  and	  Sprouty2	  expression	  goes	  down	  as	  they	  differentiate	  into	  bone.	  Development	  of	  bone	  versus	  adipose	  tissue	  from	  their	  common	  progenitors	  is	  a	  carefully	  coordinated	  process	  and	  studies	  have	  identified	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Sprouty1	  (Spry1)	  as	  a	  critical	  regulatory	  switch	  of	  mesenchymal	  stem	  cells	  fate	  choice	  (Urs	  et	  al.,	  2010).	  Specifically,	  conditional	  deletion	  of	  Spry1	  results	  in	  10%	  increase	  in	  body	  fat	  and	  decreased	  bone	  mass	  (Urs	  et	  al.,	  2010).	  	  By	  suppressing	  the	  Ras/MAPK	  pathway	  and	  generating	  a	  negative	  feedback	  loop	  during	  development,	  Sprouty	  regulates	  several	  signaling	  pathways	  and	  affects	  common	  signal	  mediators.	  Thus,	  one	  hypothesis	  is	  that	  deregulation	  of	  members	  of	  the	  Sprouty	  family	  might	  contribute	  to	  the	  altered	  in	  vitro	  differentiation	  capacity	  of	  the	  K-­‐ras	  mutant	  osteoblasts.	  To	  investigate	  if	  K-­‐rasG12D	  acts	  directly	  through	  Sprouty,	  one	  could	  knock	  down	  Sprouty	  in	  osteoblasts	  expressing	  oncogenic	  K-­‐ras	  and	  then	  assay	  their	  ability	  to	  form	  bone	  and	  fat;	  a	  reduced	  ability	  to	  form	  fat	  would	  suggest	  that	  Sprouty	  is	  essential	  in	  determining	  the	  altered	  mesenchymal	  specification	  conferred	  by	  K-­‐ras	  activation.	  	  Future	  studies	  should	  also	  focus	  on	  studying	  the	  mechanism	  through	  which	  K-­‐rasG12D	  affects	  the	  mesenchymal	  fate	  choice	  by	  looking	  at	  its	  ability	  to	  modulate	  known	  master	  regulators	  of	  bone	  differentiation	  (TAZ)	  and	  fat	  differentiation	  (C/EBP-­‐β,	  PPARγ).	  Data	  from	  the	  literature	  have	  shown	  a	  decrease	  in	  PPARγ	  expression	  both	  at	  the	  transcript	  and	  protein	  levels	  in	  a	  mouse	  model	  that	  conditionally	  expresses	  Spry1	  in	  adipocytes	  (Urs	  et	  al.,	  2010).	  Other	  studies	  have	  shown	  that	  phosphorylation	  of	  ERK1/2	  (downstream	  members	  in	  the	  MAPK	  pathway)	  induces	  C/EBP-­‐β,	  which	  then	  activates	  PPARγ’s	  transcriptional	  activity	  (Prusty	  et	  al.,	  2002).	  These	  observations	  suggest	  that	  the	  MAPK	  signaling	  pathway	  and	  its	  negative	  regulators	  play	  an	  important	  role	  in	  adipocyte	  specification.	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Future	  studies	  should	  be	  conducted	  in	  either	  osteoblasts	  isolated	  from	  Osx1-­
Cre;K-­rasG12D	  mutants	  or	  in	  mesenchymal	  stromal	  cells	  (MSCs)	  isolated	  from	  Prx1-­
Cre;K-­rasG12D	  mutant	  mice.	  We	  did	  initiate	  studies	  in	  MSCs	  isolated	  from	  Prx1-­Cre;K-­
rasG12D	  mutant	  mice	  limbs,	  but	  found	  unfortunately	  that	  K-­‐rasG12D	  expression	  affected	  cell	  viability.	  A	  new	  and	  improved	  method	  of	  MSC	  isolation	  should	  be	  developed	  to	  perform	  these	  experiments.	  The	  studies	  described	  above	  will	  be	  instrumental	  in	  describing	  the	  role	  of	  K-­‐rasG12D	  as	  a	  switch	  of	  mesenchymal	  lineage	  commitment.	  Understanding	  the	  role	  of	  K-­‐ras	  in	  a	  context	  related	  to	  cellular	  differentiation	  is	  very	  relevant	  to	  both	  normal	  development	  as	  well	  as	  cancer,	  as	  many	  tumors	  have	  cells	  that	  are	  un-­‐differentiated,	  either	  through	  blocking	  at	  progenitor	  stage	  or	  via	  cellular	  de-­‐differentiation.	  Understanding	  how	  K-­‐rasG12D	  modulates	  the	  differentiation	  of	  mesenchymal	  lineages	  in	  our	  in	  vivo	  and	  in	  vitro	  systems	  will	  thus	  yield	  insight	  into	  its	  role	  in	  derailing	  lineage	  commitment/	  maintenance,	  and	  thereby	  affecting	  normal	  development	  or	  promoting	  tumorigenesis.	  	  
4.5.	  Generation	  of	  novel	  mouse	  models	  to	  study	  Noonan	  Syndrome	  associated	  
bone	  defects	  and	  potential	  treatment	  strategies	  	  In	  chapter	  2	  we	  discuss	  our	  efforts	  trying	  to	  investigate	  the	  bone	  defects	  associated	  with	  Noonan	  Syndrome	  (NS)	  in	  a	  novel	  mouse	  model	  we	  have	  generated.	  We	  describe	  the	  histology	  of	  the	  bone	  phenotype,	  determine	  when	  the	  problem	  appears	  during	  development	  and	  	  investigate	  the	  underlying	  mechanisms.	  Furthermore,	  we	  describe	  a	  treatment	  strategy	  that	  is	  sufficient	  to	  block	  the	  skeletal	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phenotype,	  and	  identify	  a	  narrow	  developmental	  time	  window	  in	  which	  the	  treatment	  must	  be	  applied.	  	  	  	  Importantly,	  our	  treatment	  strategy	  indicates	  that	  appropriate	  MAPK	  signaling	  is	  critical	  for	  normal	  bone	  development.	  However,	  we	  also	  need	  to	  consider	  how	  expression	  of	  negative	  regulators	  of	  the	  MAPK	  pathway	  is	  affected	  in	  our	  mutants	  upon	  treatment	  with	  MEK	  inhibitors.	  Other	  studies	  have	  shown	  that	  when	  MAPK	  is	  inhibited	  in	  K-­‐ras	  driven	  tumors,	  the	  expression	  of	  negative	  regulators	  of	  the	  MAPK	  signaling	  is	  up-­‐regulated	  (Nissan	  et	  al.,	  2013).	  Thus,	  it	  remains	  an	  open	  question	  whether	  the	  bone	  defects	  we	  observe	  are	  a	  direct	  result	  of	  elevated	  MAPK	  signaling	  or	  an	  indirect	  consequence	  of	  downstream	  effects,	  including	  the	  negative	  feedback	  loops,	  that	  result	  from	  MAPK	  activation.	  	  We	  were	  not	  able	  to	  recover	  living	  Prx1-­Cre;K-­rasG12D/+	  mice	  that	  received	  treatment	  during	  embryonic	  development.	  Although	  the	  embryos	  were	  alive	  at	  E18.5	  and	  present	  in	  Mendelian	  ratios,	  none	  of	  the	  rescued	  mutants	  survived	  after	  birth.	  	  Since	  we	  also	  fail	  to	  recover	  viable	  wild	  type	  mice,	  this	  is	  clearly	  independent	  of	  K-­‐ras	  effect.	  It	  is	  possible	  that	  due	  to	  the	  daily	  injections,	  the	  mothers	  are	  stressed	  and	  thus	  fail	  to	  care	  for	  their	  litters.	  To	  test	  this	  possibility,	  one	  could	  transfer	  the	  newborns	  to	  another	  lactating	  mother	  and	  assess	  if	  Prx1-­Cre;	  K-­rasG12D/+	  mice	  can	  survive	  to	  adulthood	  in	  this	  setting.	  It	  would	  be	  interesting	  to	  know	  if	  such	  surviving	  animals	  live	  a	  normal	  lifespan	  and/or	  whether	  they	  might	  develop	  other	  bone	  defects,	  particularly	  the	  enhanced	  bone	  differentiation	  that	  is	  observed	  upon	  the	  osteoblast-­‐specific	  activation	  of	  K-­‐ras	  after	  birth	  in	  the	  Osx1-­Cre;K-­rasG12D	  mutants.	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Our	  current	  state	  of	  knowledge	  regarding	  the	  role	  of	  MAPKs	  in	  the	  skeleton	  is	  at	  an	  exciting	  balance	  between	  its	  established	  importance	  during	  bone	  development	  and	  unexplored	  and	  poorly	  understood	  functions	  that	  are	  currently	  under	  investigation.	  Furthermore,	  concomitantly	  with	  understanding	  the	  role	  of	  normal	  MAPK	  signaling	  in	  the	  skeleton,	  we	  are	  starting	  to	  decipher	  the	  effects	  or	  aberrant	  signaling	  in	  the	  bone	  compartment.	  Understanding	  how	  pathological	  MAPK	  signaling	  affects	  bone	  development	  and	  regulates	  bone	  mass	  is	  very	  important	  for	  a	  multitude	  of	  diseases	  which	  are	  caused	  by	  mutations	  in	  the	  MAPK	  pathway	  (the	  RASopathies),	  as	  well	  as	  diseases	  in	  which	  there	  is	  an	  imbalance	  of	  the	  bone	  mass,	  such	  as	  osteoporosis	  or	  osteopetrosis.	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Abstract	  Mutation	  of	  the	  RB-­‐1	  tumour	  suppressor	  occurs	  in	  one	  third	  of	  all	  human	  tumours	  and	  is	  particularly	  associated	  with	  retinoblastoma	  and	  osteosarcoma	  (Burkhart	  and	  Sage,	  2008).	  Numerous	  functions	  have	  been	  ascribed	  to	  the	  product	  of	  the	  human	  RB-­‐1	  gene,	  pRB.	  The	  best	  known	  is	  pRB's	  ability	  to	  promote	  cell	  cycle	  exit	  through	  inhibition	  of	  the	  E2F	  transcription	  factors	  and	  the	  transcriptional	  repression	  of	  genes	  encoding	  cell	  cycle	  regulators	  (Burkhart	  and	  Sage,	  2008).	  In	  addition,	  pRB	  has	  been	  shown	  in	  vitro	  to	  regulate	  several	  transcription	  factors	  that	  are	  master	  differentiation	  inducers	  (Korenjak	  and	  Brehm,	  2005).	  Depending	  on	  the	  differentiation	  factor	  and	  cellular	  context,	  pRB	  can	  either	  suppress	  or	  promote	  their	  transcriptional	  activity.	  For	  example,	  pRB	  binds	  to	  Runx2	  and	  potentiates	  its	  ability	  to	  promote	  osteogenic	  differentiation	  program	  in	  vitro	  (Thomas	  et	  al.,	  2001).	  Incontrast,	  pRB	  acts	  together	  with	  E2F	  to	  suppress	  Ppary,	  the	  master	  activator	  of	  adipogenesis	  (Fajas	  et	  al.,	  2002a;	  Fajas	  et	  a.,2002b).	  Since	  osteoblasts	  and	  adipocytes	  can	  both	  arise	  from	  mesenchymal	  stem	  cells,	  these	  observations	  suggest	  that	  pRB	  might	  play	  a	  role	  in	  the	  choice	  between	  these	  two	  fates.	  However,	  to	  date,	  there	  is	  no	  evidence	  for	  this	  in	  vivo.	  Here	  we	  use	  mouse	  models	  to	  address	  this	  hypothesis	  inthe	  context	  of	  mesenchymal	  tissue	  development	  and	  tumorigenesis.	  Our	  data	  show	  that	  Rb	  status	  plays	  a	  key	  role	  in	  establishing	  fate	  choice	  between	  bone	  and	  brown	  adipose	  tissue	  in	  vivo	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Mutations	  in	  RB-­‐1	  (70-­‐90%	  of	  cases)	  and	  TP53	  (50-­‐70%	  of	  cases)	  are	  strongly	  associated	  with	  human	  osteosarcoma	  (Kansara	  and	  Thomas,	  2007;	  Clark	  et	  al.,	  2008).	  To	  model	  osteosarcoma	  in	  the	  mouse,	  we	  crossed	  Rbfl/fl	  (Sage	  et	  al.,	  2003)	  and	  p53fl/fl	  (Jonkers	  et	  al.,	  2001)	  conditional	  mutant	  mice	  with	  a	  transgenic	  line,	  
Prxl-­Cre	  (Logan	  et	  al.,	  2002),	  which	  expresses	  Cre	  recombinase	  in	  uncommitted	  mesenchymal	  cells	  that	  contribute	  to	  bone,	  muscle,	  and	  both	  white	  and	  brown	  adipose	  tissue	  (Figure	  la-­‐c).	  The	  homozygous	  deletion	  of	  Rb	  and/or	  p53	  by	  Prxl-­Cre	  yielded	  viable	  neonates	  with	  no	  detectable	  developmental	  defects	  (data	  not	  shown),	  allowing	  us	  to	  determine	  the	  affect	  of	  Rb	  and/or	  p53	  loss	  on	  sarcomagenesis	  (Figure	  2a).	  The	  Prx1-­Cre;	  p53fl/fl	  animals	  developed	  osteosarcoma	  (62%),	  rhabdomyosarcomas	  (15%)	  and/or	  undifferentiated	  sarcomas	  (12%).	  In	  contrast,	  deletion	  of	  Rb	  alone	  did	  not	  yield	  sarcomas.	  However,	  Rb	  mutation	  had	  a	  profound	  effect	  on	  the	  tumor	  spectrum	  of	  Prx1-­Cre;	  p53fl/fl	  mice	  (Figure	  2a,b):	  deletion	  of	  one	  Rb	  allele	  increased	  the	  frequency	  of	  osteosarcomas	  (to	  92%),	  while	  mutation	  of	  both	  Rb	  alleles	  shifted	  the	  tumour	  spectrum	  away	  from	  osteosarcoma	  (now	  18%)	  and	  towards	  hibernomas	  (91	  %;	  Supplementary	  figure	  2).	  This	  propensity	  for	  brown	  fat,	  as	  opposed	  to	  white	  fat,	  tumors	  fits	  with	  prior	  studies	  showing	  that	  Rb	  loss	  promotes	  brown	  fat	  over	  white	  fat	  differentiation	  (Hansen	  et	  al.,	  2004;	  Scime	  et	  al.,	  2005;	  Dali-­‐Youcef	  et	  al.,	  2007).	  Genotyping	  confirmed	  that	  the	  tumor	  cells	  had	  undergone	  Cre-­‐mediated	  recombination	  of	  Rb	  and/or	  p53	  (Figure	  2c,	  data	  not	  shown).	  Moreover,	  it	  showed	  that	  the	  Prx1-­Cre;	  Rb+/fl;p53fl/fl	  tumors	  consistently	  retained	  the	  wild	  type	  Rb	  allele	  (Figure	  2c,	  data	  not	  shown).	  Thus	  Rb	  acts	  in	  a	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dose	  dependent	  manner	  to	  modulate	  the	  spectrum	  of	  tumors	  arising	  from	  p53-­‐	  deficient,	  uncommitted	  mesenchymal	  stem	  cells:	  osteosarcomas	  predominant	  in	  the	  presence	  of	  Rb,	  while	  Rb	  loss	  strongly	  favors	  hibernoma	  formation.	  Given	  that	  Rb	  loss	  in	  p53	  mutant	  uncommitted	  mesenchymal	  cells	  disfavors	  osteosarcoma	  formation,	  we	  also	  investigated	  the	  affect	  of	  Rb	  loss	  in	  a	  bone-­‐committed	  progenitor.	  For	  this,	  we	  deleted	  Rb	  and/or	  p53	  using	  the	  Osx-­Cre	  transgenic	  (Rodda	  and	  McMahon,	  2006)	  which	  uses	  Osterix	  promoter	  sequences	  to	  express	  Cre	  in	  the	  pre-­‐oestoblast	  (Figure	  1d).	  In	  this	  model	  (Berman	  et	  al,	  2008a),	  Osx-­Cre;	  p53fl/fl	  mice	  specifically	  develop	  osteosarcoma	  (100%)	  while	  Osx-­Cre;	  Rbfl/fl;	  p53fl/fl	  develop	  osteosarcoma	  (53%),	  hibernomas	  (46%)	  and	  sarcomas	  (2%).	  We	  established	  cell	  lines	  from	  multiple	  (3)	  independent	  Osx-­Cre;	  p53fl/fl	  and	  Osx-­Cre;	  Rbfl/fl;	  p53fl/fl	  osteosarcomas	  and	  discovered	  that	  the	  two	  genotypes	  have	  distinct	  differentiation	  properties	  (Figure	  3,	  data	  not	  shown).	  The	  Rb;	  p53	  (DKO)	  osteosarcoma	  (OS)	  cell	  lines	  expressed	  mRNAs	  that	  are	  characteristic	  of	  bone	  and	  fat	  differentiation	  (Figure	  3a).	  Indeed,	  their	  expression	  pattern	  more	  closely	  resembled	  that	  of	  mesenchymal	  stem	  cells	  (MSCs)	  than	  primary	  osteoblasts	  (Supplementary	  Figure	  2).	  Accordingly,	  culture	  in	  the	  appropriate	  differentiation	  media	  induced	  these	  DKO	  cells	  to	  adopt	  either	  the	  adipogenic	  or	  osteoblastic	  fate	  (Figure	  3a).	  In	  contrast,	  the	  p53KO	  OS	  cell	  lines	  closely	  resembled	  pre-­‐osteoblasts	  based	  on	  their	  gene	  expression	  patterns,	  but	  these	  cells	  were	  unable	  to	  differentiate	  into	  either	  bone	  or	  fat	  (Figure	  3a	  and	  Supplementary	  Figure	  2).	  Since	  this	  differentiation	  block	  occurs	  in	  the	  p53-­‐null	  OS	  cell	  lines,	  but	  not	  p53-­‐deficient	  primary	  osteoblasts	  (Lengner	  et	  al.,	  2006;	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  Figure	  6a),	  it	  likely	  reflects	  their	  transformed	  state.	  We	  used	  these	  p53KO	  OS	  cells	  to	  determine	  whether	  Rb	  loss	  was	  sufficient	  to	  alter	  the	  differentiation	  potential	  of	  blocked	  pre-­‐oestoblasts	  by	  introducing	  control	  (shLuc)	  or	  Rb-­‐specific	  (shRb)	  shRNAs.	  pRb	  was	  readily	  detectable	  in	  shLuc-­p53KO,	  but	  not	  shRb-­p53KO,	  OS	  cells	  (Figure	  3b).	  Strikingly,	  without	  addition	  of	  differentiation	  media,	  pRb	  knockdown	  downregulated	  the	  bone-­‐specific	  mRNA	  Bsp	  and	  upregulated	  the	  fat	  regulator	  Ppary	  (Figure	  3b).	  Accordingly,	  these	  shRb-­p53KO	  OS	  cells	  were	  now	  able	  to	  differentiate	  into	  either	  bone	  or	  fat	  in	  vitro	  (Figure	  3c).	  Moreover,	  when	  transplanted	  into	  nude	  mice,	  the	  shRb-­p53KO	  OS	  cells	  formed	  more	  aggressive	  tumors	  than	  the	  parental	  
p53KO	  OS	  cells,	  and	  these	  were	  of	  mixed	  lineage	  (fat,	  bone	  and	  undifferentiated	  sarcomas),	  in	  stark	  contrast	  to	  the	  undifferentiated	  osteoblastic	  tumours	  arising	  from	  either	  control	  shLuc-­p53KO	  or	  parental	  p53KO	  OS	  cell	  lines	  (Figure	  3d,	  Supplementary	  Figure	  3,	  and	  data	  not	  shown).	  Thus,	  pRB	  loss	  is	  sufficient	  to	  over-­‐ride	  the	  differentiation	  block	  of	  these	  p53-­‐deficient,	  tumor	  cell	  lines	  and	  also	  expand	  their	  fate	  commitment	  to	  include	  the	  adipogenic	  state.	  We	  also	  examined	  the	  consequences	  of	  reintroducing	  Rb	  into	  the	  DKO	  OS	  cells.	  For	  this,	  we	  induced	  pRb	  in	  confluence-­‐arrested	  DKO	  cells	  using	  a	  doxycycline-­‐inducible	  expression	  system	  
(DKO-­Rb	  Dox-­ON;	  Figure	  4).	  Remarkably,	  pRb	  restoration	  caused	  the	  DKO	  OS	  cells	  to	  adopt	  the	  differentiation	  state	  of	  the	  p53KO	  OS	  cell	  lines	  within	  two	  days:	  it	  induced	  down-­‐regulation	  of	  adipogenic	  markers	  and	  up-­‐regulation	  of	  osteogenic	  markers,	  and	  the	  cells	  were	  unable	  to	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  differentiate	  into	  fat	  (Figure	  4).	  Thus	  removal	  or	  re-­‐introduction	  of	  Rb	  appears	  sufficient	  to	  switch	  lineage	  specification	  between	  osteoblastic	  commitment	  and	  multipotency.	  In	  vitro	  studies	  have	  shown	  that	  pRB	  can	  act	  with	  E2F	  to	  enforce	  transcriptional	  repression	  of	  Pparγ	  (Fajas	  et	  al.,	  2002a;	  Fajas	  et	  al.,	  2002b),	  and	  also	  bind,	  and	  potentiate	  the	  transcriptional	  activity	  of,	  the	  osteogenic	  regulator	  RUNX2	  (Thomas	  et	  al.,	  2001).	  We	  hypothesized	  that	  pRb's	  role	  in	  these	  processes	  might	  underlie	  Rb's	  affect	  on	  adipogenesis	  versus	  osteogenesis.	  Thus,	  we	  used	  our	  DKO-­
RbDox-­ON	  cells	  to	  determine	  whether	  the	  presence	  or	  absence	  of	  pRb	  modulated	  these	  transcriptional	  regulators	  (Figure	  5).	  First,	  we	  used	  chromatin-­‐immunoprecipitation	  assays	  to	  investigate	  promoter	  regulation	  of	  Pparγ and	  representative	  Runx2-­‐responsive	  genes	  Coilla	  (Figure	  5a)	  and	  osteocalcin	  (Oc;	  data	  not	  shown).	  pRb-­‐induction	  caused	  both	  pRb	  and	  E2f4,	  the	  predominant	  repressive	  E2f,	  to	  be	  recruited	  to	  the	  Pparγ promoter	  (Figure	  5a)	  and	  this	  correlated	  with	  
Pparγ mRNA	  downregulation	  (Figure	  5a).	  Contemporaneously,	  pRb	  bound	  to	  Col1α	  and	  Oc	  and	  this	  was	  accompanied	  by	  increased	  promoter	  occupancy	  of	  Runx2	  and	  upregulation	  of	  Col1α	  and	  Oc	  mRNAs	  (Figure	  5a,	  data	  not	  shown).	  Importantly,	  these	  changes	  in	  Pparγ,	  Col1α	  and	  Oc	  regulation	  were	  all	  detected	  within	  2	  days	  of	  pRb	  induction	  and	  without	  addition	  of	  differentiation-­‐inducing	  media.	  In	  addition,	  we	  found	  that	  Runx2	  associated	  with	  pRb	  in	  the	  p53KO,	  but	  not	  the	  DKO,	  OS	  cells	  and	  its	  transcriptional	  activity	  was	  8	  fold	  higher	  in	  the	  former,	  versus	  the	  latter,	  population	  (Figure	  5b).	  Thus	  the	  presence	  or	  absence	  of	  pRb	  directly	  modulates	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the	  levels	  and	  activity	  of	  Pparγ	  and	  Runx2	  in	  accordance	  with	  the	  preferential	  commitment	  of	  our	  OS	  cell	  lines	  to	  the	  osteogenic	  versus	  the	  adipogenic	  lineage.	  The	  preceding	  experiments	  establish	  a	  clear	  role	  for	  pRb	  in	  fate	  commitment	  bias	  in	  
vivo	  and	  in	  vitro.	  However,	  since	  this	  analysis	  was	  conducted	  in	  p53-­‐deficient	  cells,	  it	  is	  unclear	  whether	  Rb	  alone	  is	  sufficient	  to	  determine	  this	  plasticity	  or	  whether	  transformation	  is	  also	  required.	  To	  address	  this,	  we	  isolated	  primary	  osteoblasts	  from	  the	  calvaria	  of	  Rbfl/fl,	  p53fl/fl	  or	  Rbfl/fl;p53fl/fl	  e8.5	  embryos.	  We	  brought	  these	  cells	  to	  confluence,	  to	  minimize	  the	  influence	  of	  altered	  proliferation,	  infected	  them	  with	  adenoviruses	  expressing	  Cre	  or	  a	  GFP	  control	  and	  then	  assayed	  differentiation.	  As	  expected,	  the	  control-­‐infected	  osteoblasts	  were	  able	  to	  undergo	  osteogenesis	  but	  not	  adipogenesis	  (Figure	  6a;	  data	  not	  shown).	  Similarly,	  p53	  loss	  had	  no	  effect	  on	  this	  fate	  commitment	  (Lengner	  et	  al.,	  2006;	  Figure	  6a).	  In	  stark	  contrast,	  deletion	  of	  
Rb,	  either	  alone	  or	  together	  with	  p53,	  allowed	  these	  cells	  to	  adopt	  either	  the	  bone	  or	  fat	  lineage	  (Figure	  6a;	  data	  not	  shown).	  This	  switch	  to	  multipotency	  correlated	  with	  the	  significant	  upregulation	  of	  adipogenic	  markers	  prior	  to	  the	  induction	  of	  differentiation	  (Figure	  6b).	  Thus,	  pRb-­‐loss	  is	  sufficient	  to	  alter	  the	  fate	  commitment	  in	  otherwise	  wild	  type	  calvarial	  osteoblasts.	  In	  vitro	  culture	  can	  modulate	  the	  plasticity	  of	  cells.	  Thus,	  we	  wished	  to	  examine	  Rb's	  role	  in	  fate	  choice	  in	  vivo.	  For	  this,	  we	  employed	  a	  third	  transgenic	  strain,	  Meox2-­Cre,	  which	  expresses	  Cre	  in	  the	  embryo	  proper	  from	  e6.5	  (Tallquist	  and	  Soriano,	  2000).	  Meox2-­Cre;	  Rbfl/fl	  embryos	  survive	  to	  birth	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(Wu	  et	  al.,	  2003).	  We	  isolated	  wildtype	  (Meox2-­Cre;	  Rb+/+)	  and	  Rb	  mutant	  
(Meox2-­Cre;	  Rbfl/fl)	  littermates	  at	  e15.5	  and	  e18.5	  and	  examined	  both	  bone	  and	  brown	  fat	  development.	  First,	  there	  was	  a	  significant	  reduction	  in	  the	  level	  of	  calcified	  bone	  matrix	  in	  both	  the	  calvaria	  and	  long	  bones	  of	  Rb	  mutant	  versus	  wildtype	  embryos	  (Berman	  et	  al.,	  2008b;	  Figure	  6c).	  Moreover,	  qPCR	  analysis	  established	  that	  Runx2	  mRNA	  was	  present	  at	  appropriate	  levels	  in	  the	  Rb	  mutant	  e8.5	  calvarial	  osteoblasts,	  but	  there	  was	  a	  downregulation	  of	  other	  bone	  markers	  and	  a	  clear	  upregulation	  of	  fat-­‐associated	  mRNAs	  (Figure	  6c).	  In	  parallel,	  we	  found	  that	  the	  level	  of	  brown	  fat	  was	  dramatically	  increased	  in	  the	  e8.5	  Rb	  mutant	  versus	  the	  wildtype	  controls	  (Figure	  6d	  and	  Supplementary	  Figure	  4).	  Thus,	  Rb	  loss	  in	  an,	  otherwise	  wildtype,	  embryo	  impairs	  bone	  differentiation	  and	  expands	  the	  fat	  compartment.	  Our	  data	  establish	  a	  clear	  role	  for	  pRB	  in	  determining	  the	  fate	  choice	  of	  mesenchymal	  progenitors	  and	  the	  lineage	  commitment	  of	  pre-­‐osteoblasts.	  This	  occurs	  both	  in	  vitro	  and	  in	  vivo	  and	  irrespective	  of	  whether	  these	  cells	  are	  transformed	  or	  otherwise	  wildtype.	  In	  vivo,	  Rb-­‐loss	  favours	  adipogenesis	  over	  osteogenesis	  to	  the	  extent	  that	  it	  can	  reduce	  the	  levels	  of	  calcified	  bone	  and	  greatly	  increase	  the	  levels	  of	  brown	  fat.	  Moreover,	  Rb-­‐loss	  in	  pre-­‐osteoblasts	  is	  sufficient	  to	  disfavor	  commitment	  to	  the	  osteogenic	  state	  and	  restore	  multipotency.	  It	  is	  possible	  that	  Rb	  loss	  allows	  expansion	  of	  a	  rare	  multipotent	  progenitor	  population	  that	  exists	  within	  the	  pre-­‐osteoblast	  compartment.	  Alternatively,	  Rb	  loss	  could	  be	  actively	  reprogramming	  the	  pre-­‐osteoblasts	  by	  driving	  either	  trans-­‐differentiation	  to	  the	  adipogenic	  lineage	  or	  true	  dedifferentiation	  to	  the	  multipotent	  progenitor	  stage.	  Between	  the	  two	  reprogramming	  models	  we	  favor	  de-­‐differentiation	  based	  on	  both	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the	  expression	  of	  multi-­‐lineage	  differentiation	  markers	  in	  the	  DKO	  OS	  cells	  (Supplementary	  Figure	  4)	  and	  the	  broadening	  of	  the	  tumor	  spectrum	  from	  solely	  osteosarcomas	  in	  the	  Osx-­Cre;p53fl/fl	  animals	  to	  include	  not	  only	  osteosarcomas	  and	  hibernomas	  but	  also	  sarcomas	  in	  the	  Osx-­Cre;Rbfl/fl;p53fl/fl	  mice.	  Finally,	  our	  data	  offers	  potential	  insight	  into	  the	  cell	  of	  origin	  for	  osteosarcomas.	  Specifically,	  given	  the	  high	  frequency	  of	  RB-­1	  mutations	  in	  human	  osteosarcoma,	  we	  were	  surprised	  to	  find	  that	  Rb	  mutation	  predisposes	  mesenchymal	  cells	  away	  from	  the	  osteoblastic	  state.	  Given	  this	  finding,	  we	  speculate	  that	  RB-­1	  mutant	  osteosarcomas	  are	  likely	  to	  arise	  from	  more	  committed	  osteoblastic	  lineages	  than	  from	  uncommitted	  mesenchymal	  progenitors.	  In	  this	  setting,	  RB-­1	  loss	  could	  enable	  de-­‐differentiation	  and	  thereby	  synergize	  with	  other	  mutations	  to	  promote	  tumorigenesis.	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Experimental	  Procedures	  
Animal	  maintenance	  and	  histological	  analyses	  Animal	  procedures	  followed	  protocols	  approved	  by	  MIT's	  Committee	  on	  Animal	  Care.	  The	  Rbfl/fl,	  p53fl/fl,	  Osxl-­GFP::Cre,	  Prxl-­Cre,	  Rosa26-­LSL-­IacZ	  (REF),	  and	  
Meox2-­Cre	  animals	  were	  maintained	  on	  a	  mixed	  genetic	  background.	  Skeletal	  stainings	  were	  conducted	  as	  described.	  The	  transplant	  assays	  were	  conducted	  in	  NOD/SCID	  mice	  using	  104	  cells.	  Tissues	  were	  fixed	  in	  PBS	  with	  3.7%	  formaldehyde.	  Prior	  to	  paraffin	  sectioning,	  soft	  tissues	  were	  dehydrated	  via	  an	  ethanol	  series,	  while	  bone-­‐containing	  tissue	  was	  decalcified	  in	  0.46M	  EDTA,	  2.5%	  Ammonium	  Hydroxide	  pH	  7.2.	  	  
Mouse	  genotyping	  The	  Rb	  conditional	  band	  was	  detected	  using	  the	  primers	  5'lox:	  5'-­‐	  CTCTAGATCCTCTCATTCTTC-­‐3'	  and	  3'lox:	  5'-­‐CCTTGACCATAGCCCAGCAC-­‐	  3'.	  Primer	  Rbcre3.2	  (5'-­‐GGTTAATGAAGGACTGGG-­‐3')	  was	  used	  in	  conjunction	  with	  primer	  5'lox	  to	  detect	  the	  recombined	  band.	  To	  identify	  the	  p53	  conditional	  allele	  we	  used	  primer	  p53A:	  5'-­‐CACAAAAACAGGTTAAACCCAG-­‐3'	  and	  primer	  p53B:	  5'-­‐AGCACATAGGAGGCAGAGAC-­‐3'.	  The	  recombined	  allele	  was	  detected	  using	  primer	  p53A	  in	  conjunction	  with	  primer	  p53D:	  5'-­‐GAAGACAGAAAAGGGGAGGG-­‐3'.	  	  
Tumor	  monitoring	  and	  analysis	  The	  criteria	  for	  euthanasia	  (by	  CO2	  inhalation)	  were	  a	  total	  tumor	  burden	  of	  2cm3,	  tumor	  ulceration/bleeding,	  signs	  of	  infection,	  respiratory	  distress,	  impaired	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mobility,	  220%	  reduction	  in	  body	  weight	  or	  general	  cachexia.	  All	  tissues	  were	  collected	  and	  hip	  bones,	  femurs	  and	  tibias	  were	  separated	  and	  fixed	  overnight	  in	  PBS	  with	  3.7%	  formaldehyde.	  Soft	  tissues	  were	  transferred	  into	  70%	  ethanol	  and	  dehydrated	  via	  an	  ethanol	  series	  prior	  to	  embedding	  in	  paraffin	  for	  sectioning.	  Tissues	  containing	  bone	  was	  either	  decalcified	  in	  0.46M	  EDTA,	  2.5%	  Ammonium	  Hydroxide	  pH	  7.2	  for	  two	  weeks	  then	  processed	  for	  paraffin	  sectioning.	  All	  paraffin	  embedded	  sections	  were	  cut	  at	  5pm,	  dewaxed	  and	  stained	  with	  H&E.	  Sirius	  red	  staining	  was	  performed	  by	  treating	  sections	  briefly	  stained	  with	  hematoxylin	  with	  
0.1	  %	  Sirius	  red	  in	  saturated	  picric	  acid	  (Electron	  Microscopy	  Sciences)	  for	  one	  hour,	  washing	  in	  5%	  v/v	  glacial	  acetic	  acid	  and	  then	  dehydration	  in	  ethanol/xylene	  prior	  to	  mounting.	  	  
Generation	  of	  osteosarcoma	  cell	  lines	  Osteosarcomas	  were	  dissected,	  minced,	  filtered	  through	  a	  70gm	  filter,	  and	  plated	  in	  normal	  growth	  medium	  (10%	  FBS	  in	  DME,	  1%	  P/S,	  L-­‐glutamine)	  to	  generate	  the	  OS	  cell	  lines.	  Cells	  were	  passaged	  as	  they	  reached	  confluence.	  For	  RNA	  purification,	  cells	  were	  rinsed	  2x	  with	  PBS,	  and	  RNA	  extraction	  was	  performed	  using	  RNAeasy	  kit	  (Quiagen).	  First-­‐strand	  cDNA	  was	  transcribed	  from	  1	  pg	  of	  RNA	  using	  Superscript	  Ill	  reverse	  transcriptase	  (Invitrogen)	  following	  the	  manufacturer's	  instructions.	  Quantitative	  RT-­‐PCR	  with	  20	  to	  100	  ng	  cDNA	  was	  done	  using	  SYBR	  Green	  (Applied	  Biosystems).	  Reactions	  were	  run	  on	  the	  ABI	  Prism	  7000	  Sequence	  Detection	  System	  and	  analyzed	  using	  the	  7000	  SDS	  software.	  Primers	  used	  for	  qPCR	  are	  shown	  in	  Supplementary	  Table	  1.	  Knockdown	  of	  Rb	  in	  the	  p53KO-­OS	  cells	  was	  achieved	  using	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the	  pMLP-­‐miR30-­‐based	  shorthairpin	  (Rb	  targeted	  sequence:	  CACGGACGTGTGAACTTATATA).	  Adenoviruses	  expressing	  Cre	  or	  GFP	  were	  provided	  by	  the	  U.	  of	  Iowa	  Gene	  Transfer	  Vector	  Core.	  For	  immunoprecipitations	  and	  immunoblotting,	  proteins	  were	  extracted	  with	  a	  Triton	  X-­‐1	  00	  based	  buffer	  and	  quantified	  by	  the	  BCA	  assay	  reagent	  (Pierce,	  Inc).	  Antibodies	  were	  from	  Santa	  Cruz	  Biotechnology	  [pRb	  (H-­‐153),	  E2F1	  (C-­‐20),	  and	  E2F4	  (C-­‐20)],	  BD	  Pharmingen	  (pRb),	  Ambion	  (GAPDH)	  and	  MBL	  (Runx2).	  Dual	  luciferase	  assays	  were	  performed	  as	  described	  by	  the	  manufacturer	  (Promega).	  The	  Runx2	  reporter	  p60SE2-­‐Luc	  and	  control	  p4Luc	  were	  provided	  by	  Dr.	  Gerard	  Karsenty.	  	  
Immunohistochemistry	  (IHC)	  Runx2	  IHC	  was	  performed	  using	  a	  modified	  citric	  acid	  unmasking	  protocol.	  Briefly,	  slides	  were	  deparaffinized	  in	  xylene	  and	  rehydrated	  through	  ethanol.	  Slides	  were	  boiled	  for	  30	  min	  in	  citrate	  buffer,	  pH	  6.0,	  and	  then	  cooled	  in	  running	  tap	  water.	  Slides	  were	  then	  washed	  in	  PBS	  for	  5	  min	  followed	  by	  inactivation	  of	  endogenous	  peroxidases	  by	  incubation	  0.5%	  H202	  in	  methanol.	  Slides	  were	  blocked	  in	  10%	  Goat	  Serum	  for	  1	  h	  at	  room	  temperature.	  Primary	  antibody	  (MBL	  anti-­‐Runx2	  Clone	  8G5)	  was	  diluted	  1:200	  in	  PBS	  0.15%	  Triton	  and	  incubated	  overnight	  at	  4	  *C.	  The	  following	  day,	  slides	  were	  washed	  three	  times	  in	  PBS.	  Secondary	  antibodies	  (Vectastatin	  ABC	  kits,	  Vector	  laboratories)	  were	  diluted	  1:500	  in	  PBS	  containing	  0.4%	  Goat	  Serum	  and	  detected	  using	  a	  DAB	  substrate	  (Vector	  Laboratories).	  All	  samples	  were	  counterstained	  with	  hematoxylin.	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Skeletal	  Staining	  Embryos	  were	  sacrificed,	  skinned	  and	  eviscerated.	  The	  remaining	  tissue	  was	  fixed	  in	  95%	  ethanol	  for	  4	  days,	  transferred	  to	  acetone	  for	  3	  days,	  and	  subsequently	  transferred	  to	  staining	  solution	  of	  0.015%	  Alcian	  blue	  8GX	  (Sigma),	  0.005%	  alizarin	  red	  S	  (Sigma),	  and	  5%	  glacial	  acetic	  acid	  in	  ethanol	  at	  370C	  for	  2	  days	  and	  at	  room	  temperature	  for	  a	  one	  more	  day.	  Tissue	  was	  cleared	  in	  1	  %	  potassium	  hydroxide	  for	  several	  days	  and	  then	  stored	  in	  glycerol.	  	  
Calvarial	  Osteoblasts	  Preparation	  and	  Culture	  Calvaria	  from	  embryonic	  day	  18.5	  embryos	  were	  removed	  and	  carefully	  cleaned	  in	  sterile	  PBS	  from	  contaminating	  tissue.	  Then	  treated	  with	  several	  rounds	  of	  collagenase/trypsin	  digestion	  at	  37*C,	  and	  plated	  onto	  six-­‐well	  plates	  for	  2	  days	  in	  
αMEM	  with	  10%	  fetal	  bovine	  serum	  and	  penicillin/streptomycin.	  For	  differentiation,	  3.5x1	  05	  cells	  were	  plated	  onto	  a	  well	  of	  a	  6-­‐well	  tissue	  culture	  plates.	  Upon	  reaching	  confluence,	  calvarial	  osteoblasts	  were	  treated	  with	  medium	  supplemented	  with	  50	  pg/mL	  of	  ascorbic	  acid	  and	  10	  mmol/L	  of	  β-­‐glycerol-­‐	  phosphate.	  Adenovirus	  (University	  of	  Iowa	  Gene	  Transfer	  Vector	  Core)	  was	  added	  to	  the	  medium	  at	  100	  plaque-­‐forming	  units	  per	  cell	  and	  washed	  away	  24	  h	  later.	  To	  assay	  for	  calcium	  deposits,	  plates	  were	  stained	  with	  1	  %	  alizarin	  red	  S	  solution	  (pH	  5.0).	  	  
Chromatin	  Immunoprecipitation	  assay	  Protein	  complexes	  were	  cross-­‐linked	  to	  DNA	  in	  living	  nuclei	  by	  adding	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formaldehyde	  (Sigma,	  Inc.)	  to	  give	  a	  final	  concentration	  of	  1	  %.	  After	  incubation	  for	  10	  min	  at	  37	  *C,	  crosslinking	  was	  stopped	  by	  addition	  of	  glycine	  to	  a	  final	  concentration	  of	  0.125	  M	  for	  5	  min.	  Cross-­‐linked	  cells	  were	  washed	  twice	  with	  PBS	  containing	  PMSF	  1	  mM	  (phenylmethylsulfonyl	  fluoride),	  scraped	  and	  pelleted.	  Nuclei	  were	  extracted	  with	  a	  20mM	  Tris	  pH	  8,	  3mM	  MgCl2,	  20	  mM	  KCI	  buffer	  containing	  protease	  inhibitors,	  pelleted	  by	  microcentrifugation	  and	  lysed	  by	  incubation	  in	  SDS	  lysis	  buffer	  (1%	  sodium	  dodecyl	  sulfate,	  10	  mM	  EDTA,	  50	  mM	  Trischloride	  pH	  8.1),	  containing	  protease	  inhibitors.	  The	  resulting	  chromatin	  solution	  was	  sonicated	  to	  generate	  500-­‐1000	  bp	  DNA	  fragments.	  After	  microcentrifugation,	  the	  supernatant	  was	  diluted	  1:10	  with	  a	  dilution	  buffer	  (0.01%	  sodium	  dodecyl	  sulfate,	  1.1%	  Triton	  X-­‐100,	  1.2	  mM	  EDTA,	  16.7	  mM	  Trischloride	  pH	  8.1,	  167	  mM	  NaCI,	  containing	  protease	  inhibitors),	  precleared	  with	  blocked	  protein	  A-­‐positive	  Staph	  cells	  (Santa	  Cruz,	  Inc),	  and	  divided	  into	  aliquots.	  Five	  micrograms	  of	  the	  indicated	  antibodies	  was	  added	  to	  each	  aliquot	  and	  incubated	  for	  12	  to	  16	  hours	  at	  4*C	  with	  rotation.	  Antibody-­‐protein-­‐DNA	  complexes	  were	  isolated	  by	  immunoprecipitation	  with	  blocked	  protein	  A-­‐positive	  Staph	  A	  cells.	  Following	  extensive	  washing,	  bound	  DNA	  fragments	  were	  eluted	  and	  analyzed	  by	  Quantitative	  RT-­‐PCR	  using	  primers	  shown	  in	  Supplementary	  Table	  2.	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pRB	  is	  pro-­apoptotic	  in	  response	  to	  TNFα	  treatment	  even	  in	  the	  presence	  of	  an	  
inhibitor	  of	  translation.	  











Figure 1. pRB is pro-apoptotic in response to TNFα and MG132.  (A) RAT16 cells with 
and without induced expression of pRB for 24 hours were treated with TNF  and MG132 
for 48 hours and analyzed for apoptosis by AnnexinV staining.  Induced expression of pRB 
resulted in increased levels of apoptosis without TNF  treatment and greatly enhanced 
TNF /MG132-induced apoptosis.  (B) Western blot showing induction of pRB expression in 
RAT16 cells and procaspase 3, cleaved caspase 3, procaspase 7, and cleaved caspase 7 
protein levels.  Induced expression of pRB for 24 hours resulted in increased levels of 
cleaved caspase 3 and 7 protein levels in response to 48 hours of TNF /MG132 treatment.  
(C) Stable pRB knockdown in RAT16 cells decreased levels of apoptosis in response to 
treatment with TNF /MG132 for 48 hours and (D) did not affect cell cycle phasing.  
Western blot verifying knockdown of pRB in inset.  (E) Stable pRB knockdown in IMR90 
cells decreased TNF /MG132-induced.  Western blot verifying knockdown of pRB in inset.  
(F) Induced expression of pRB does not significantly change expression levels of apoptotic, 
inflammatory, or autophagic genes with or without TNF /MG132 treatment as assessed by 





	   We	  anticipated	  that	  pRB’s	  contribution	  to	  the	  pro-­‐apoptotic	  TNFα	  response	  would	  reflect	  its	  ability	  to	  transcriptionally	  activate	  pro-­‐apoptotic	  genes,	  as	  observed	  in	  our	  prior	  DNA	  damage	  studies	  (Ianari	  et	  al.,	  2009).	  	  However,	  we	  did	  not	  detect	  any	  significant	  changes	  in	  the	  levels	  of	  apoptotic,	  inflammatory,	  or	  autophagic	  mRNAs,	  including	  known	  pRB:E2F1	  targets,	  in	  response	  to	  pRB	  induction	  in	  our	  RAT16-­‐TNFα	  experiments	  (Fig.	  1F).	  	  This	  led	  us	  to	  consider	  that	  perhaps	  pRB	  might	  be	  acting	  independently	  of	  transcription.	  To	  explore	  this	  possibility,	  we	  took	  advantage	  of	  the	  fact	  that	  cycloheximide	  (CHX)	  can	  be	  used	  instead	  of	  MG132	  to	  block	  activation	  of	  NFκB	  (Karin	  and	  Lin,	  2002;	  Traenckner	  et	  al.,	  1994).	  	  Since	  CHX	  acts	  to	  block	  translation,	  this	  would	  preclude	  any	  effects	  that	  required	  gene	  expression	  changes.	  	  Strikingly,	  induction	  of	  pRB	  in	  RAT16	  cells	  was	  able	  to	  potentiate	  apoptosis	  in	  response	  to	  TNFα	  and	  CHX	  (Fig.	  2A),	  with	  control	  experiments	  verifying	  translation	  inhibition	  by	  CHX	  (Fig.	  2B).	  	  Moreover,	  pRB	  knockdown	  in	  IMR90s	  impaired	  TNFα/CHX-­‐induced	  apoptosis	  (Fig.	  2C).	  	  Thus,	  taken	  together,	  our	  data	  show	  that	  pRB	  synergizes	  with	  TNFα	  to	  promote	  apoptosis	  in	  both	  primary	  and	  immortalized	  human	  and	  rodent	  cell	  lines	  in	  the	  absence	  of	  translation.	  	  This	  strongly	  suggests	  that	  pRB	  can	  act	  through	  a	  previously	  unappreciated	  mechanism.	  
pRB	  activates	  mitochondrial	  apoptosis	  in	  a	  BAX-­dependent	  manner.	  








	   	  
 
Figure 2. pRB promotes TNFα-induced apoptosis in a transcription-independent 
manner.  (A) Induced expression of pRB for 24 hours in RAT16 cells increased 
apoptosis resulting from 24 hours of TNF  and CHX treatment.  (B) Upper panel: 
Schematic of experiment. Lanes 1 and 2, pRB expression was induced for 24 hours and 
subsequently cells were left untreated or treated with TNF /CHX, respectively.  Lane 3 
and 4, pRB expression was induced and concurrently cells were left untreated or treated 
with TNF /CHX, respectively.  Lane 5 and 6, pRB expression was never induced and 
cells were left untreated or treated with TNF /CHX, respectively.  Samples were 
collected after 24 hours of TNF /CHX treatment and analyzed by western blotting 
(middle panel) and by FACS (lower panel).  The addition of CHX concurrently to 
induction of pRB expression in Lane 4 resulted in no visible pRB protein, similar levels 
of apoptosis as no pRB expression (Lane 6) and less apoptosis than pRB expression for 
24 hours prior to treatment (Lane 2).  This suggests that CHX inhibited expression of 
pRB.  (C) Stable knockdown of pRB in IMR90 cells decreased apoptosis induced by 24 
hour treatment with TNF  and CHX.  (A, C) Graph bars represent average of at least 








Figure 3. pRB promotes mitochondrial apoptosis in a BAX-dependent manner. 
(A) pRB expression was induced for 24 hours in stable pools of wild-type, Bak-/-, Bax-/-, 
and Bax-/-;Bak-/- immortalized MEFs by doxycycline addition and confirmed by western 
blotting using antibodies against pRB, BAK, BAX, and tubulin.  (B) Wild-type, Bak-/-, 
Bax-/-, and Bax-/-;Bak-/- immortalized MEFs with or without 24 hours of pRB expression 
were left untreated or treated with TNF  and CHX for 10 hours and analyzed for 
apoptosis by AnnexinV staining.  Induction of pRB in wildtype and Bak-/-, but not Bax-/- or 
Bax-/-;Bak-/-, MEFs sensitized to TNF /CHX-induced apoptosis.  Each MEF variant was 
independently generated twice.  Graph bars represent average of three representative, 




	  BAX/BAK-­‐dependence	  of	  any	  pRB	  effect,	  rather	  than	  a	  general	  difference	  in	  the	  apoptotic	  potential	  of	  the	  various	  Bax/Bak	  genotypes,	  we	  conducted	  these	  experiments	  using	  treatment	  conditions	  that	  yielded	  minimal	  response	  to	  TNFα/CHX	  in	  the	  uninduced	  (basal	  pRB)	  cells	  (Fig.	  3B).	  	  Remarkably,	  pRB	  induction	  enhanced	  TNFα-­‐induced	  apoptosis	  in	  both	  wildtype	  (p=0.01)	  and	  Bak-­/-­	  (p<0.005)	  MEFs,	  but	  had	  no	  effect	  in	  either	  Bax-­/-­	  or	  Bax-­/-­;Bak-­








	   	  
 
 
Figure 4.  A fraction of pRB localizes to mitochondria. (A) IMR90 cell mitochondria 
were fractionated and equal amounts (in  g) of mitochondrial fraction (mito) versus total 
lysate were analyzed by western blotting using an antibody against pRB and a cocktail of 
antibodies against phosphorylated pRB.  A fraction of pRB, including phospho-pRB 
localizes to mitochondria.  The purity of the mitochondrial fraction was verified using 
control nuclear and cytoplasmic markers.  (B) Mitochondria of IMR90 cells treated with 
camptothecin (CPT; 5 hours) or TNF  (24 hours) were isolated and analyzed by western 
blotting.  The levels of mitochondrial pRB are unaffected by treatment with these drugs.  
(C) Mitochondria were isolated from mouse livers and analyzed by western blotting.  A 
fraction of pRB is present at mouse liver mitochondria.  (D) Mouse liver mitochondria were 
subfractionated into mitoplast and non-mitoplast (SN).  Mitochondrial pRB localizes 





	   To	  further	  validate	  the	  mitochondrial	  localization	  of	  pRB	  in	  vivo,	  we	  next	  examined	  mitochondria	  from	  mouse	  livers.	  	  Again,	  western	  blotting	  showed	  that	  a	  fraction	  of	  pRB	  existed	  within	  the	  mitochondrial	  fraction	  (Fig.	  4C).	  	  Finally,	  subfractionation	  of	  mouse	  liver	  mitochondria	  localized	  pRB	  outside	  of	  the	  mitoplast	  (inner	  mitochondrial	  membrane	  and	  enclosed	  matrix;	  Fig.	  4D),	  consistent	  with	  the	  notion	  that	  it	  is	  associated	  with	  the	  outer	  mitochondrial	  membrane	  and	  therefore	  coincident	  with	  the	  site	  of	  BAX/BAK	  action.	  	  
pRB	  directly	  activates	  Bax	  and	  induces	  cytochrome	  c	  release	  from	  isolated	  
mitochondria.	  








	   	  
 
Figure 5.  pRB induces MOMP by directly activating BAX.  (A) Mouse liver mitochondria 
were isolated, supplemented with recombinant, monomeric BAX and incubated with and without 
recombinant cleaved BID (positive control) or baculovirus-expressed, recombinant human pRB.  
Cytochrome c release was assessed following incubation and centrifugation by western blotting 
of pellet versus supernatant.  Addition of either pRB or cleaved BID was sufficient to release 
cytochrome c into the supernatant.  (B) Mitochondria isolated from Bax-/-;Bak-/- mouse livers 
were incubated with indicated amounts of recombinant pRB only or recombinant pRB and 
monomeric BAX.  Recombinant pRB promotes cytochrome c release in a dose-dependent and 
BAX-dependent manner.  Data are representative of two independent experiments.  (C) 
ANTS/DPX-loaded liposomes were incubated with 50, 100, and 250nM recombinant pRB in the 
presence or absence of recombinant, monomeric BAX.  ANTS/DPX release was assessed over 
time.  pRB yielded dose-dependent liposome permeabilization in a BAX-dependent manner.  (D) 
In vitro binding assay using recombinant pRB and recombinant, monomeric BAX.  Activated 
BAX was immunoprecipitated using an active-conformation specific BAX antibody (6A7) and 
binding was assessed by western blotting using an antibody against total BAX (inactive + active) 
and pRB. When co-incubated with inactive BAX, pRB bound to (lower panels) and stimulated 
formation of (upper panels) conformationally active BAX.  (E) Co-immunoprecipitation 
experiment using IMR90 cells treated with TNF /CHX for 3 hours. Endogenous pRB was 
immunoprecipitated from cell extracts and endogenous BAX association was assessed by western 
blotting.  pRB and BAX form an endogenous complex in vivo in TNF /CHX-treated cells.  (A, 
C-E) Data are representative of at least three independent experiments. 
1. Structure of the Retinoblastoma Protein.  pRB is comprised of three general domains, the 
N-terminal domain, the Small Pocket, and the C-terminal domain.  Together the Small Pocket 
and C-terminal domain form the Large Pocket, which is both necessary and sufficient for tumor 
suppression.  The LxCxE binding cleft is localized in the Small Pocket and the Nuclear 








and	  run’	  nature	  of	  these	  interactions	  (Eskes	  et	  al.,	  2000;	  Perez	  and	  White,	  2000;	  Walensky	  and	  Gavathiotis,	  2011).	  	  Thus,	  to	  enable	  detection	  of	  such	  transient	  interactions,	  we	  treated	  primary	  human	  IMR90	  fibroblasts	  with	  TNFα/CHX	  and	  then	  crosslinked	  using	  the	  amine-­‐reactive	  crosslinking	  agent	  DSP.	  	  Using	  this	  approach,	  we	  were	  able	  to	  detect	  BAX	  within	  immunoprecipitates	  of	  the	  endogenous	  pRB	  protein	  (Fig.	  5E).	  	  Thus,	  taken	  together,	  our	  in	  
vitro	  and	  in	  vivo	  experiments	  show	  that	  pRB	  can	  bind	  directly	  to	  BAX	  and	  induce	  it	  to	  adopt	  the	  active	  conformation	  that	  triggers	  MOMP	  and	  cytochrome	  c	  release.	  
The	  mitochondrial	  function	  of	  pRB	  induces	  apoptosis	  even	  in	  the	  absence	  of	  pRB’s	  
nuclear	  functions.	  
















Figure 6. The Small Pocket of pRB is sufficient to induce transcription-independent 
apoptosis.  (A) Schematic of pRB domains: the N-terminus (RB_N; residues 1-372), the 
small pocket domain (RB_SP; residues 373-766) and the C-terminus (RB_C; residues 767-
928).  (B) Stable variants of RAT16 cells allowing for inducible expression of HA-tagged 
full-length pRB, RB_N, RB_SP, and RB_C by doxycycline withdrawal were generated 
and expression was verified after 24 hours by western blotting using an HA-antibody.  (C) 
RAT16 cells with and without expression of pRB, RB_N, RB_SP, and RB_C for 24 hours 
were treated with TNF  and CHX for 24 hours and levels of apoptosis were assessed by 
AnnexinV staining.  Induced expression of full-length pRB and RB_SP, but not RB_N or 
RB_C, sensitized to TNF /CHX-induced apoptosis.  (B-C) Each RAT16 variant was 
independently generated three times.  Graph bars represent average of three representative, 





	   As	  an	  alternative	  approach,	  we	  sought	  to	  study	  the	  impact	  of	  the	  mitochondrial	  pRB	  activity	  in	  the	  absence	  of	  pRB’s	  canonical	  nuclear	  functions	  by	  targeting	  pRB	  specifically	  to	  the	  mitochondria.	  	  Mutation	  of	  the	  NLS	  and	  direct	  targeting	  to	  the	  outside	  of	  the	  mitochondria	  using	  the	  transmembrane	  domain	  of	  Bcl2	  proved	  insufficient	  for	  exclusive	  mitochondrial	  localization	  (data	  not	  shown),	  and	  instead	  we	  combined	  NLS	  mutation	  with	  fusion	  to	  the	  mitochondrial	  leader	  peptide	  of	  ornithine	  transcarbamylase	  (mitoRBΔNLS;	  Fig.	  7A).	  	  We	  note	  that	  this	  leader	  peptide	  targets	  to	  the	  matrix	  of	  mitochondria,	  but	  it	  has	  been	  used	  successfully	  to	  study	  protein	  function	  at	  the	  outer	  mitochondrial	  membrane,	  presumably	  by	  allowing	  resorting	  to	  other	  mitochondrial	  compartments	  (Marchenko	  et	  al.,	  2000).	  	  We	  confirmed	  that	  expression	  of	  mitoRBΔNLS	  did	  not	  cause	  general	  mitochondrial	  cytotoxicity,	  as	  judged	  by	  the	  absence	  of	  increased	  ROS	  production	  (data	  not	  shown).	  	  We	  also	  localized	  a	  control	  protein,	  REL,	  to	  mitochondria	  to	  further	  control	  for	  any	  non-­‐specific	  effect	  of	  mitochondrial	  targeting.	  	  Stable,	  inducible	  RAT16	  cell	  lines	  were	  used	  to	  express	  mitoRBΔNLS,	  wildtype	  pRB,	  or	  mitoREL	  upon	  doxycycline	  withdrawal.	  	  Importantly,	  we	  confirmed	  specific	  targeting	  of	  mitoRBΔNLS	  and	  the	  control	  mitoREL	  protein	  to	  mitochondria	  (Fig.	  7B,	  C).	  	  Consistent	  with	  its	  restricted	  localization,	  mitoRBΔNLS	  was	  unable	  to	  perform	  nuclear	  pRB	  functions,	  as	  judged	  by	  its	  inability	  to	  mediate	  the	  transcriptional	  repression	  of	  cell	  cycle	  genes	  that	  are	  known	  pRB	  targets	  (cdc2,	  mcm3,	  








	   	  
 
Figure 7. Mitochondria-targeted pRB is deficient for pRB’s nuclear function, but 
induces apoptosis in response to various apoptotic stimuli.  (A)  Schematic of 
mitoRB NLS construct.  pRB was targeted to mitochondria by fusion to the mitochondrial 
leader peptide of ornithine transcarbamylase and mutation of the NLS.  (B) Stable variants of 
RAT16 cells allowing for inducible expression of mitoRB NLS, wildtype pRB, mitoREL, 
and wildtype REL were generated and cellular localization following 24 hours induction was 
assessed by immunofluorescence using antibodies against pRB and REL.  Mitochondria were 
visualized using MitoTracker.  mitoRB NLS and mitoREL localized to mitochondria.  (C) 
Western blotting showing induced expression levels of mitoRB NLS and wildtype pRB at 
mitochondria and total lysate.  mitoRB NLS expressed at lower levels than wildtype pRB, 
even when considering the mitochondrial fraction.  (D) pRB, but not mitoRB NLS, 
repressed E2F target genes cdc2, mcm3, mcm5, mcm6, PCNA, cycA2 as measured by RT-
qPCR and normalized to ubiquitin. Average of two independent experiments (±SD).  (E) 
Induced expression of mitoRB NLS and wildtype pRB, but not mitoREL or REL, sensitized 
to apoptosis induced by 24 hour treatment with TNF  and CHX.  (B-E) Each RAT16 variant 
was independently generated three times.  Graph bars represent average of three 




	  TNFα/CHX-­‐induced	  apoptosis.	  	  As	  an	  additional	  control	  against	  non-­‐specific	  mitochondrial	  cytotoxicity,	  we	  wanted	  to	  verify	  that	  mitoRBΔNLS	  works	  through	  the	  same	  directed	  mechanism	  as	  wildtype	  pRB.	  	  Thus,	  we	  assessed	  the	  BAX/BAK	  dependence	  of	  this	  protein	  by	  generating	  stable	  variants	  of	  immortalized	  wildtype,	  Bak-­/-­,	  Bax-­/-­,	  or	  Bax-­/-­;Bak-­/-­	  MEFs	  to	  allow	  doxycycline-­‐inducible	  mitoRBΔNLS	  expression	  (Fig.	  7F).	  	  Expression	  of	  mitoRBΔNLS	  in	  wildtype	  and	  Bak-­/-­,	  but	  not	  Bak-­/-­	  or	  Bax-­/-­;Bak-­/-­	  MEFs,	  enhanced	  TNFα-­‐induced	  apoptosis	  (Fig.	  7G).	  Thus,	  mitoRBΔNLS	  promotes	  apoptosis	  in	  a	  BAX-­‐dependent	  manner,	  exactly	  like	  wildtype	  pRB.	  	  Targeting	  pRB	  directly	  to	  the	  mitochondria	  therefore	  successfully	  generates	  a	  separation	  of	  function	  mutant	  that	  is	  deficient	  for	  pRB’s	  classic	  nuclear	  functions	  but	  retains	  the	  ability	  induce	  apoptosis	  in	  a	  transcription-­‐independent,	  BAX-­‐dependent	  manner	  in	  response	  to	  TNFα.	  In	  our	  earlier	  experiments,	  induction	  of	  wildtype	  pRB	  and	  RB_SP	  consistently	  yielded	  a	  small,	  but	  significant	  increase	  in	  apoptosis	  even	  in	  the	  absence	  of	  TNFα	  treatment.	  	  This	  led	  us	  to	  hypothesize	  that	  mitochondrial	  pRB	  may	  function	  in	  a	  broader	  manner	  in	  apoptosis.	  	  We	  therefore	  evaluated	  the	  effect	  of	  mitoRBΔNLS	  expression	  on	  apoptosis	  induced	  by	  apoptotic	  factors	  other	  than	  TNFα.	  	  Immortalized	  wildtype	  or	  Bax-­/-­
;Bak-­/-­	  MEFs	  with	  and	  without	  mitoRBΔNLS	  expression	  were	  treated	  with	  two	  drugs,	  etoposide	  and	  staurosporine	  (STS),	  that	  work	  via	  distinct	  mechanisms.	  Notably,	  mitoRBΔNLS	  expression	  enhanced	  both	  etoposide	  and	  STS-­‐induced	  apoptosis	  (Fig.	  7H).	  Thus,	  mitochondrial	  pRB	  can	  be	  activated	  in	  response	  to	  a	  	  
by doxycycline addition for 24 hours in stable variants of wild-type, Bak-/-, Bax-/-, and Bax-/-;Bak-
/- immortalized MEFs and confirmed by western blotting using antibodies against pRB, BAK, 
BAX, and tubulin.  (G) Induction of mitoRB NLS in wildtype and Bak-/-, but not Bax-/- or Bax-/-
;Bak-/-, MEFs sensitized to 10 hour treatment with TNF  and CHX.  (H) Wildtype and Bax-/-
;Bak-/- MEFs with and without induced expression of mitoRB NLS were treated with 




	  variety	  of	  apoptotic	  stimuli,	  including	  both	  intrinsic	  and	  extrinsic	  stimuli.	  	  This	  argues	  that	  mitochondrial	  pRB	  function	  may	  contribute	  to	  pRB-­‐induced	  apoptosis	  in	  various	  settings.	  	  	  
Mito-­targeted	  pRB	  suppresses	  tumor	  growth	  in	  vivo.	  














Figure 8.  Mitochondria-targeted pRB induces apoptosis in transformed Rb-/-;p53-/- 
osteosarcoma cells.  (A) Representative image showing localization of mitoRB NLS and 
pRB in transformed, Rb-/-;p53-/- osteosarcoma cells by immunofluorescence.  mitoRB NLS 
localized to mitochondria and not the nucleus.  (B) Western blot showing relative expression 
levels of mitoRB NLS and pRB after 24 hours of induction.  mitoRB NLS expressed 
poorly compared to pRB.  (C) Expression of mitoRB NLS or pRB, but not mitoREL, in 
transformed, Rb-/-;p53-/- osteosarcoma cells for 24 hours resulted in increased levels of 
apoptosis, even in the absence of TNF  treatment.  Graph bars represent average of three 
independent experiments (±SD).  (D) Rb-/-;p53-/- osteosarcoma cells (parental) were injected 
into the flank of nude mice.  Once a tumor volume of approximately 0.05 cm3 was reached, 
half the mice were fed dox food and tumor volume was monitored for 11 days (±SEM).  
Doxycycline had no effect on the growth of xenografted tumors.  Tumor volume normalized 









Figure 9. Mitochondria-targeted pRB induces apoptosis in vivo and is tumor-
suppressive. (A) Rb-/-;p53-/- osteosarcoma cell variants allowing for doxycycline inducible 
expression of mitoRB NLS or wildtype pRB were injected into the flank of nude mice (2 
injection sites per mouse; 12 injections per cell line variant).  Once a tumor volume of 
approximately 0.05 cm3 was reached, mitoRB NLS or wildtype pRB expression was 
induced in half the mice and tumor volume was monitored for 11 days (n=6/condition, 
±SEM).  Induced expression of mitoRB NLS or wildtype pRB suppressed growth of 
xenografted tumors.  Tumor volume normalized to Day 1.  (B) Induced expression of 
mitoRB NLS or wildtype pRB resulted in increased levels of apoptosis as measured by 
immunohistochemistry using a cleaved caspase 3 antibody (top).  Tumors expressing 
mitoRB NLS also contained small areas with very high levels of apoptosis (inset).  
Induced expression of wildtype pRB, but not mitoRB NLS decreased proliferation as 
measured by Ki67 staining (bottom).  Images representative of respective 6 tumor 
sections.  (C) Murine p16 was knocked down in immortalized wildtype MEF variants that 
allow for doxycycline-inducible expression of pRB.  Phosphorylation status of pRB (as 
judged by mobility) and knockdown of p16 using two distinct siRNAs was confirmed by 
western blotting.  Induced expression of pRB enhances TNF /CHX-induced apoptosis in 
the presence and absence of p16 and this activity is not inactivated by pRB 








































Materials	  and	  Methods	  
Cell	  Culture	  and	  Drug	  Treatment	  	  	  
RAT16	  and	  IMR90	  cells	  were	  grown	  in	  MEM	  with	  Earle’s	  Salts	  and	  10%	  FBS,	  Pen-­‐Strep,	  L-­‐Glutamine,	  Sodium	  Pyruvate,	  and	  NEAA.	  	  All	  other	  cell	  lines	  were	  grown	  in	  DMEM	  with	  10%	  FBS	  and	  Pen-­‐Strep.	  	  For	  TNFα	  treatments,	  50ng/ml	  of	  recombinant	  mouse	  TNFα	  (Sigma)	  was	  used	  with	  0.1μM	  MG132	  (Calbiochem)	  for	  48	  hours	  or	  0.5μg/ml	  CHX	  (Sigma)	  for	  24	  hours	  unless	  noted	  otherwise.	  	  MEFs	  were	  treated	  with	  TNFα/CHX	  for	  10	  hours,	  1μM	  staurosporine	  (Sigma)	  for	  6	  hours,	  or	  25μM	  etoposide	  (Sigma)	  for	  12	  hours.	  	  TET	  System	  approved	  FBS	  (Clontech)	  and	  1μg/ml	  doxycycline	  (Clontech)	  were	  used	  for	  inducible	  cell	  lines	  unless	  noted	  otherwise.	  	  Overexpression	  was	  induced	  for	  24	  hours	  prior	  to	  TNFα	  treatment.	  	  20µg/ml	  and	  15µg/ml	  doxycycline	  were	  used	  in	  wildtype,	  Bax-­/-­,	  and	  
Bak-­/-­	  MEFS	  to	  induce	  expression	  of	  pRB	  and	  mitoRBΔNLS,	  respectively.	  	  5µg/ml	  doxycycline	  was	  used	  in	  Bax-­/-­;Bak-­/-­	  MEFs	  to	  adjust	  for	  expression	  levels.	  
FACS	  Apoptosis	  Analysis	  




suspensions	  were	  processed	  as	  previously	  described	  (Ianari	  et	  al.,	  2009)	  and	  analyzed	  by	  FACScan	  and	  FlowJo.	  
	  
Plasmid	  and	  Stable	  Cell	  Line	  Generation	  








IMR90	  mitochondria	  were	  fractionated	  as	  follows:	  cells	  were	  resuspended	  in	  cold	  Buffer	  A	  [250mM	  Sucrose,	  20mM	  Hepes	  pH	  7.5,	  10mM	  KCl,	  1.5mM	  MgCl2,	  1mM	  EDTA,	  1mM	  EGTA,	  1mM	  DTT,	  protease	  inhibitors	  (Roche)]	  and	  homogenized	  using	  20	  strokes	  in	  a	  ¼’’	  cylinder	  cell	  homogenizer	  (H&Y	  Enterprises,	  Redwood	  City,	  CA),	  0.1558’’	  ball.	  Nuclei	  and	  unlysed	  cells	  were	  removed	  by	  low-­‐speed	  centrifugation	  and	  mitochondria	  and	  10%	  of	  initial	  cell	  suspension	  (for	  Total	  Lysate)	  were	  lysed	  using	  RIPA	  buffer	  (0.5%	  Sodium	  Deoxycholate,	  50mM	  Tris	  HCl	  pH	  7.6,	  1%	  NP40,	  0.1%	  SDS,140mM	  NaCl,	  5mM	  EDTA,	  100mM	  NaF,	  2mM	  NaPPi,	  protease	  inhibitors)	  and	  quantified	  using	  BCA	  Protein	  Assay	  reagent	  (Pierce).	  




lysed	  in	  RIPA	  buffer.	  	  For	  subfractionation,	  the	  mitochondrial	  pellet	  was	  resuspended	  at	  2mg/ml	  in	  Hypotonic	  Buffer	  (10mM	  KCl,	  2mM	  HEPES/K	  pH7.9),	  incubated	  on	  ice	  for	  20	  minutes	  and	  centrifuged	  at	  14000rpm.	  	  The	  pellet	  was	  washed	  twice	  with	  Wash	  Buffer	  (150mM	  KCl,	  2mM	  HEPES/K	  pH7.9)	  and	  all	  three	  supernatants	  combined	  yielded	  the	  non-­‐mitoplast	  fraction.	  	  The	  mitoplast	  was	  resuspended	  in	  Hypotonic/Wash	  Buffer	  and	  equal	  fractions	  were	  analyzed	  by	  SDS-­‐PAGE	  and	  western	  blotting.	  	  Mitochondria	  were	  isolated	  from	  livers	  of	  Alb-­crepos;Baxf/-­;Bak-­/-­	  mice	  as	  reported	  previously	  (Walensky	  et	  al.,	  2006).	  
In	  Vitro	  Cytochrome	  C	  Release	  Assay	  
The	  assay	  was	  performed	  as	  previously	  described	  (Chipuk	  et	  al.,	  2005).	  	  Briefly,	  wildtype	  mitochondria	  were	  resuspended	  in	  Mitochondrial	  Isolation	  Buffer	  (200mM	  Mannitol,	  68mM	  Sucrose,	  10mM	  HEPES/K	  pH	  7.4,	  100mM	  KCl,	  1mM	  EDTA,	  1mM	  EGTA,	  0.1%BSA)	  to	  a	  concentration	  of	  1μg/μl	  and	  incubated	  with	  pRB	  (Sigma),	  GST-­‐Bax	  (Sigma),	  or	  cl.	  BID	  (R&D	  Systems)	  for	  1	  hour,	  37˚C.	  	  DKO	  mitochondria	  were	  resuspended	  in	  experimental	  buffer	  (125mM	  KCl,	  10mM	  Tris-­‐MOPS	  [pH	  7.4],	  5mM	  glutamate,	  2.5mM	  malate,	  1mM	  KPO4,	  10μM	  EGTA-­‐Tris	  [pH	  7.4])	  to	  a	  concentration	  of	  1.5	  mg/ml,	  and	  incubated	  with	  monomeric	  BAX	  (purified	  as	  previously	  described	  (Gavathiotis	  et	  al.,	  2008))	  and	  pRB	  (ProteinOne)	  for	  45	  min,	  room	  temperature.	  	  Samples	  were	  centrifuged	  at	  5500g	  and	  pellets	  versus	  supernatants	  were	  analyzed	  by	  SDS-­‐PAGE	  and	  immunoblotting.	  
Liposomal	  Release	  Assay	  




mixture	  of	  48%	  phosphatidylcholine,	  28%	  phosphatidylethanolamine,	  10%	  phosphatidylinositol,	  10%	  dioleoyl	  phosphatidylserine	  and	  4%	  tetraoleoyl	  cardiolipin	  as	  chloroform	  stocks	  (Avanti	  Polar	  Lipids).	  	  The	  lipid	  mixture	  was	  dried	  in	  glass	  test	  tubes	  under	  nitrogen	  gas	  and	  then	  under	  vacuum	  for	  15	  h.	  	  The	  fluorescent	  dye	  ANTS	  (6.3	  mg)	  and	  the	  quencher	  DPX	  (19.1	  mg)	  were	  added	  to	  1	  mg	  of	  dry	  lipid	  film,	  and	  the	  mixture	  resuspended	  in	  assay	  buffer	  (200mM	  KCl,	  1mM	  MgCl2,	  10mM	  HEPES,	  pH	  7.0).	  After	  five	  freeze-­‐thaw	  cycles,	  the	  lipid	  mixtures	  were	  extruded	  through	  a	  100	  nm	  nucleopore	  polycarbonate	  membrane	  (Whatman)	  using	  a	  mini	  extruder	  (Avanti).	  	  Liposomes	  were	  isolated	  by	  gravity	  flow	  SEC	  using	  a	  crosslinked	  Sepharose	  CL-­‐2B	  column	  (Sigma	  Aldrich).	  LUVs	  (5	  µl)	  were	  treated	  with	  the	  indicated	  concentrations	  of	  BAX	  and	  pRB	  in	  384-­‐well	  format	  (Corning)	  in	  a	  total	  reaction	  volume	  of	  30	  µl.	  After	  time-­‐course	  fluorescence	  measurement	  on	  a	  Tecan	  Infinite	  M1000	  spectrophotometer	  (excitation	  355	  nm,	  emission	  520	  nm),	  Triton	  X-­‐100	  was	  added	  to	  a	  final	  concentration	  of	  0.2%	  (v/v)	  to	  determine	  maximal	  release.	  
Immunoprecipitation	  




For	  the	  endogenous	  interaction	  study,	  IMR90	  cells	  were	  treated	  with	  50ng/ml	  TNFα	  and	  0.5μg/ml	  CHX	  for	  3	  hours	  total	  and	  crosslinked	  with	  1mg/ml	  DSP	  (Pierce)	  for	  1	  hour.	  	  Proteins	  were	  extracted	  using	  an	  NP40	  based	  buffer	  (50mM	  HEPES	  pH7.9,	  10%	  glycerol,	  150mM	  NaCl,	  1%NP40,	  1mM	  NaF,	  10mM	  B-­‐Glycerophosphate,	  protease	  inhibitors).	  	  The	  following	  antibodies	  were	  used:	  pRB	  (Cell	  Signaling,	  9309),	  normal	  rabbit	  IgG	  (Santa	  Cruz).	  
	  
Western	  Blotting	  









Xenograft	  Model:	  	  All	  animal	  procedures	  followed	  protocols	  approved	  by	  MIT’s	  Committee	  on	  Animal	  Care.	  	  Nude/SCID	  mice	  (Taconic)	  were	  injected	  subcutaneously	  with	  107	  tumor	  cells	  per	  site,	  2	  sites	  per	  mouse.	  	  After	  euthanasia,	  tumors	  were	  removed,	  fixed	  overnight	  in	  formalin	  followed	  by	  overnight	  incubation	  in	  70%	  ethanol,	  and	  subjected	  to	  histological	  processing.	  
Immunofluorescence	  and	  Immunohistochemistry	  Cells	  were	  plated	  at	  low	  density	  on	  coverslips	  and	  protein	  expression	  was	  induced	  for	  48	  hours.	  	  Mitochondria	  were	  labeled	  using	  MitoTracker	  Deep	  Red	  (Invitrogen)	  at	  100nM	  for	  45	  minutes,	  37˚C.	  	  Cells	  were	  fixed	  in	  4%	  Formaldehyde	  (Thermo	  Scientific),	  permeabilized	  with	  0.25%	  TritonX-­‐100/PBS,	  and	  blocked	  with	  5%	  Goat	  Serum	  in	  0.2%	  Tween20/PBS	  for	  30	  minutes,	  37˚C.	  	  The	  following	  antibodies	  were	  used	  at	  1:200	  for	  1	  hour,	  room	  temperature:	  pRB	  (Cell	  Signaling,	  9309),	  c-­‐REL	  (Cell	  Signaling,	  4727).	  	  Alexa	  Fluor	  488	  (Invitrogen)	  was	  used	  at	  1:1000	  for	  1	  hour,	  room	  temperature	  and	  slides	  were	  mounted	  using	  SlowFade	  Gold	  Antifade	  Reagent	  with	  DAPI	  (Invitrogen)	  and	  observed	  under	  a	  fluorescence	  microscope	  (Zeiss).	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